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Abstract 
Enzymes in isoprenoid biosynthesis pathway play important roles in all living organisms.  
Here we report the first structure of heptaprenyl diphosphate synthase from Staphylococcus aureus 
(SaHepPPS) together with an investigation of its mechanism of action, and inhibition.  HepPPS is 
involved in menaquinone biosynthesis, a key electron transporter in many pathogens.  It is a 
heterodimer consisting of a catalytic subunit and a regulatory subunit.  High concentrations of 
substrates (FPP and IPP) inhibit the enzyme, which is also inhibited by bisphosphonates.  The most 
active inhibitors (Ki ~ 200 nM) were N-alkyl analogs of zoledronate containing ~C6 alkyl side-
chains. They were modestly active against S. aureus cell growth, and growth inhibition was 
partially “rescued” by addition of menaquinone-7.  Helicobacter pylori utilizes a completely 
different menaquinone biosynthesis pathway. Orthologs of Men genes (MenA-MenG) involved in 
menaquinone biosynthesis are absent in H. pylori.  Recently, an alternate biosynthesis, called 
futalosine pathway was discovered in H. pylori, which uses a novel substrate, 6-carboxy-1,4-
naphthoquinone as an intermediate in the menaquinone biosynthesis.  We report the first 
expression and characterization of H. pylori UbiD and UbiX.  We demonstrate that UbiD is the 
menaquinone decarboxylase that is dependent on a prenyltransferase enzyme, UbiX.  UbiD family 
of enzymes are reported in literature as phenolic acid decarboxylase and ubiquinone 
decarboxylase.  We report the first UbiD functioning as menaquinone decarboxylase in futalosine 
pathway, active with 6-carboxy-1,4-naphthoquinone substrate.   
We successfully expressed active, recombinant farnesyl diphosphate synthase (FPPS) and 
geranylgeranyl diphosphate synthase (GGPPS) for subsequent kinetic characterization and testing 
against a variety of bisphosphonates.  Characterization of the substrate utilization of FPPS and 
GGPPS indicates that they have overlapping substrate specificities.  Against FPPS, several 
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bisphosphonates had IC50s in the low micromolar to nanomolar range; these inhibitors had 
significantly less activity against GGPPS.  Several lipophilic bisphosphonates were active against 
ex vivo adult S. mansoni worms with worm death occurring over 4-6 days.  These results indicate 
that FPPS and GGPPS are important for development of new drug against schistosomiasis.  FPPS 
is also a suitable target for development of new antibiotics against gram-negative bacteria.  We 
report bisphosphonates with electron-withdrawing aryl-alkyl sidechains, which inhibited the 
growth of gram-negative bacteria (Acinetobacter baumannii, Klebsiella pneumoniae, E. coli and 
Pseudomonas aeruginosa) at ~1-4 µg/mL levels. They were potent inhibitors of FPPS; bacterial 
cell growth was partially "rescued" by addition of farnesol or overexpression of FPPS; and there 
was synergistic activity with known isoprenoid biosynthesis pathway inhibitors. 
In bacteria, farnesyl diphosphate (FPP) is further utilized in downstream isoprenoid 
biosynthesis pathway to synthesize undecaprenyl diphosphate (UPP, catalyzed by UPP synthase) 
and undecaprenyl monophosphate (UP, catalyzed by UPP phosphatase).  Undecaprenyl 
monophosphate is an essential lipid carrier involved in cell wall biosynthesis in bacteria, which is 
not present in humans; thus it’s a suitable drug target.  We report a series of lipophilic hydroxy-
monophosphonates, dihydroxy acids, and benzoic acids that inhibit UPPS and UPPP at µM levels. 
Lipophilic hydroxy-phosphonates were active (~2-6 µg/mL) against gram-positive organisms (S. 
aureus and B. subtilis) and exhibited synergistic activity with known isoprenoid/cell wall 
biosynthesis inhibitors, but only indifferent effects with other inhibitors.  One of the most active 
benzoic acid (IC50 ~ 0.15 µg/mL) acted synergistically with seven antibiotics known to target 
bacterial cell wall biosynthesis (fractional inhibitory concentration index, FICI~0.35, on average).  
Benzoic acids were active against UPPS and UPPP and there were good correlations between S. 
aureus cell growth inhibition and SaUPPS inhibition (r = 0.85).  
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Chapter 1 
Introduction 
 
1.1 Isoprenoid Biosynthesis  
 With over 50,000 structurally diverse naturally occurring organic chemicals, isoprenoids 
carry out various biological functions, such as membrane lipids (cell wall biosynthesis), prenylated 
proteins (membrane trafficking and cell signaling), steroids (hormones and membrane 
components), carotenoids (photopigments and photoprotective agents), dolichols (glycoprotein 
synthesis and bacterial cell wall biosynthesis), monoterpenes (insect pheromones and forest 
aerosols), sesquiterpenes (plant defensive agents), vitamins (antioxidants and anti-inflammatory 
agents), and quinones (electron transport) (1).  Because of their widespread role in biology, many 
drugs target enzymes of isoprenoid biosynthesis.  For example, statins (lipid-lowering 
medications) that target 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (EC# 
1.1.1.34) have widely been in use for last few decades as a treatment for hypercholesterolemia (2).  
Other drugs such as bisphosphonates (osteoporosis and anti-cancer drugs) target farnesyl 
pyrophosphate synthase (FPPS, EC# 2.5.1.10) (3, 4) and fosmidomycin (antibacterial and 
antimalarial) targets 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXP reductoisomerase 
or DXR, EC# 1.1.1.267), an enzyme in non-mevalonate pathway of isoprenoid biosynthesis (5, 6). 
Ergosterol synthesis inhibitors such as terbinafine and many azole family of compounds 
(antifungal agents) target squalene epoxidase (EC# 5.4.99.7) and lanosterol-14 α-demethylase 
(EC# 1.14.13.70) respectively (7, 8).  
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 Despite of the massive size of isoprenoid family of compounds and their diverse structures 
and functions, all compounds are derived from four fundamental coupling reactions: chain 
elongation through condensation, branching, cyclo-propanation, and cyclo-butanation (9).  
Isoprenoid biosynthesis network is routed in two distinct metabolic pathways—mevalonate 
pathway and non-mevalonate pathway (10, 11).  Mevalonate pathway is found in eukaryotes, 
archaea, some bacteria and plant cytosol; whereas non-mevalonate pathway is present in many 
lower level plant organisms such as algae, chloroplasts of plant cells, many bacteria such as 
Escherichia coli and Helicobacter pylori (12), and in the apicomplexa such as Plasmodium 
falciparum and Toxoplasma gondii (6). 
 The first step in mevalonate pathway (also known as HMG-CoA reductase pathway) is the 
condensation of two acetyl-CoA molecules to yield acetoacetyl-CoA by acetoacetyl-CoA synthase 
(EC# 6.2.1.16). A second condensation of acetyl-CoA by HMG-CoA synthase (EC# 4.1.3.5) forms 
HMG-CoA.  HMG-CoA reductase, which is a target of statins, converts HMG-CoA into 
mevalonate.  The final product of mevalonate pathway isopentenyl pyrophosphate (IPP) is formed 
through several reactions including phosphorylation, decarboxylation, and dehydration.  
Dimethylallyl pyrophosphate (DMAPP) is formed through isomerization of IPP by the enzyme 
isopentenyl pyrophosphate isomerase (EC# 5.3.3.2) (13) 
 Non-mevalonate pathway (MEP/DOXP pathway) begins with formation of 1-deoxy-D-
xylulose-5-phosphate (DOXP) by DXP synthase (EC# 2.2.1.7) using pyruvate and 
glyceraldehyde-3-phosphate (G3P) (14).  DOXP reductase (also known as IspC, EC# 1.1.1.267), 
which is the target of fosmidomycin converts DOXP into 2-C-methylerythritol-4-phosphate 
(MEP) using NADPH as reducing agent (15). After five more steps of isomerization, 
phosphorylation, and reduction through enzymes IspD-IspH, IPP and DMAPP are formed from 
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(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), which is the natural activator of 
human Vγ9/Vδ2 T cells, the major γδ T cell population in the circulatory system (16). 
 Typically, longer chain isoprenoid biosynthesis begins with sequential condensation of 
DMAPP with two molecules of IPP to generate farnesyl diphosphate (FPP) by farnesyl 
diphosphate synthase (FPPS).  Geranylgeranyl diphosphate synthase (GGPPS) then condenses one 
more IPP molecule in a head-to-tail fashion to generate a diterpene called geranylgeranyl 
diphosphate.  FPP and GGPP are involved in protein prenylation of eukaryotic Ras GTPase and 
Rab GTPase (17, 18).  Protein prenylation is essential for functions like cell proliferation, 
membrane trafficking and cytoskeletal structure and dynamics. 
 Two molecules of FPP undergo head-to-head condensation to generate a triterpene called 
presqualene diphosphate (19), which then undergoes skeletal rearrangement and further loss of 
diphosphate group to produce squalene (20). Squalene is the biochemical precursor to the whole 
family of steroids and virulence factor such as staphyloxanthin (dehydrosqualene) (21).  Similarly, 
heptaprenyl diphosphate synthase (HepPPS), a heterodimeric enzyme complex catalyzes 
sequential head-to-tail condensation of four IPP molecules with FPP to generate a C35 isoprenoid 
called heptaprenyl diphosphate (HepPP).  In Staphylococcus aureus and Bacillus subtilis, 
heptaprenyl diphosphate is utilized by MenA in a conjugation reaction of a prenyl chain with 
dihydroxynaphthoic acid (DHNA) to produce demethylmenaquinone (DMK) (22). 
 Besides synthesis of sterols and quinones, isoprenoids are also involved in cell wall 
biosynthesis.  Undecaprenyl diphosphate synthase (UPPS), a cis-prenyltransferase condenses eight 
molecules of IPP to an FPP to generate a C55 isoprenoid called undecaprenyl diphosphate (UPP) 
(23).  UPP is then dephosphorylated by undecaprenyl diphosphate phosphatase (UPPP), an integral 
membrane protein to yield undecaprenyl monophosphate (UP), (24). Undecaprenyl phosphate is 
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an essential carrier lipid in the bacterial cell membrane for the biosynthesis of peptidoglycan and 
various carbohydrate polymers, such as lipopolysaccharides, teichoic acids, and osmoregulated 
periplasmic glucans (25).   
Due to their widespread existence and importance in bacteria as well as helminth, 
apicomplexa, and protozoa (26, 27, 28) isoprenoid biosynthesis is a viable target for the 
development of novel antibacterial and antiparasitic agents. Besides targeting the enzymes of 
mevalonate and non-mevalonate pathways (29, 30), targeting enzymes that synthesize longer chain 
isoprenoids such as FPPS (31), GGPPS (32), UPPS (33), as well as enzymes involved in quinone 
and sterol synthesis (34, 35) have been reported.   
Bisphosphonates are a class of drugs used in prevention of bone mineral loss, osteoporosis, 
bone metastasis and bone pain (36), multiple myeloma, (37), as well as in breast and lung cancers 
(38, 39).  The basic structure of bisphosphonates is that two phosphate groups are linked to a 
carbon atom, thus generating a pyrophosphate analog in P-C-P backbone fashion.  There are two 
classes of bisphosphonates licensed in the market, namely nitrogen-containing and non-nitrogen 
containing bisphosphonates.  Needless to say, many pharmaceutical companies have 
bisphosphonate drugs in their portfolio due to their widespread applications in variety of disorders.  
For nitrogen-containing bisphosphonates, farnesyl diphosphate synthase (FPPS) is inhibited, thus 
preventing the formation of two metabolites - farnesol and geranylgeraniol that are essential in 
protein prenylation and anchoring these prenylated proteins to the cell membrane.  Disruption of 
lipid modification of Rab, Ras, Rho and Rac proteins have been speculated as the mechanism of 
action of bisphosphonates (40, 41). Other than being used to alter human pathophysiology such as 
osteoporosis or cancer, bisphosphonates also have potential antibacterial and antiparasitic activity.   
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Bisphosphonates came to existence as analogs of pyrophosphates.  However, for longer 
chain isoprenoids functioning as cell wall components, such as squalene and undecaprenyl 
diphosphate that contain a large lipid moiety, lipophilic bisphosphonates and hydrophobic 
molecules with terminal electron withdrawing groups (e.g. benzoic acids, phosphonic acids, 
dihydroxy carboxylic acids) have been shown to be potent competitive inhibitors (42, 43). Electron 
withdrawing groups at terminal mimic phosphonate moiety, while large lipid fragment of the 
inhibitor is believed to be housing the hydrophobic pocket of active site of enzymes. Such 
lipophilic inhibitors passing Lipinski’s rule of five have greater chances to be active against cell 
growth than their rather hydrophilic counterparts.  Furthermore, because they are lipophilic, they 
are less likely to concentrate in bone tissue, and thus more likely to be potent against pathogens 
infecting soft tissues such as lungs (Mycobacterium tuberculosis), liver (Schistosoma mansoni), 
skin (Staphylococcus aureus), or blood (Plasmodium falciparum) (21, 32, 34, 35). 
 
1.2 Research Summary 
 In chapter 2 we demonstrated that Staphylococcus aureus heptaprenyl diphosphate 
synthase (SaHepPPS) is a heterodimeric enzyme and both subunits are required for activity.  In 
the presence of FPP and Mg2+ two subunits form an active heterodimeric complex, which 
condenses 4 IPP molecules on FPP, yielding a C35 isoprenoid called heptaprenyl diphosphate 
(HepPP).  In S. aureus, HepPP is involved in menaquinone biosynthesis.  Conserved residues on 
the regulatory subunit (SaHepPPS-1) are located on the interface of two components.  The catalytic 
subunit (SaHepPPS-2) is a "typical" trans-prenyltransferase with two aspartate rich motifs 
containing DDXXD sequences.  SaHepPPS-1 presents with a unique structure having high 
homology only to Bacillus and Staphylococcus heptaprenyl pyrophosphate synthases.  Thus it 
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provides some domain for future antimicrobial development.  FPP and to some extent IPP 
substrates induce enzyme inhibition at high concentrations.  Bisphosphonates containing an 
imidazolium substituent with mid-range (C8-C12) chain length are good SaHepPPS and S. aureus 
cell growth inhibitors.  S. aureus cell growth inhibition was partially rescued (~9x increase in IC50) 
by addition of menaquinone-7, thus proving that menaquinone biosynthesis is one of the pathways 
targeted by bisphosphonates.   
 Chapter 3 shows Helicobacter pylori enzymes UbiD and UbiX are involved in 
menaquinone biosynthesis and are only active with a novel substrate not reported in literature.  
HpUbiX functions as a flavin prenyltransferase, modifying the flavin mononucleotide cofactor by 
formation of a fourth ring structure.  This cofactor is then involved in the decarboxylation reaction 
with HpUbiD.  Hence, HpUbiD and HpUbiX both are needed for a successful decarboxylation.  
HpUbiD and HpUbiX did not show any activity (using time-scaled, enzyme concentration 
dependent NMR technique) with previously reported decarboxylation substrates such as cinnamic 
acid, 4-hydroxy-benzoic acid, and 2-carboxy-1,4-naphthoquinone.  However, a newly synthesized 
substrate 6-carboxy-1,4-naphthoquinone did get consumed as apparent by slowly disappearing 
peaks in NMR spectra.  These results prove that a carboxyl group on the 6th carbon of 
naphthoquinone structure is essential for menaquinone biosynthesis in H. pylori.  However, due to 
not being able to extract the reaction product, we could not demonstrate whether 6-carboxy,1-4-
naphthoquinone is indeed the substrate of HpUbiD, or a prenylation step by HpUbiA (yielding 2-
polyprenyl-6-carboxy-1,4-naphthoquinone) precedes the carboxylation step in the menaquinone 
biosynthesis pathway.   
In chapter 4, we reported the first characterization of FPPS and GGPPS enzymes from a 
helminth parasite Schistosoma mansoni and use of bisphosphonates against schistosomiasis.  
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SmFPPS and SmGGPPS show overlapping substrate specificities and redundancy in their 
functions.  Several bisphosphonates as well as a benzoic acid derivatives inhibited FPPS and 
GGPPS and some of them were potent against ex vivo adult S. mansoni worms. SmFPPS and 
SmGGPPS have some sequence differences to the human orthologs, which could be exploited for 
selective enzyme inhibition and drug development.  However, because of overlapping 
functionality, both FPPS and GGPPS need to be simultaneously inhibited in order to effectively 
kill S. mansoni worms. 
Chapter 5 describes inhibition of FPPS from E. coli and P. aeruginosa by lipophilic 
aromatic bisphosphonates. Novel bisphosphonates containing electron withdrawing aryl 
substituents inhibited E. coli, Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas 
aeruginosa cell growth in the 1-4 µg/mL range. Gram-negative bacterial growth inhibition was 
partially rescued (~8x increase in IC50) by addition of farnesol as well as recombinantly 
overexpressing P. aeruginosa FPPS enzyme in E. coli competent cells.  FICI values of one 
bisphosphonate with fosmidomycin were 0.42 ± 0.17, consistent with an isoprenoid biosynthesis 
target.  This is the first report of bisphosphonates inhibiting gram-negative bacteria with inhibition 
activity in single-digit micromolar range.  Given that antimicrobial resistance is on rise, especially 
with Acinetobacter and Pseudomonas species, this results are of interest in the efforts toward 
developing new antibiotics.  
In chapter 6, we showed that lipophilic benzoic acids with terminal electron-withdrawing 
groups have activity against S. aureus and B. subtilis cell growth.  One of the most potent 
compound had IC50 of 0.15 µg/mL against bacterial cell growth and 0.32 µM against S. aureus 
undecaprenyl pyrophosphate synthase (SaUPPS), as well as 2.7 µM against E. coli undecaprenyl 
pyrophosphate phosphatase (EcUPPP).  It also exhibited synergistic activity with numerous known 
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cell wall biosynthesis inhibitors (FICIavg ~ 0.35, n=13 different cell/inhibitor combinations), but 
an indifferent effect (FICIavg ~1.45, n=11 cell/inhibitor combination) with non-cell wall 
biosynthesis antibiotics.  Most of the compounds were active against SaUPPS, but some also 
inhibited EcUPPP. There were good correlations between cell growth inhibition and UPPS (r = 
0.85) as well as UPPP inhibition (r = 0.84), but UPPS inhibition was more potent. 
In Chapter 7, we reported that lipophilic dihydroxy carboxylic acids and phosphonic acids 
were potent inhibitors of S. aureus and B. subtilis cell growth.  Through synergy/antagonism 
assays, we narrowed down the possible targets to enzymes involved in cell wall biosynthesis.  
These inhibitors were active against S. aureus undecaprenyl diphosphate synthase (SaUPPS) and 
E. coli undecaprenyl diphosphate phosphatase (EcUPPP).  A series of analogs were found to be 
inhibiting UPPS as well as UPPP, and gram-positive cell growth.  A hydroxyphosphonate inhibitor 
exhibited synergistic activity with numerous known cell wall biosynthesis inhibitors (FICIavg ~ 
0.31, n=13 different cell/inhibitor combinations), but an indifferent effect (FICIavg ~1.54, n=11 
cell/inhibitor combination) with non-cell wall biosynthesis antibiotics.  Bacterial growth inhibition 
was partially rescued (~10x increase in IC50) by recombinantly overexpressing EcUPPS enzyme 
in E. coli competent cells.  In the event of rising threat of methicillin-resistant Staphylococcus 
aureus (MRSA), this results are of interest in developing a new anti-Staph antibiotic.   
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Chapter 2 
Structure, Function and Inhibition of Staphylococcus aureus 
Heptaprenyl Diphosphate Synthase 
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2.2 Introduction 
 With the increasing rise in resistance to antibiotics, there is a need for new drug targets, 
and inhibitors.  Isoprenoid biosynthesis is of interest in this context because isoprenoids are 
involved in the production of a diverse range of compounds including sterols, membrane lipids, 
carotenoids, quinones, hemes, as well as in bacterial cell wall biosynthesis (1). Moreover, many 
17 
	
drugs such as statins, azoles, and bisphosphonates, act in these pathways.  Isoprenoid biosynthesis 
in general begins with the condensation of dimethylallyl diphosphate (DMAPP) with two 
molecules of isopentenyl diphosphate (IPP) to produce farnesyl diphosphate (FPP) in a reaction 
catalyzed by farnesyl diphosphate synthase (FPPS) (Figure 2.1) (2).  FPP is then converted to e.g. 
the C55-isoprenoid undecaprenyl diphosphate (involved in cell wall biosynthesis); to virulence 
factors such as staphyloxanthin (Staphylococcus aureus) or tuberculosinyl adenosine 
(Mycobacterium tuberculosis), or to quinones such as menaquinone and ubiquinone, used in 
electron transport.  Many of the enzymes involved in these reactions are present only in bacteria 
and are essential for survival or virulence, so they are drug targets (3-5).  In Staphylococcus aureus, 
the major quinone is menaquinone-7 (MK-7), which contains a C35 side-chain (made from 7 
isoprenoid C5 subunits).  Because S. aureus does not contain ubiquinone (CoQ), menaquinone is 
the only quinone electron transporter (6).  MK-7 is produced by the condensation of 1,4-
dihydroxy-2-naphthoic acid (Figure 2.1) with heptaprenyl diphosphate in a reaction catalyzed by 
MenA (7), and the heptaprenyl diphosphate substrate is produced by the condensation of FPP with 
four molecules of IPP in a reaction catalyzed by heptaprenyl diphosphate synthase (HepPPS, 
Figure 2.1).  HepPPS from S. aureus is a heterodimeric trans-prenyl transferase that consists of a 
regulatory protein (190 residues) and a catalytic protein (319 residues), called here SaHepPPS-1 
and SaHepPPS-2, respectively.  In this work, we report the X-ray structure of the heterodimeric 
protein (SaHepPPS), its activity, its inhibition by a series of compounds, together with the 
inhibition of S. aureus cell growth, growth rescue by menaquinone, as well as synergy assays with 
a range of known antibiotics that help elucidate inhibitor targets.   
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2.3 Results and Discussions  
 Active SaHepPPS is thought to consist of two proteins, SaHepPPS-1 and SaHepPPS-2, so 
we first consider their sequence similarities to other proteins, using bioinformatics.  We then report 
the SaHepPPS structure, its activity, and inhibition.  
Sequence Similarity Network for SaHepPPS 
Sequence similarity networks for HepPPS-1 and HepPPS-2 were generated by using 
enzyme similarity tools in the Enzyme Function Initiative (EFI-EST) (8).  The sequences of close 
relatives were obtained by using BLAST searches (9) and were then used to generate an output 
network in Cytoscape 3.1.0.  Results for the putative regulatory domain (HepPPS-1) and the 
putative catalytic domain (HepPPS-2) are shown in Figures 2.2, 2.3 respectively. There are 3,414 
relevant nodes in the HepPPS-2 network (Figure 2.3), but only 212 in the HepPPS-1 network 
(Figure 2.2).   
As can be seen in Figure 2.3, there are many sequences (from a broad range of organisms) 
with close sequence similarity to SaHepPPS, and the vast majority are annotated as polyprenyl 
diphosphate synthases with ≥ C20 side-chains, many being found in Bacillus species.  Shorter chain 
synthases, such as farnesyl diphosphate synthase (FPPS), are largely absent.  Due to use of a 25% 
sequence identity cut-off, no human genes were identified as close relatives in the HepPPS-2 
network.  However, a BLAST search for SaHepPPS-2 against the Homo sapiens genome did reveal 
one homolog, decaprenyl diphosphate synthase (HsDPPS-1) having a 22% sequence identity as 
calculated using MultiSeq (10).  In contrast, the BLAST analysis revealed no significant sequence 
similarities between SaHepPPS-1 and any human enzymes. This is of particular interest since it is 
desirable to obtain inhibitors which selectively target S. aureus enzymes and as we show below, 
both SaHepPPS-1 and SaHepPPS-2 are essential for SaHepPPS activity. What the SaHepPPS-1 
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network analysis also clearly shows is that the majority of putative regulatory proteins are 
annotated as heptaprenyl diphosphate synthases—not the much more diverse set of polyprenyl 
diphosphate synthases found with the catalytic domain, suggesting the possibility that selective 
inhibition might be possible by targeting the regulatory domain and/or its interaction with the 
catalytic domain.  
Structure of S. aureus Heptaprenyl Diphosphate Synthase 
We next determined the structure of the heterodimeric protein, SaHepPPS.  We crystallized 
the protein and solved its structure as described in Methods and Materials. Full data acquisition 
and refinement details are given in Table 2.1. The HepPPS (HepPPS-1 plus HepPPS-2) structure 
is shown in Figure 2.4A and contains two Asp-rich motifs (the first Asp-rich motif (FARM) 
DDVID and the second Asp-rich motif (SARM) DDVLD) involved in catalysis, shown by the red 
spheres, and as expected for a head-to-tail trans-prenyl transferase, the catalytic domain is highly 
helical. Using the SSM server (11), we find that the closest known structure is that of hexaprenyl 
diphosphate synthase from Micrococcus luteus (PDB:3AQB) (12) where there is a 1.27 Å Cα 
RMSD for the catalytic domain (over 304 residues) and a 2.33 Å Cα RMSD for the regulatory 
domain (over 128 residues) (13). Structural superpositions of the two proteins are shown in Figure 
2.4B. The catalytic domains are clearly more similar than are the regulatory domains, but also of 
interest, there are a cluster of highly conserved residues (pink spheres, Figure 2.5) that lie at the 
interface between the two proteins. Partial sequence alignments of the regulatory proteins (Figure 
2.6A) and catalytic proteins (Figure 2.6B) annotated as heptaprenyl and hexaprenyl diphosphate 
synthases from S. aureus, S. haemolyticus, S. epidermidis, Streptococcus pneumoniae, Bacillus 
subtilis, and Micrococcus luteus reveal that 9 out of a total of 13 residues that are conserved in the 
regulatory proteins are located at the interface of HepPPS-1 and HepPPS-2. Also, as expected, the 
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majority of the conserved residues in the catalytic subunits are either at the interface, or are in 
close proximity to the substrate binding sites (FARM and SARM). So, even though there is low 
overall sequence homology between the different regulatory proteins, most of the residues that are 
conserved are located at the interface and are close to conserved (non-active site) residues in the 
catalytic proteins, implying that they play an important role in catalysis. 
We then sought to see how the SaHepPPS monomer structures compared with the 
structures of a broad range of other prenyl synthases by using QH (14) scores obtained by using 
the MultiSeq program (10).  The QH score is a structural homology score that attempts to account 
for errors in structural alignments when the numbers of residues in target and query proteins differ. 
Homologous proteins have QH>0.4.  When QH has a low value (0.1–0.3), structures are considered 
to have low homology. As can be seen in Figure 2.7A, the regulatory protein SaHepPPS-1 clusters 
with the M. luteus protein, MlHexPPS-1, but the cluster is isolated and the QH = 0.31 value 
indicates low homology. On the other hand, the catalytic domain of SaHepPPS-2 is very highly 
homologous (QH = 0.80) to that found in M. luteus HexPPS-2 (Figure 2.7B), and is also clustered 
with other long-chain (C40, C50) prenyl transferases. These observations reinforce the idea that 
SaHepPPS-1 has an unusual structure.   
Enzyme Kinetics and Substrate Inhibition 
We next investigated the kinetics of SaHepPPS catalysis, and its inhibition. In SaHepPPS, 
we find that the two components are not active individually, but form a heterodimeric complex 
that is catalytically active in the presence of IPP, FPP and Mg2+.  Proteins that were separately 
expressed using the pET-28a vector had the same activity as proteins co-expressed using the 
pRSFDuet-1 vector. As detailed in Methods and Materials, we used a coupled assay in which 
diphosphate released in isoprenoid biosynthesis is converted by pyrophosphatase (baker’s yeast) 
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to monophosphate, which in the presence of purine nucleotide phosphorylase (PNP) converts 7-
methyl-6-thioguanosine to 7-methyl-6-thioguanine (E = 11,000 M–1•cm–1 at 360 nm), and the rate 
of increase in absorbance at 360 nm is taken to reflect the rate of HepPPS synthesis (15).  
The observation that the two individual HepPPS components were inactive individually, 
but were active when mixed, is basically as observed with MlHexPPS (12) and other heterodimeric 
prenyl synthases (16).  However, the activity of the SaHepPPS heterodimeric complex at high 
substrate concentrations deviated very considerably from the hyperbolic dependence of velocity 
on substrate concentration seen with most enzymes, decreasing with increases in either IPP or FPP 
substrate concentration.  One possible explanation for this behavior is formation of a ternary 
substrate-enzyme-substrate (SES) complex in which a second molecule of substrate binds to the 
ES complex, forming an inactive, ternary SES complex (17). The rates of reaction observed with 
the active SaHepPPS heterodimer as a function of IPP and FPP substrate concentrations are shown 
in Figure 2.8.  If this mechanism of substrate inhibition (i.e.  negative feedback) is correct, then 
the effect of second substrate binding (and SES complex formation) on activity will be given by 
the following equation, where Kd represents the dissociation constant for the inhibitory SES ternary 
complex: 𝑉 = 𝑉#$%1 + 𝐾#𝑆 + 𝑆𝐾*  
As shown in Figure 2.8, we estimated the Km and Kd values by splitting the velocity 
function domain at the maximum, because at low substrate concentrations HepPPS follows 
Michaelis-Menten kinetics (Figures 2.8A, 2.8B). The results suggest strong substrate inhibition, 
in particular with FPP.  As can be seen in Figures 2.8C, 2.8D, the experimental results for both 
IPP as well as FPP inhibition (at high concentrations) can be very well fitted by using the above 
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equation using a Kd of 300 ± 40 µM for IPP, and 35 ± 5 µM for FPP (Table 2.2). We interpret these 
results to indicate that—at high concentrations—both FPP as well as IPP may bind to the 
regulatory protein, SaHepPPS-1, and indeed, Suzuki et al. have found, using atomic force 
microscopy, that FPP can bind to the regulatory domain in a Bacillus subtilis HepPPS (18).  It is 
thus possible that at high levels, FPP may disrupt the HepPPS-1/HepPPS-2 protein-protein 
interaction required for catalysis. There might also, in principle, be feedback inhibition by HepPP 
(or other, not fully-elongated) products. However, this latter possibility seems unlikely since the 
longer (C20) chain species geranylgeranyl diphosphate (GGPP) did not exhibit the same substrate-
inhibition effect at high concentrations, having a lower Vmax and a much larger Km (Vmax = 2.2 
µM/min and Km = 652 µM) than did FPP (Figure 2.9). As controls, we also investigated whether 
high FPP and IPP levels might inhibit the coupling enzymes (phosphatase and purine nucleoside 
phosphorylase), but as can be seen in Figure 2.10, this is not the case.  It thus appears that FPP 
may play a role in regulating menaquinone biosynthesis in S. aureus. 
SaHepPPS Inhibition by Other Compounds 
We next investigated a series of compounds that in earlier work were found to inhibit a 
diverse range of prenyl synthases since one of the objectives of our work is to find new drug leads 
with new targets.  The structures of the 55 compounds tested are given in Figure 2.11 and their 
syntheses and characterization were previously reported (19-25). Of the several families of 
compounds tested—benzoic acids, sulfonic acids, diketo acids, bisphosphonates, and dicationic 
species—only the lipophilic bisphosphonates were active. Representative dose-response curves 
for imidazolium and pyridinium bisphosphonates are shown in Figures 2.12A, B, and Table 2.3 
shows more extensive data for zoledronate and 28 analogs (containing 1-H or 1-OH groups, and 
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varying N-alkyl substituents). The effects of chain length on activity for both 1-H and 1-OH 
analogs are illustrated in Figures 2.13A, B. 
What is clear from the results shown in Figure 2.13 (and Table 2.3) is that the most potent 
inhibitors have ~C6-C8 side-chains, which results in an overall length of ~22 Å, about that of the 
FPP substrate (~24 Å). Surprisingly, zoledronate itself (and its short N-alkyl chain-containing 
analogs) had very little activity with IC50 values of ~100 µM. Zoledronate has potent activity (<1 
µM) against human FPPS (26) as well as a (bifunctional) Plasmodium geranylgeranyl diphosphate 
synthase (P. vivax GGPPS) (20) and both of these proteins have similar folds. However, 
zoledronate has much less activity against human GGPPS due, it has been suggested, to the lack 
of the third Asp in the second aspartate rich motif (DDYAN) that coordinates to Mg2+ in the 
catalytic site (27).   So, the pattern of inhibition activity we observe is far more similar to that 
found in human GGPPS than in human FPPS or PvGGPPS. We also find that the lipophilic 
bisphosphonates are competitive inhibitors of HepPPS (Figure 2.14A).  As shown in Figure 2.14B, 
the reaction rate is significantly slowed down in the presence of 1 µM 1216 (a 1-H analog of 
zoledronate with a C6 side chain).  Plus, the reaction rate does not increase at higher FPP 
concentrations, due to the substrate-induced inhibition discussed above. 
Effects of Bisphosphonate Inhibitors on S. aureus Cell Growth 
We next tested zoledronate and 28 analogs against S. aureus cell growth.  14 out of 28 
inhibitors showed modest activity with a similar chain-length dependency to that seen with 
SaHepPPS enzyme inhibition with the most active inhibitors (IC50 ~ 7-10 µg/mL) being the C8-
C12 N-alkyl analogs. Dose-response curves for the 14 bisphosphonates inhibiting S. aureus cell 
growth are shown in Table 2.3.  As can be seen in Figure 2.15A, there is a good correlation between 
the pIC50 (= –log10 IC50 [µM]) values for SaHepPPS and S. aureus cell growth inhibition (a Pearson 
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r-value correlation-coefficient r = 0.91).  This is suggestive that HepPPS might be a target, but 
there could be other targets, for example enzymes such as farnesyl diphosphate synthase (which is 
known to be inhibited by bisphosphonates), undecaprenyl diphosphate synthase (involved in cell 
wall biosynthesis and inhibited by some bisphosphonates) as well as MenA, another enzyme 
involved in quinone biosynthesis.   
To test whether FPPS or UPPS inhibition was likely contributing to S. aureus cell growth 
inhibition, we investigated synergistic interactions with a series of known drugs that target, or do 
not target, bacterial cell wall biosynthesis since synergistic activity would be expected with FPPS 
or UPPS inhibitors (28). We carried out 12 fractional inhibitory concentration index (FICI) 
determinations using one of the most potent bisphosphonates 10 (IC50 = 7 µg/mL) together with 
either a known antibacterial isoprenoid/cell wall biosynthesis inhibitor (fosmidomycin, 
carbenicillin, vancomycin, ampicillin, bacitracin, cefotaxime, fosfomycin) or an antibacterial 
compound that does not target these pathways (kanamycin, tetracycline, chloramphenicol, 
spectinomycin, sulfamethoxazole, trimethoprim). We obtained FICI values for each combination 
using the FICI formula (29, 30): 
𝐹𝐼𝐶𝐼 = 𝐹𝐼𝐶. + 𝐹𝐼𝐶/ = 𝑀𝐼𝐶(𝐴𝐵)𝑀𝐼𝐶(𝐴) + 𝑀𝐼𝐶(𝐵𝐴)𝑀𝐼𝐶(𝐵)  
where FICA and FICB are fractional inhibitory concentrations of drugs A and B, MIC(A) and 
MIC(B) are the MIC values of drugs A and B acting alone, and MIC(AB) and MIC(BA) are the 
MIC values of the most effective combination of drug A or B in the presence of drug B and A. 
FICI values of <0.5 are taken to represent synergy, >0.5 and <1.0 represent additivity, >1 and <2 
represent an indifferent effect, and ≥2 represents antagonism (31). In addition, we evaluated 
isobolograms (32).  FICI values are shown in Table 2.4 and selected isobolograms are in Figure 
2.16.  We actually obtained data on two organisms: B. subtilis, chosen because it utilizes the non-
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mevalonate (MEP) pathway and is inhibited by fosmidomycin (which targets 1-deoxy-D-xylulose-
5-phosphate reductoisomerase, DXR) as well as of course S. aureus, which uses the mevalonate 
pathway. The results shown in Table 2.4 show that in both organisms, there is—in almost all—
cases an indifferent interaction with all drugs in combination with 10 (FICIavg = 1.43 ± 0.37, n = 
24). The only exception is with fosmidomycin where there is a synergistic interaction, albeit in B. 
subtilis (FICI = 0.29 ± 0.094, Figure 2.16). The synergy between fosmidomycin and 10 but an 
absence of synergies with other cell wall biosynthesis inhibitors rules out FPPS and UPPS as 
targets since the cell wall biosynthesis inhibitors used would be expected to act in synergy with 
FPPS or UPPS inhibitors. However, HepPPS and MenA remain as possible candidates because 
fosmidomycin targets 1-deoxy-D-xylulose 5-phosphate reductoisomerase, reducing FPP levels 
and thence, HepPP biosynthesis.  
We next tested whether S. aureus cell growth inhibition was “rescued” by addition of 
menaquinone-7 (MK-7). As can be seen in Figure 2.15B, we investigated the effects of 200 µM 
MK-7 on S. aureus growth inhibition by the two most potent inhibitors finding that there was, on 
average, an ~8x increase in the IC50 for cell growth inhibition, consistent with an HepPPS target. 
Unfortunately, this is not a proof of HepPPS being a singular target since we also find that 23 
inhibits MenA (from E. coli) with an IC50 of ~10 µM (Figure 2.17), and MK-7 should show a 
similar rescue effect if SaMenA were being targeted.  
 
2.4 Conclusions 
The results we have described above are of significance for several reasons. We obtained 
the first structure of Staphylococcus aureus heptaprenyl diphosphate synthase, HepPPS, an anti-
infective drug target. The protein crystallizes as a heterodimer containing a catalytic (HepPPS-2) 
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as well as a regulatory (HepPPS-1) chain. In addition to the highly conserved (DDXXD) residues 
in the catalytic protein we found 22 highly conserved residues that exist at the interface between 
the two subunits.  HepPPS was only catalytically active when both subunits were present and we 
found substrate inhibition with FPP with a Kd ~ 35 µM. We also discovered several µM inhibitors, 
N-alkyl zoledronate analogs, whose activity was dependent on alkyl side-chain length with Ki as 
low as ~200 nM. These compounds had modest activity against S. aureus cell growth (best IC50 = 
7 µg/mL), which was partially rescued by menaquinone-7.  These inhibitors acted synergistically 
with fosmidomycin but not with other known cell-wall-targeting antibiotics, indicating that FPPS 
and UPPS are not being targeted.  This is consistent with an HepPPS target although since we also 
find activity against a MenA (from E. coli), multi-site targeting is possible. Since SaHepPPS has 
high structural homology only to M. luteus hexaprenyl diphosphate synthase, not the more 
common trans-prenyl transferases such as human FPPS and GGPPS, this opens up the possibility 
of future in silico screening targeting both the catalytic and regulatory domains to find selective 
SaHepPPS inhibitors as new drug leads.  
 
2.5 Methods and Materials  
Materials  
The synthesis and characterization of FPP, IPP, and the 55 potential inhibitors were 
reported previously (19–25). Purine nucleoside phosphorylase (PNP) and pyrophosphatase 
(inorganic, baker’s yeast) were purchased from Sigma-Aldrich (St. Louis, MO).  7-Methyl-6-
thioguanosine (MESG) was purchased from Berry Associates (Dexter, MI).  pET28a, pRSF-
Duet1, pET46, and pET15b vectors were purchased from Novagen.  Escherichia coli BL21-
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CodonPlus (DE3)-RIPL cells were obtained from Agilent Technologies (Santa Clara, CA).  
Isopropyl-β-D-thiogalactopyranoside (IPTG) was from Gold Biotechnology (St. Louis, MO).   
Clones and Plasmids 
Staphylococcus aureus genomic DNA (ATCC, #700699) was used to amplify the gene 
sequences of the two components of HepPPS.  PCR amplification of HepPPS-1 and HepPPS-2 
was accomplished using gene-specific (IDT, Coralville, IA) primers designed from sequences 
identified in the S. aureus genome.  HepPPS-1 forward 5’-
GCCGCTAGCATGGAAACAACTGTTAGCAAATTGGAAAGACAAATA GAAGAAAGA 
and HepPPS-1 reverse 5’-GCCCTCGAGTAATTACCTCTACTTTTTAAATAACTTTTTT 
GGATATCGTGTAAGTAATGCTTTACTTCACT were used to amplify the HepPPS-1 
sequence.  HepPPS-2 forward 5’-GCCGCTAGCATGGCAAAGTTAAACATGAACAATG 
AAATTAAGAAAGTGGAACAAC and HepPPS-2 reverse 5’- 
GCCCTCGAGCTATGTGTTTCTTGACCCCATTTTTTTCGTCAAACTTAAAAGTAGT were 
used to amplify the HepPPS-2 sequence.  Both HepPPS-1 and HepPPS-2 amplified sequences 
were incorporated into a pET28-a vector (Novagen, #69864-3).  For co-expression of both 
components, HepPPS-1 forward 5’- GCCGGATCCCTGGTGCCGCGCGGCAGCATGGAA 
ACAACTGTTAGCAAATTGGAAAGACAAATAGAAGAAAGA, HepPPS-1 reverse 5’- 
GCCGCGGCCGCTAATTACCTCTACTTTTTAAATAACTTTTTTGGATATCGTGTAAGTA
ATGCTTTACTTCACT, HepPPS-2 forward 5’-GCCAGATCTATGGCAAAGT 
TAAACATGAACAATGAAATTAAGAAAGTGGAACAAC, and HepPPS-2 reverse 5’- 
GGCCTCGAGCTGGGCCGCGCGGCAGCTGTGTTTCTTGACCCCATTTTTTTCGTCAAAC
TTAAAAGTAGT primers were used.  HepPPS-1 and HepPPS-2 genes were incorporated into 
multi-cloning sites 1 and 2 of a pRSFDuet-1 vector (Novagen, #71341-3), respectively, with 
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thrombin cleavage site-containing linker sequences (DPLVPRGS) inserted between the N-
terminal His6-tag and HepPPS-1, and between the C-terminal S-tag and HepPPS-2.  The cloned 
products were transformed into E. coli BL21-CodonPlus (DE3)-RIPL cells, plated on LB 
containing 50 µg/mL kanamycin and 34 µg/mL chloramphenicol, and cultured overnight at 37°C 
to select kanamycin/chloramphenicol resistant clones, which were then confirmed by DNA 
sequencing (ACGT Inc., Wheeling, IL).   
Recombinant Protein Expression and Purification 
A single colony was used to inoculate 100 mL of LB broth containing 50 µg/mL kanamycin 
and 34 µg/mL chloramphenicol at 37°C, overnight.  The overnight culture was transferred to six 
1 L flasks of LB broth containing the same antibiotic concentrations.  Flasks were shaken at 200 
RPM at 37°C until the OD600 reached ~0.5.  Recombinant protein expression was induced with 
1mM IPTG and cells were incubated at room temperature, overnight.  Cells were then harvested 
by centrifugation at 10,800 ×g for 10 minutes.  Protein was obtained by lysing the cells by three 
freeze-thaw cycles, followed by sonication for 6 minutes.  Cell lysates were centrifuged at 
57,200×g for 30 minutes. Recombinant proteins were purified from the supernatant by Ni-NTA 
affinity chromatography using 10 mM HEPES, pH 7.5 buffer containing 500 mM NaCl, 35 mM 
imidazole, then eluted with increasing concentrations of imidazole in a gradient (35 mM to 500 
mM) in the same buffer.  The purified protein fractions were run on a 4-20% SDS polyacrylamide 
gel to ascertain size and purity. SaHepPPS-1 had an apparent MW of 22 kDa and SaHepPPS-2 had 
an apparent MW 36 kDa.  
For co-expression of the two components using the pRSFDuet-1 vector, basically the same 
protocol was used except that the kanamycin concentration was reduced to 30 µg/mL, and protein 
expression was induced with 0.3 mM IPTG.  For purification of co-expressed proteins, 20 mM 
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HEPES, pH 7.0 buffer containing 150 mM NaCl, 2 mM CHAPS, 10 mM β-mercaptoethanol, 35 
mM imidazole, 6% glycerol was used, and protein was eluted with increasing concentrations of 
imidazole in a gradient (35 mM to 500 mM) in the same buffer.  SaHepPPS-1 was cloned with a 
His6-tag and SaHepPPS-2 with an S-tag, however, Ni-NTA affinity chromatography alone was 
sufficient to purify both enzymes in the heterodimeric structure because of strong intermolecular 
binding affinity.  
For the crystallization experiments, the HepPPS-1 gene was inserted into an ampicillin 
resistant pET46 EK/LIC (Novagen) by using an EK/LIC cloning kit, creating a pET46-HepPPS-1 
construct which expressed HepPPS-1 with an N-terminal His6-tag. The HepPPS-2 gene was 
inserted into a kanamycin resistant pET28a (Novagen) and the pET28a-HepPPS-2 construct 
expressed HepPPS-2 without any tag. Both plasmids were transformed into E. coli BL21(DE3) 
cells and target proteins were expressed by inducing with IPTG.  Cells overexpressing HepPPS-1 
and HepPPS-2 were mixed and harvested by centrifugation at 5,000×g for 20 minutes. The mixed 
cells were re-suspended in lysis buffer containing 50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10 
mM imidazole and 10% glycerol.  Cells were disrupted by a French press and the debris removed 
by centrifugation at 17,000×g for 1 hour. The supernatant was then loaded onto a Ni-NTA column. 
HepPPS-1 and HepPPS-2 formed a complex and the target proteins eluted at ~150 mM imidazole. 
The purified protein fractions were run on a 4-12% SDS-PAGE to ascertain size and purity. The 
complex showed two bands: at 22 kDa for SaHepPPS-1 and at 36 kDa for SaHepPPS-2.  Proteins 
were concentrated to 1 mL and applied to a size exclusion column (Sephacryl S-200 26/60, 320 
mL, GE Healthcare) equilibrated with buffer (25 mM Tris-HCl, pH 7.5, 150 mM NaCl) at a flow 
rate of 1 mL/min. Unknown proteins, HepPPS complex, and HepPPS-1 showed three peaks on the 
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elution profile. The second peak contained the HepPPS complex. The purified proteins were then 
concentrated to 5 mg/mL in 25 mM Tris-HCl, pH 7.5, 150 mM NaCl buffer. 
Crystallization, Data Collection, Structure Determination and Refinement 
SaHepPPS crystals were obtained using the No. 40 solution of the PEG/Ion 2 screen kit 
(Hampton Research) (0.03 M citric acid, 0.07 M bis-tris propane / pH 7.6, 20% w/v polyethylene 
glycol 3350) using the sitting-drop vapor method.  In general, 1 µL 5 mg/mL SaHepPPS was mixed 
with 1 µL of reservoir solution in 48-well Cryschem plates, then equilibrated against 100 µL of 
the reservoir at 25°C. Within 3 days, the crystals reached dimensions suitable for X-ray diffraction. 
X-ray diffraction datasets were collected at beam lines BL13B1, BL13C1, and BL15A1 of the 
National Synchrotron Radiation Research Center (NSRRC, Hsinchu, Taiwan) and were processed 
by using the HKL2000 program (33).  Prior to structure refinement, 5% randomly selected 
reflections were set aside for calculating Rfree as a monitor of model quality (34).  The SaHepPPS 
structure was solved by using molecular replacement (MR) using the crystal structure of 
hexaprenyl diphosphate synthase from Micrococcus luteus B-P 26, which shares 44% identity with 
SaHepPPS-2 (PDB:3AQB), as template. Model building was carried out by using Coot (35). 
Refinement employed PHENIX (36) or REFMAC (37).  The final MR model gave R and Rfree 
values of 0.24 and 0.29 respectively at 2.68 Å resolution after refinement against the native 
SaHepPPS dataset using the CNS program (38) All graphics for the protein structures were 
prepared by using the PyMOL program (http://pymol.sourceforge.net/.) 
Enzyme Kinetics and Inhibition 
All putative inhibitors were prepared in 10 mM stock solutions in either DMSO or sodium 
carbonate buffer, and were then serially diluted in a gradient from 1 mM to 1 nM.  Inhibitors were 
incubated with 25 µg of co-expressed enzymes at room temperature for 10 minutes in assay buffer 
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(10 mM HEPES, 150 mM NaCl, 1 mM MgCl2, pH 7.5) before adding “reaction mixture” 
containing 20 µM FPP, 80 µM IPP, 3 U/mL purine nucleoside phosphorylase, 1 U/mL 
phosphatase, and ~ 600 µM MESG, again in the assay buffer.  Reactions were monitored for 15 
minutes.  The rate of increase in absorbance at 360 nm was taken as the rate of HepPP synthesis.  
The 50% inhibitory concentration (IC50) values were calculated by using Prism 5 (GraphPad 
Software, Inc., La Jolla, CA). 
MenA Inhibition Assay 
The MenA inhibition assay was carried out as described previously (39). 
S. aureus and B. subtilis Growth Inhibition Assay 
IC50 values for S. aureus cell growth inhibition were determined by using a microdilution 
method. An overnight starter culture of S. aureus (Newman strain) in tryptic soy broth was diluted 
1000-fold in fresh tryptic soy media to create a “working solution”.  200 µL of working solution 
was transferred into each well of a 96-well culture plate (Corning 3370). Inhibitors were then 
added at 1 mM and sequentially diluted 3× to 46 nM, keeping volume and culture broth 
composition constant.  Plates were incubated for 12 hours at 37°C, shaking at 200 RPM, then 
absorbance at 600 nm was measured to assess bacterial cell growth. IC50 values were determined 
using nonlinear regression whereas minimum inhibitory concentration (MIC) values in the synergy 
assays were calculated by using a Gompertz function in Prism 5 (GraphPad Software, Inc., La 
Jolla, CA). For the B. subtilis cell growth inhibition assay, an overnight starter culture (in LB 
broth) of B. subtilis (subsp. subtilis (Ehrenberg) Cohn ATCC 6051) was diluted 1000-fold (in fresh 
LB media) to create a “working solution”. Working solutions were then transferred into flat-
bottom 96-well plates and inhibitors were added at 1 mM and sequentially diluted 3× to 46 nM. 
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Plates were incubated at 37°C, shaking at 200 RPM overnight. The OD600 was then measured to 
determine bacterial growth inhibition. 
Synergy/Antagonism Assays 
In order to investigate possible synergistic interactions between compound 10 and a range 
of antibiotics, we carried out two-drug combination assays.  Bacteria were incubated with a 3× 
gradient of antibiotic typically ranging from 40 µg/mL to 18 ng/mL (200 µg/mL to 90 ng/mL for 
bacitracin, fosfomycin, and sulfamethoxazole) in the presence of half-MIC concentrations of 10, 
in addition to a 3× gradient of 10 ranging from 40 µg/mL to 18 ng/mL in the presence of half-MIC 
concentrations of each antibiotic.  New MIC values were calculated by using a Gompertz function 
in Prism 5 (GraphPad Software, Inc., La Jolla, CA). 
  
33 
	
2.6 Tables and Figures 
 
Table 2.1      Data collection and refinement statistics for S. aureus HepPPS (wild-   
type) crystals. 
PDB code 5H9D 
Data Collection Refinement 
space group C2221 no. of reflections 33531 (2743) 
unit-cell Rwork[a] (95% of data) 0.244 (0.324) 
a [Å] 137.394 Rfree[a] (5 % of data) 0.287 (0.359) 
b [Å] 137.642 r.m.s.d. bonds [Å] 0.011 
c [Å] 144.05 r.m.s.d. angles [º] 1.718 
α /β /γ (°) 90.00/90.00/90.00 dihedral angles 
resolution [Å] 25-2.68 (2.78-2.68) most favored [%] 85.7 
unique reflection 35313 (3582) allowed [%] 8.9 
redundancy 5.0 (5.0) disallowed [%] 5.4 
completeness [%] 92.0 (94.3) # non-H atoms / average B [Å2] 
average I/σ(I) 38.07 (3.59) Protein 8446 / 76 
Rmerge[a] [%] 5.2 (48.0) Water 118 / 67 
  Ion 20 / 120 
Values in parentheses are for the highest resolution shell. 
aRmerge = ∑hkl∑i|Ii(hkl)-<I(hkl)>| / ∑hkl∑iIi(hkl) 
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Table 2.2     Kinetic parameters of S. aureus heptaprenyl diphosphate synthase. Kd represents 
the dissociation constant of substrate-enzyme-substrate complex. 
Substrate Km (µM) Vmax (µM/min) SES Kd (µM) 
FPP 11 ± 2.0 4.7 ± 0.26 35 ± 4.9 
IPP 41 ± 7.4 3.8 ± 0.18 303 ± 42 
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Table 2.3 IC50 (µM) values of 55 compounds inhibiting S. aureus heptaprenyl diphosphate 
synthase and S. aureus cell growth. 
Cpd 
HepPPS 
IC50 
(µM) 
S. aureus 
IC50 
(µM) 
Cpd 
HepPPS 
IC50 
(µM) 
S. aureus 
IC50 
(µM) 
Cpd 
HepPPS 
IC50 
(µM) 
S. aureus 
IC50 
(µM) 
1 136 – 22 2.6 – 43 >100 – 
2 154 – 23 4.7 18 44 >100 – 
3 96 23 24 6.7 26 45 >100 – 
4 42 – 25 9.1 52 46 >100 – 
5 0.83 – 26 7 55 47 >100 – 
6 1.6 – 27 53 290 48 >100 – 
7 3.2 19 28 77 230 49 >100 – 
8 2.7 51  29 113 330  50 >100 – 
9 1.1 21 30 2 – 51 >100 – 
10 6.6 16 31 1 – 52 >100 – 
11 17 53 32 2 – 53 >100 – 
12 72 240 33 166 – 54 >100 – 
13 117 – 34 57 – 55 >100 – 
14 84 – 35 82 –    
15 82 – 36 >100 –    
16 139 – 37 >100 –    
17 120 – 38 >100 –    
18 99 – 39 >100 –    
19 52 – 40 >100 –    
20 5.2 – 41 >100 –    
21 1.2 – 42 >100 –    
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Table 2.4      Effects of combinations of 10 and known antibiotics against B. subtilis and S. aureus 
cell growth. 
B. subtilis 
 Antibiotic MIC antibiotic  (µg/mL) 
FIC  
antibiotic 
MIC 
1329 
(µg/mL) 
FIC 1329 FIC Index 
Cell Wall 
Biosynthesis 
Inhibitors 
Fosmidomycin 5 0.17 ± 0.041 42 0.12 ± 0.053 0.29 ± 0.094 
Carbenicillin 5 0.41 ± 0.047 42 0.70 ± 0.37 1.11 ± 0.42 
Cefotaxime 2.5 0.39 ± 0.045 42 0.51 ± 0.21 0.90 ± 0.25 
Vancomycin 0.5 0.82 ± 0.18 42 0.43 ± 0.16 1.25 ± 0.34 
Fosfomycin 200 0.11 ± 0.024 42 0.89 ± 0.37 1.00 ± 0.40 
Ampicillin 0.5 0.54 ± 0.10 42 0.95 ± 0.40 1.49 ± 0.51 
Bacitracin 200 0.73 ± 0.19 42 0.93 ± 0.40 1.66 ± 0.59 
Protein 
Biosynthesis 
Inhibitors 
Kanamycin 1.5 0.79 ± 0.16 42 0.92 ± 0.39 1.71 ± 0.55 
Tetracycline 5 0.70 ± 0.25 42 0.78 ± 0.30 1.48 ± 0.55 
Chloramphenicol 0.5 0.59 ± 0.13 42 0.99 ± 0.40  1.58 ± 0.54 
Nucleic Acid 
Inhibitors 
Sulfamethoxazole 200 0.69 ± 0.21 42 1.05 ± 0.16 1.73 ± 0.37 
Trimethoprim 0.5 0.87 ± 0.18 42 0.78 ± 0.52 1.66 ± 0.52 
       
S. aureus 
 Antibiotic MIC antibiotic  (µg/mL) 
FIC  
antibiotic 
MIC 
1329 
(µg/mL) 
FIC 1329 FIC Index 
Cell Wall 
Biosynthesis 
Inhibitors 
Carbenicillin 15 0.55 ± 0.017 42 0.97 ± 0.36 1.51 ± 0.38 
Cefotaxime 2 0.66 ± 0.062 42 0.95 ± 0.42 1.62 ± 0.48 
Vancomycin 1.5 0.55 ± 0.022 42 0.50 ± 0.19 1.05 ± 0.21 
Fosfomycin 200 0.81 ± 0.13 42 0.94 ± 0.35 1.75 ± 0.48 
Ampicillin 0.5 0.85 ± 0.18 42 0.55 ± 0.30 1.40 ± 0.48 
Bacitracin 200 0.65 ± 0.14 42 0.43 ± 0.17 1.08 ± 0.31 
Protein 
Biosynthesis 
Inhibitors 
Kanamycin 1.5 0.92 ± 0.30 42 0.92 ± 0.47 1.84 ± 0.77 
Tetracycline 0.5 0.74 ± 0.35 42 1.10 ± 0.46 1.85 ± 0.81 
Chloramphenicol 5 0.71 ± 0.12 42 0.90 ± 0.36 1.61 ± 0.48 
Spectinomycin 40 0.68 ± 0.25 42 0.84 ± 0.40 1.52 ± 0.65 
Nucleic Acid 
Inhibitors 
Sulfamethoxazole 200 0.75 ± 0.20 42 1.02 ± 0.44 1.77 ± 0.63 
Trimethoprim 15 0.69 ± 0.32 42 0.73 ± 0.30 1.42 ± 0.62 
             
Mean  
FICIs: 
B. subtilis 
inhibitors targeting cell wall biosynthesis 1.10 ± 0.45 
inhibitors targeting nucleic acids and protein biosynthesis 1.63 ± 0.10 
S. aureus 
inhibitors targeting cell wall biosynthesis 1.40 ± 0.29 
inhibitors targeting nucleic acids and protein biosynthesis 1.67 ± 0.18 
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Figure 2.1 Schematic illustration of the biosynthesis of several isoprenoids in Staphylococcus 
aureus.  Condensation of one DMAPP and two IPP to produce FPP is carried out by FPPS. 
Condensation of 8 IPP with FPP yields a C55-isoprenoid, undecaprenyl diphosphate, which is an 
essential intermediate in the cell wall biosynthesis pathway. Sequential condensation of FPP with 
4 IPP yields heptaprenyl diphosphate, which then alkylates dihydroxynaphthoic acid in a reaction 
catalyzed by MenA to generate demethylmenaquinone (DMK-7), an intermediate in menaquinone  
biosynthesis.  
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Figure 2.2 Sequence similarity network based on regulatory domain (SaHepPPS-1) sequence 
constructed with E=10-50.  Major clusters are: 1, HepPPS from Staphylococcus spp.; 2, HepPPS 
from Geobacillus spp.; 3, HepPPS from Paenibacillus spp.; 4, HepPPS from Bacillus spp.; 5, 
ParB-like protein from Burkholderia and Ralstonia spp.; 6, HepPPS from Anoxybacillus spp.; 7, 
HepPPS from Planomicrobium spp.; 8, tyrosine recombinase from Rhodopirellula spp.; 9, 
peptidase from Prevotella spp.; 10, HexPPS from Micrococcus spp.  
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Figure 2.3 Sequence similarity network based on the catalytic domain (SaHepPPS-2) 
sequence constructed with an E=10-70.  Major clusters are:  1, HepPPS and polyprenyl 
pyrophosphate synthase (PPPPS) from Bacillus, Staphylococcus and sulfate reducing bacteria; 2, 
HepPPS and PPPPS from Lactococcus, Enterococcus, Streptococcus, and Lactobacillus spp.; 3, 
PPPPS from Selanomonas, Thermosinus and Paelosinus spp.; 4, eukaryotic DPPS from 
Drosophila and Polysphondylium spp.; 5, solanesyl pyrophosphate synthase (SPPS) from 
eukaryotes and bacteria, plant species and Cyanobacteria; 6, octaprenyl pyrophosphate synthase 
(OPPS) from soil bacteria and Pseudomonas spp.; 7, PPPPS from flavobacteria, Prevotella and 
Bacteriodes spp.; 8, FPPS and GGPPS from methanogenic archaea, 9, GGPPS and PPPPS from 
Streptomyces, Micrococcus and Mycobacterium spp.; 10, GGPPS from sulfate reducing 
Desulfitobacteria spp.   
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Figure 2.4 X-ray structures of heptaprenyl and hexaprenyl diphosphate synthases.   
A.  Structure of the dimeric protein SaHepPPS (PDB:5H9D) where HepPPS-1 is shown in teal. 
and HepPPS-2 is shown in yellow. The FARM and SARM Asp-rich motifs in the active site are 
shown as red spheres and are in the HepPPS-2 catalytic protein.   B. Superimposition of 
SaHepPPS (cyan, PDB:5H9D) and MlHexPPS (green; PDB:3AQB) structures.   
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Figure 2.5  View of the highly conserved residues (in pink) that are located at or near the 
interface between SaHepPPS-1 (teal) and SaHepPPS-2 (yellow); FARM/SARM motifs are shown 
in red. The conserved residues at or near the interface were deduced from the ClustalW alignments. 
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Figure 2.6 ClustalW alignments of regulatory and catalytic proteins in heptaprenyl and 
hexaprenyl diphosphate synthase heterodimers.  A.  S. aureus, S. epidermidis, S. haemolyticus, S. 
pneumoniae, B. subtilis, and M. luteus HepPPS-1 and HexPPS-1 sequences.  Conserved residues 
in the interface of the two subunits are shown in orange. This is the regulatory protein.  B.  S. 
aureus, S. epidermidis, S. haemolyticus, S. pneumoniae, B. subtilis, and M. luteus HepPPS-2 and 
HexPPS-2 sequences.  Conserved residues in the interface of the two subunits are shown in orange. 
This is the protein that contains the Asp-rich domains involved in catalysis. 
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Figure 2.7 Results of multiple structural alignment in MultiSeq using QH scores.  PDB ID 
codes are shown for each protein except human decaprenyl pyrophosphate synthase (HsDPPS-1 
and HsDPPS-2), which were predicted using Phyre2 web portal: (40).  A.  Alignment in which 
the regulatory domains of SaHepPPS and M. luteus HexPPS were incorporated.  B.  As part A, 
but incorporating the catalytic domains of SaHepPPS and MlHexPPS. 
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Figure 2.8 Rates of reaction of SaHepPPS as a function of substrate (IPP, FPP) concentration.  
A. Low [IPP].  B. Low [FPP].  C. High [IPP]. D. High [FPP].  
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Figure 2.9 Initial rate of reaction of SaHepPPS as a function of GGPP concentration. 
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Figure 2.10 Rate of formation of 7-methyl-6-thioguanine as a function of IPP and FPP 
concentration: A.  FPP with 200 µM of orthophosphate. B.  FPP with 200 µM of pyrophosphate. 
C.  IPP with 200 µM of orthophosphate. D.  IPP with 200 µM of pyrophosphate. 
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Figure 2.11 Structure of 55 compounds tested against heptaprenyl diphosphate synthase and S. 
aureus cell growth.   
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Figure 2.11 (continued).  
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Figure 2.11 (continued).  
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Figure 2.12 Dose-response curves for HepPPS by bisphosphonates.  A. Dose-response 
curves for SaHepPPS inhibition by 1-H analogs of zoledronate. Structures are shown in Figure 
2.11.  B. Dose-response curves for SaHepPPS inhibition by pyridinium bisphosphonates. 
Structures are shown in Figure 2.11. 
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Figure 2.13 Chain-length dependence of log(IC50) for HepPPS by bisphosphonates.  A. Effects 
of chain length on SaHepPPS inhibition (log IC50) for 1-H analogs of zoledronate.  B. Effect of 
chain length on SaHepPPS inhibition (log IC50) for zoledronate analogs. 
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Figure 2.14 Rate of reaction of HepPPS in the presence of 5 as a function of FPP substrate.   
A. Lineweaver-Burk plot for SaHepPPS in the presence of 1 µM 1216.  B. Enzyme kinetics of 
SaHepPPS in the presence of 1 µM 1216.  
53 
	
Figure 2.15 Identification of targets of bisphosphonates inhibiting S. aureus cell growth.   
A. Correlation between S. aureus cell growth inhibition and SaHepPPS inhibition based on pIC50 
(= -log10IC50 [µM]) results.  B.  Addition of 200 µM menaquinone-7 (MK-7) to the growth medium 
increases the IC50 of 1329 and 1222 for cell growth inhibition by a factor of ~8. 
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Figure 2.16 Identification of targets of bisphosphonates inhibiting bacterial cell growth.   
A. 10+fosmidomycin in B. subtilis showing synergy (FICI=0.27) of 10 with a cell wall 
biosynthesis inhibitor (that targets DXR, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, in 
the nonmevalonate pathway).  B. 10+sulfamethoxazole in B. subtilis showing an indifferent effect 
(FICI=1.73) of 10 with a nucleic acid biosynthesis inhibitor (that targets dihydropteroate synthase).  
C. 10+ampicillin in S. aureus showing an indifferent effect (FICI=1.40) of 10 and a cell wall 
biosynthesis inhibitor (that targets transpeptidase).  D.  10+tetracycline in S. aureus showing an 
indifferent effect (FICI=1.85) of 10 with a protein synthesis inhibitor (that targets ribosome). 
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Figure 2.17  HPLC chromatograms of reaction product (2-farnesyl-1,4-dihydroxy-naphthalene) 
catalyzed by E. coli MenA in the presence of varying concentrations of 23. 
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Chapter 3 
Identification of a Novel Intermediate in the Menaquinone 
Biosynthesis Pathway in Helicobacter pylori 
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Dr. Furong Sun from the Mass Spectrometry Center of the School of Chemical Sciences at 
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Sciences.  I thank Dr. Dean Olson for providing me NMR spectroscopy training.   
 
3.2 Introduction  
More than half of the world population harbor Helicobacter pylori in their upper 
gastrointestinal tract, mainly stomach and duodenum.  While the incidence rate is declining in the 
Western countries, the infection is on rise in developing countries.  Because H. pylori infection is 
not a disease, but a condition mutually associated with ulcer and acidity of upper GI tract, it is 
rarely diagnosed (1).  Majority of upper GI tract disorders like ulcer and heartburn are treated with 
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over-the-counter proton-pump inhibitors (2).  A subset of infected demographic develops gastric 
adenocarcinoma or mucosa-associated lymphoid tissue (MALT) lymphoma due to prolonged 
infection and resulting chronic inflammation, respectively (3).  Current treatment against H. pylori 
infection exists in the form of a one-week long “triple therapy”, where two potentially synergistic 
antibiotics, (clarithromycin and amoxicillin) and one proton-pump inhibitor is used to reduce 
gastric acid production while simultaneously eradicating the H. pylori from the gastric epithelium 
(4).  However, there is a rise of clarithromycin-resistant H. pylori infection, which demands of 
multi-week long “quadruple therapy” involving levofloxacin (5).  In the interest of rising 
antibiotic-resistance, there is a need for new drug targets.  Quinone biosynthesis is of interest in 
this context because they are essential electron transporter in bacteria.   
H. pylori uses menaquinone (vitamin K2) as the only electron transporter (6), but lacks 
MenB, MenC, MenD, MenE, and MenF genes, Figure 3.1 (7).	 	H. pylori utilizes a completely 
different menaquinone biosynthesis pathway (8-10). Orthologs of Men genes (MenA-MenG) 
involved in menaquinone biosynthesis are absent in H. pylori as well as C. jejuni genome, albeit 
these gram-negative bacteria synthesize menaquinone. An alternate pathway existing in H. pylori, 
called futalosine pathway was discovered by Hiratsuka et al., which employs a novel substrate, 6-
carboxy-1,4-naphthoquinone as an intermediate in the menaquinone biosynthesis (7).  The 
futalosine biosynthesis pathway branches out at chorismate, from where MqnA, MqnB, MqnC, 
and MqnD enzymes convert chorismate into 1,4-dihydroxy-6-naphthoic acid (7).  As depicted in 
Figure 3.1, using bioinformatics, four genes namely, UbiA, UbiE, UbiD, and UbiX are speculated 
to be involved in further prenylation, methylation, and decarboxylation reaction respectively, to 
yield an active menaquinone electron transporter.  Recently function of UbiX in Escherichia coli 
and Pseudomonas aeruginosa have been determined.  White et al. reported that UbiX functions as 
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flavin prenyltransferase (11), although this is UbiX function in ubiquinone biosynthesis.  Given 
that H. pylori does not have ubiquinone, and exclusively utilizes menaquinone as electron 
transporter (6), and furthermore E. coli and P. aeruginosa utilize UbiX in the ubiquinone 
biosynthesis pathway (12, 13), UbiX involvement in the alternate menaquinone biosynthetic 
pathway still remains to be deciphered.  Moreover, Payne, et al. reported last year that UbiD from 
Aspergillus niger, a yeast system, utilizes a prenylated flavin (catalyzed by UbiX) cofactor to 
catalyze decarboxylation of cinnamic acid through 1,3-dipolar cycloaddition (14).  Because A. 
niger does not have menaquinone and synthesizes ubiquinone through CoQ family of genes (15), 
function of UbiD in H. pylori must be different than in a yeast system.  In this work, we report the 
first cloning and expression of UbiX and UbiD from a bacterial system and H. pylori UbiX 
(HpUbiX) dependent function of H. pylori UbiD (HpUbiD) in the decarboxylation of 6-carboxy-
1,4-naphthoquinone, a novel substrate in the menaquinone biosynthesis.   
 
3.3 Results and Discussions 
 Two distinct enzymes H. pylori UbiX (HpUbiX) and H. pylori UbiD (HpUbiD) are thought 
to be involved in the decarboxylation of naphthoquinone intermediate in the menaquinone 
biosynthesis pathway.  We first consider their sequence similarities with other UbiX and UbiD 
orthologs, using bioinformatics.  We then characterize HpUbiX and HpUbiD functionalities.  
Sequence Similarity Network for HpUbiX and HpUbiD 
Sequence similarity networks for HpUbiX and HpUbiD were generated by using enzyme 
similarity tools in the Enzyme Function Initiative (EFI-EST) (16).  The sequences of close relatives 
with 20% sequence identity were obtained by using BLAST searches (17) and were then used to 
generated an output network in Cytoscape 3.1.0.  Results for UbiX and UbiD are shown in Figure 
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3.2 and Figure 3.4, respectively.  There were 3521 relevant nodes in the UbiX network (Figure 
3.2), and 3597 nodes in the UbiD network (Figure 3.4).  
 There are no UbiX and UbiD gene orthologs in human genome because ubiquinone 
biosynthesis in humans is carried out by CoQ family of genes, as also found in yeasts and fungi.  
Therefore, no human genes were identified as close relatives in the UbiX or UbiD network.  As 
can be seen in Figure 3.2, there are many sequences (from a broad range of organisms) with close 
sequence similarity to HpUbiX.  UbiX contains a nucleotide binding motif, Rossmann fold that is 
essential in catalyzing the condensation of a prenyl (varying species) chain onto a flavin 
mononucleotide (FMN) substrate (11, 18).  While all protein sequences are annotated as flavin 
prenyltransferases (i.e. UbiX), a vast majority of them are from bacteria, with only one cluster 
containing UbiX sequences (cluster # 1) from archaea and eukaryotes (yeast/fungus).  Moreover, 
one bacterial species is not exclusively represented in only one cluster.  For example, protein 
sequences from Klebsiella, Enterobacter, etc. are represented in multiple clusters.  This indicates 
that at least in bacteria, there are no distinct differences between various UbiX enzymes, due to 
highly conserved functional similarity amongst UbiX enzymes.  Figure 3.3 shows a sequence 
identity correlation heatmap for various gram-negative, gram-positive, and yeast UbiX enzymes, 
where green represents highest similarity and red represents lowest similarity.  As can be seen in 
Figure 3.3, there are no district clusters forming in the correlation matrix, which implies that 
sequence similarities amongst various UbiX enzymes is relatively high.   
 In Figure 3.4, there are many sequences from archaea and bacteria (but not eukaryotes) 
with close sequence similarity to HpUbiD.  UbiD in yeast catalyzes decarboxylation of cinnamic 
acid converting it into styrene through 1,3-dipolar cycloaddition (14).  But in bacteria UbiD is 
speculated to decarboxylate 4-hydroxy-benzoic acid (ubiquinone biosynthesis) or 6-carboxy-1,4-
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dihydroxy-naphthalene (menaquinone biosynthesis) (7, 12).  Since in bacteria, UbiD catalyzes 
decarboxylation of an aromatic carboxylic acid and in yeast, it catalyzes decarboxylates aliphatic 
acids, no eukaryotic UbiD is present in HpUbiD network.  The Cytoscape network of HpUbiD is 
mainly divided in two parts – enzymes of ubiquinone biosynthesis (clusters 2-6) and of 
menaquinone biosynthesis (clusters 7-13).  This difference is also apparent in the sequence identity 
correlation heatmap for the same set of bacteria and yeast species (as in HpUbiX).  As can be seen 
in Figure 3.5, the correlation matrix distinctly falls into three regions – red, yellow, and green.  
Furthermore, H. pylori UbiD is very dissimilar to yeast UbiD and other ubiquinone synthesis 
UbiD, while similarities with Campylobacter jejuni UbiD is very high, due to differences in 
catalytic mechanisms.   
Cloning and Expression of HpUbiX and HpUbiD 
HpUbiX, HpUbiD, and HpUbiA – three genes were cloned into pET28-a vector.  
Overexpression attempts of UbiA were dropped after facing difficulties with membrane protein 
expression and purification.  To optimize expression rate, UbiD plasmid was incorporated into E. 
coli BL21 (DE3) pLysS cells, and UbiX was transformed into E. coli BL21-CodonPlus (DE3) 
RIPL cells.  UbiX was purified in HEPES buffer and concentrated to 5 mg/mL concentration, 
whereas, UbiD was purified in Tris-NaCl buffer and concentrated to ~6 mg/mL concentration.  
UbiX expressed and purified as bound to prenylated flavin mononucleotide, appeared bright 
yellow.  SDS-PAGE purity and mass spectrometry results are shown in Figure 3.6 for HpUbiX 
and in Figure 3.7 for HpUbiD.  
Characterization of HpUbiX and HpUbiD 
This is the first characterization of H. pylori UbiD and UbiX.  Because 6-carboxy-1,4-
naphthoquinone is indeed a substrate in the menaquinone biosynthesis pathway in H. pylori, (10) 
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we synthesized that intermediate in our lab.  Although there is no report in literature of H. pylori 
UbiX and UbiD enzymes, E. coli and P. aeruginosa UbiX (EcUbiX and PaUbiX) activity has been 
reported in literature (11-13, 18).  UbiX involved in ubiquinone biosynthesis is found to be a flavin 
prenyltransferase, incorporating a fourth ring structure onto flavin mononucleotide cofactor.  
Although EcUbiX and HpUbiX share high sequence identity, because HpUbiX is involved in 
menaquinone biosynthesis pathway, its function can still be different in H. pylori. Also, modified 
flavin cofactors by EcUbiX and PaUbiX reported had different molecular weights (661g and 525g 
respectively). Because, H. pylori UbiX is not involved in ubiquinone biosynthesis, (6) it might be 
synthesizing a different cofactor suitable for menaquinone biosynthesis.  We did not investigate 
UbiX catalysis in the formation of prenylated flavin mononucleotide, but rather UbiD dependence 
on UbiX is proven in this work.  
Similarly, UbiD from P. aeruginosa has been purified and crystallized, but its function still 
remains unknown (19) also PaUbiD is predicted to be involved in ubiquinone biosynthesis.  
Recently, UbiD from Aspergillus niger (AnUbiD), a yeast system was characterized as a UbiX 
dependent decarboxylase which converts cinnamic acid into styrene. However, yeast system is 
known to decarboxylate compounds like sorbic acid and cinnamic acid found in antimicrobial 
compounds commonly used in preservatives and flavorings. This detoxification process removes 
CO2 and yields rather volatile byproducts pentadiene and styrene (20).  Also AnUbiD and HpUbiD 
has 16% sequence identity and out of 9 amino acids forming the reaction site of AnUbiD, only 2 
amino acids were found to be conserved in HpUbiD.  Furthermore, AnUbiD decarboxylates 
cinnamic acid, an aliphatic carboxylic acid; whereas, HpUbiD is speculated to be decarboxylating 
an aromatic naphthoic acid.  All these suggest that HpUbiD indeed has a different function in H. 
pylori than other UbiD enzymes found in yeast and bacterial systems.   
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We began characterizing these two enzymes individually as well as together because 
AnUbiD was reported to be dependent on the cofactor synthesized by UbiX.  We used four 
different substrates known to be “UbiD substrates” based on functionalities of bacterial and yeast 
UbiD enzymes.  These four substrates are shown in Scheme 3.1.  
 
 
Scheme 3.1  Four substrates used to characterize HpUbiD and HpUbiX. 
 
 Real-time NMR experiment characterizing UbiX, UbiD, and UbiD+UbiX combination 
with cinnamic acid, 4-hydroxy-benzoic acid, and 2-carboxy-1,4-naphthoquinone resulted in no 
changes in substrate concentration over four hours of period (Figure 3.8, Figure 3.9, and Figure 
3.10).  This proved that HpUbiX and HpUbiD do not interact with reported substrates and indeed 
a new substrate 6-carboxy-1,4-naphthoquinone might be the right fit for these enzymes.  We 
synthesized this new substrate in our lab and carried out enzyme activity assay as described in the 
Methods and Materials.  HpUbiX and HpUbiD did not show any activity with 6-carboxy-1,4-
naphthoquinone individually, however, presence of both enzymes in the reaction mixture resulted 
in time and enzyme concentration dependent reduction of area-under-curve of NMR peaks (Figure 
3.11, Figure 3.12).  This coincides with previous reports that HpUbiX is involved in formation of 
a prenylated FMN cofactor, which is then used by HpUbiD in the decarboxylation reaction of 
carboxylic acid substituent on the 6th carbon of the naphthoquinone structure.  However, genetic 
69 
	
mutation experiments in E. coli have shown that, particularly in ubiquinone biosynthesis, 
prenylation of the aromatic ring occurs before the decarboxylation (12).  Given that HpUbiX, 
HpUbiD, and HpUbiA are similar to E. coli orthologs, it is plausible that in H. pylori menaquinone 
biosynthesis, prenylation of naphthalene ring structure through HpUbiA may precede the 
decarboxylation reaction catalyzed by HpUbiD. Because the classical pathway of menaquinone 
biosynthesis has prenylation and decarboxylation occurring in one step catalyzed by MenA, 
HpUbiD/HpUbiX duo involved in the alternate menaquinone biosynthesis pathway might be 
following the same reaction flowchart as found in ubiquinone biosynthesis in E. coli, Figure 3.13 
(21).  
Extraction of Reaction Product 
 The reaction came to completion (as detected by NMR spectrum) within 30 minutes of 
addition of both HpUbiD and HpUbiX in the reaction mixture.  However, the product precipitates 
within minutes and thus no new product peaks are visible in the NMR spectrum.  We attempted to 
extract the reaction product in various organic solvents considering the putative product 1,4-
naphthoquinone would be soluble in the organic layer.  However, the product was not soluble in 
chloroform, dichloromethane, ethyl acetate or nonpolar solvents like hexanes.  The product was 
moderately soluble in dimethylsulfoxide (DMSO).  During the extraction process, the product 
forms a visible layer between the organic and aqueous layer and it is not soluble in either of those 
two layer.  After the completion of the reaction, the product was extracted without using any 
organic solvent, but by centrifuging at 14,000 RPM in a 1.5 mL eppendorf tube.  The precipitated 
product, which appeared to be “polymer like” was then dissolved in 6 M guanidine hydrochloride 
(Gdn-HCl).  Adduct formation is likely, due to it has been reported that flavin cofactors can form 
a variety of covalent adducts, esp. with aromatic compounds, such as dihydroxynaphthoic acid, 
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containing multiple reactive groups (22).  Gdn-HCl is widely used denaturant that unfolds three-
dimensional structure of protein turning folded protein into a linear peptide.  To our surprise, the 
precipitated reaction product readily dissolved in Gdn-HCl solution.  Increasing the pH of this 
solution by dropwise addition of 12 M NaOH results in the solution turning reddish brown, which 
indicates that 1,4-naphthoquinone structure is intact and the enzymes are not degrading the 
substrate into smaller species (23).  Decreasing the pH of the product solution in 6 M Gdn-HCl by 
dropwise addition of 12 M HCl results in the solution turning pale yellow and product 
precipitating, which is also consistent with naphthoquinone behavior.   
 Co-expression of HpUbiD and HpUbiX in E. coli BL21 (DE3) pLysS cells gave the same 
results as individually expressed and purified HpUbiD and HpUbiX.  1,4-naphthoquinone does 
not appear to be an intermediate in menaquinone biosynthesis because further methylation or 
prenylation to synthesize an active vitamin K2 becomes increasingly difficult in a very stable 
aromatic system such as naphthoquinone.  As described above, prenylation step might be occurring 
before the decarboxylation step in H. pylori menaquinone biosynthesis pathway.  And HpUbiD 
decarboxylates 2-polyprenyl-6-carboxy-1,4-naphthoquinone with help of modified flavin cofactor 
(flavin prenylation catalyzed by HpUbiX), and converts the substrate into 2-polyprenol-1,4-
naphthoquinone, which is also known as demethylmenaquinone (DMK). 
 
3.4 Conclusions 
The results we have described above are of significance for several reasons. First, this is 
the first recombinant expression of UbiX and UbiD enzymes from Helicobacter pylori.  We tested 
these two enzymes against known ubiquinone and menaquinone biosynthesis pathway 
intermediates, as well as, phenolic acids such as cinnamic acid.  Proving that none of the reported 
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intermediates in the literature were suitable substrates for these enzymes, we report the first 
synthesis of 6-carboxy-1,4-naphthoquinone and characterize these two enzymes involved in the 
decarboxylation of this substrate, in the menaquinone biosynthesis pathway.  In classical pathway 
of menaquinone biosynthesis, prenylation and decarboxylation of 2-carboxy-1,4-naphthoquinone 
is a concerted reaction, due to what we believe, that carboxyl substituent is on the aliphatic ring 
containing quinone moiety.  However, with carboxyl group on the 6th carbon, which is a part of 
the aromatic ring, a totally different reaction mechanism can be involved.  And indeed that is the 
case here, as shown by the essential function of prenylated flavin mononucleotide cofactor that 
plays part in the catalysis of decarboxylation.  Given that H. pylori is an infectious agent and there 
is a rise of clarithromycin-resistant H. pylori which potentially can cause gastric cancer and MALT 
lymphoma, this discovery aids in the process of understanding menaquinone biosynthesis in H. 
pylori through an alternate pathway, and in future efforts of successfully identifying drug leads 
against menaquinone biosynthesis, an essential electron transporter in Helicobacter pylori. 	
 
3.5 Materials and Methods  
Materials 
Various substrate compounds for enzyme activity and intermediates involved in the 
synthesis of 6-carboxy-1,4-naphthoquinone were purchased from Sigma-Aldrich.  
SIGMAFAST™ Protease Inhibitor Cocktail Tablets were purchased from Sigma-Aldrich.  
pET28a and pET15b vectors were purchased from Novagen.  Escherichia coli BL21-CodonPlus 
(DE3)-RIPL and BL21 (DE3) pLysS cells were obtained from Agilent Technologies (Santa Clara, 
CA).   
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Clones and Plasmids 
Helicobacter pylori genomic DNA (ATCC, #700392) was used to amplify gene sequences 
of HpUbiA, HpUbiD, and HpUbiX enzymes. PCR amplification of all three enzymes was 
accomplished using gene-specific (IDT, Coralville, IA) primers designed from sequences 
identified in H. pylori genome. UbiA forward 5’-	
GCCCATATGCTTAAAAAAATCACGCACAAAATCAAAGCTTTAAGCGA and UbiA 
reverse 5’-GCCCTCGAGTCATGCATGCTTAAACCCCACATCAAGGAC were used to 
amplify the UbiA sequence. UbiD forward 5’- 
GCCCATATGCGAGATTTTTTAAAACTTTTAAAAAAGCATGATGAATTAAAAATCATT
GACACC and UbiD reverse 5’- 
GCCCTCGAGTTATAGATCTTCTTTGTGCGTGCTGAAAGAATGCGT were used to amplify 
the UbiD sequence. UbiX forward 5’- 
GCCCATATGAAATTGGTTTTAGGCATCAGTGGAGCGAGC and UbiX reverse 5’- 
GCCCTCGAGTCAGTTCATTCCCCATCGTGGGTATAAGTCATTTT were used to amplify 
the UbiX sequence. All three amplified sequences were incorporated into kanamycin resistant 
pET28-a vector (Novagen, #69864-3).  For co-expression of UbiD and UbiX same amplified 
sequences were used, but UbiD was incorporated in kanamycin resistant pET-28a vector, while 
UbiX was incorporated in ampicillin resistant pET-15b vector (Novagen, #69661-3). The HpUbiA 
and HpUbiX clones were transformed into E. coli BL21-CodonPlus (DE3)-RIPL cells, while 
HpUbiD clone was transformed into E. coli BL21 (DE3) pLysS cells.  For co-expression of 
HpUbiD and HpUbiX, pET-28a and pET-15b vectors were co-transformed in E. coli BL21 (DE3) 
pLysS cells. Transformed cells were plated on LB containing recommended concentration of 
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kanamycin or ampicillin antibiotics and cultured overnight at 37°C to select antibiotic resistant 
clones, which were then confirmed by DNA sequencing (ACGT Inc., Wheeling, IL).  
Recombinant Protein Expression and Purification  
HpUbiA recombinant expression was attempted two times, but no active protein was 
purified.  Further optimization of expression and purification of the protein was not attempted. 
Therefore, HpUbiA will not be discussed any further. 
For HpUbiX expression, basically the same protocol was used except cells were induced 
with 1 mM IPTG at 37°C for 4 hours and then were harvested by centrifuge. Recombinant UbiX 
was purified using 10mM HEPES, pH 7.0 buffer containing 150 mM NaCl, 35 mM imidazole, 
then eluted with increasing concentration of imidazole in a gradient (35 mM to 1 M).  Because 
UbiX forms a dodecamer, the protein binds strongly with Ni-NTA column, and elutes at ~500mM 
imidazole concentration. HpUbiX elutes as bright yellow protein due to already bound flavin 
cofactor.   Purity of HpUbiX was determined using SDS-PAGE and MALDI mass spectrometry.  
The purified protein was ~100% pure as apparent from Figure 3.6. 
For HpUbiD, basically the same protocol was used except cells were lysed in the presence 
of SIGMAFAST™ Protease Inhibitor Cocktail Tablets, EDTA-Free (one tablet per 20g of cell 
mass). Recombinant UbiD was purified using 50mM Tris-HCl, pH 7.0 buffer containing 150 mM 
NaCl, 35 mM imidazole, then eluted with increasing concentration of imidazole in a gradient (35 
mM to 500 mM). HpUbiD elutes at 250 mM imidazole as pale yellow protein plausibly due to 
bound modified flavin mononucleotide cofactor.  For co-expression of HpUbiD and HpUbiX, to 
assess if HpUbiD is fully bound to prenylated flavin cofactor, same protocol was used as of 
HpUbiD overexpression.  Both UbiD and UbiX sequences contained a His6-tag, thus both proteins 
were eluted at ~500 mM imidazole.  UbiD could have been eluted first at 250 mM imidazole to 
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separate it from UbiX, but to ascertain presence of UbiD and UbiX in the protein solution, higher 
imidazole concentration was used for elution.  Purity of HpUbiD was determined using SDS-
PAGE and protein mass fingerprinting (PMF) spectrometry.  As shown in Figure 3.7, HpUbiD 
was about ~50% pure, with other 50% being HpUbiX.  Due to two enzymes present in the sample, 
MALDI was not appropriate technique for determining purity.  HpUbiD presence in the enzyme 
was determined by PMF, with 42% coverage, which indicates very high probability of purified 
enzyme being H. pylori UbiD with p<0.0001.  
Enzyme Characterization  
For HpUbiX and HpUbiD activity assay, because there is not feasible detection technique 
to measure decarboxylation rate of naphthoquinone derivatives, real-time NMR technique was 
used.  Three different protein samples – HpUbiX, HpUbiD and HpUbiD co-expressed with 
HpUbiX were used in the assay.  For each reaction assay, 5 mM of various substrate solutions 
were prepared in pH 7.0 D2O buffer containing 10mM HEPES and 150 mM NaCl. 50 µg of UbiD 
or 20 µg of UbiX or 70 µg of UbiD co-expressed with UbiX were added after collecting a negative 
control spectrum (substrate only, without any enzymes).  Enzymatic reaction was kept at room 
temperature and NMR spectra were collected every 30 minutes to observe changes in the peaks of 
substrates. Enzyme kinetics parameters (Km and Vmax) were not calculated as a real-time kinetics 
measurement protocol for decarboxylation of naphthoquinone derivatives was not developed.   
Synthesis of 6-Carboxy-1,4-Naphthoquinone 
 All chemicals were reagent grade. 1H NMR and 13C NMR spectra were obtained on Varian 
(Palo Alto, CA) Unity spectrometers at 400 and 500 MHz for 1H. HPLC/MS analyses were 
performed by using an Agilent LC/MSD Trap XCT Plus system (Agilent Technologies, Santa 
Clara, CA) with an 1100 series HPLC system including a degasser, an autosampler, a binary pump, 
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and a multiple wavelength detector. Purity was determined by HPLC and structures were 
characterized by 1H NMR and HRMS, which are provided in Figure 3.14 and Figure 3.15.  6-
carboxy-1,4-naphthoquinone was synthesized following Scheme 3.2.  
 
 
Scheme 3.2 General synthesis route for 6-carboxy-1,4-naphthoquinone (24–27). 
 
6-Methyl-1,4-naphthoquinone (c): A mixture of 5.4 g (50 mmol) of p-benzoquinone (a), 3.4 g 
(50 mmol) of isoprene (b), and 30 mL of glacial HOAc was stored with occasional shaking in a 
stoppered flask for 3 days at rt. It was filtered and then warmed to 60°C to evaporate any unreacted 
isoprene (bp 34.07°C). The residue was stirred with a mechanical stirrer at 50°C while a preheated 
solution of 20.0 g of Na2CrO4.2H2O, 1.0 mL of concd H2SO4, and 12 mL of water was added. Ice-
water bath was used to maintain the temperature 50°C for 30 min and then at 65-68°C for 45 min. 
The resultant solution was poured into 60 g of ice and 100 mL of water, and this was stored 
overnight at rt. A solid separated and was collected by filtration and washed with water. It was 
dissolved in 200 mL of HOAc, and a solution of 10 g of Na2CrO4 in 10 mL of water was added 
while stirring. The solution was heated in a steam bath for 15-20 min. Water was added to the 
cloud point, a solid precipitated on standing, and the mixture was filtered. The product was 
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recrystallized from HOAc to afford 5.7 g (67%) of c as a yellow solid. 1H NMR (400 MHz, 
CDCl3): 7.98 (d, J = 7.9 Hz, 1H), 7.87 (s, 1H), 7.56-7.54 (m, 1H), 6.94 (s, 2H), 2.50 (s, 3H). 
6-(Bromomethyl)-1,4-naphthoquinone (d): To a solution of c (0.900 g, 5.226 mmol) in 20 mL 
of dry CCl4, NBS (1.39 g, 7.839 mmol) and 0.1 g of AIBN was added, and the result was heated 
to reflux for 4 h. The solvent was removed, and the residue was purified by silica gel column 
chromatography (20% EA/PE) to give compound d (0.76 g, 58%) as a yellow solid. 1H NMR (400 
MHz, CDCl3): 8.10-8.07 (m, 2H), 7.78 (dd, J = 1.9, 8.0 Hz, 1H), 6.99 (m, 2H), 4.55 (s, 2H). 
6-(Hydroxymethyl)-l,4-naphthoquinone (e): 6-(Bromomethyl)-l,4-naphthoquinone (d, 0.100 g, 
6 mmol) in 5 mL of water-dioxane (3:2, v/v) was refluxed with stirring for 1 h. The solution was 
then diluted with water (30 mL) and extracted with CHC13 (2X, 15 mL). The CHC13 solution was 
dried (Na2SO4), concentrated, and purified by silica gel column chromatography (CHC13-EtOAc, 
7:3, v/v) to yield 0.049 g (65%) of e as a yellow solid. 1H NMR (400 MHz, CDCl3): 8.08-8.05 (m, 
2H), 7.78-7.76 (m, 1H), 6.97 (m, 2H), 4.86 (s, 2H). 
5,8-Dioxo-5,8-dihydronaphthalene-2-carbaldehyde (f): To a solution of e (0.100 g, 0.531 
mmol) in 5 mL of dry DCM, PCC (0.171 g, 0.797 mmol) was added at room temperature and then 
stirred for 12 h. The solvent was evaporated and crude material purified by silica gel column 
chromatography (20% EA/PE) to give compound f (0.077 g, 78%) as a yellow solid. 1H NMR 
(400 MHz, CDCl3): 10.19 (s, 1H), 8.58 (s, 1H), 8.29-8.24 (m, 2H), 7.11-706 (m, 2H) 
6-Carboxy-1,4-naphthoquinone (g): To a solution of f (0.100 g, 0.531 mmol) in 1 mL of dry 
DMF, oxone was added at room temperature. The reaction mixture was allowed to stir at same 
temperature for 12 h. The solvent was evaporated and crude material purified by silica gel column 
chromatography (70% EA/PE) to give compound g (0.076 g, 70%) as a yellow solid.  1H NMR 
(400 MHz, CDCl3): 13.71 (bs, 1H), 8.45-8.35 (m, 2H), 8.10 (d, J = 8.0 Hz, 1H), 7.16 (s, 2H).	
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3.6 Tables and Figures 
 
Figure 3.1  Schematic representation of two menaquinone biosynthetic pathways.  
A. Classical pathway. Chorismate, which is derived from shikimate pathway is converted to 
isochorismate by MenF (isochorismate synthase), which then is converted into 2-succinyl-6-
hydroxy-2,4-cyclohexadiene-1-carboxylate by MenD, a thiamine dependent enzyme.  MenC then 
catalyzes dehydration reaction of this compound, producing an aromatic compound o-
succinylbenzoate.  Coenzyme A (CoA) condensation by MenE yields o-succinylbenzoyl-CoA, 
which then is converted to 1,4-dihydroxy-2-naphthoate by MenB.  The last two steps involve 
decarboxylation, prenylation and methylation.  MenA prenylates and decarboxylate in a one-step 
catalysis.  Methylation by MenG is S-adenosylmethionine dependent reaction.  
B, Alternate pathway. Chorismate is converted into aminodeoxyfutalosine (AFL) in an adenosine 
dependent reaction by MqnA.  MqnB then deadenylates AFL yielding dehypoxanthinylfutalosine 
(DHFL), which is then converted into cyclic DHFL by MqnC.  MqnD then removes the pentose 
sugar moiety, generating 1,4-dihydroxy-6-naphthoate. From here a series of enzymes UbiA, UbiD, 
UbiX, and UbiE are speculated to be catalyzing prenylation, decarboxylation, and methylation 
reaction.  In the alternate pathway, decarboxylation and prenylation are two separate reactions 
catalyzed by two different enzymes, UbiA and UbiD/UbiX. 
 
 
 
 
 
78 
 
Figure 3.1  (continued) 
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Figure 3.2  Sequence similarity network for HpUbiX constructed with 20% sequence identity 
threshold.  Major clusters are: 1. UbiX from archaea and yeasts/fungi, 2. UbiX from Bacillus, 
Enterobacter, E. coli, Klebsiella, Mycobacterium, and Streptomyces, 3. UbiX from Salmonella, 
Ralstonia, and Burkholderia, 4. UbiX from Citrobacter, Enterobacter, Klebsiella, and Yersinia, 
5. UbiX from Bradirhizobium, Burkholderia, and Legionella, 6. UbiX from Microcystis, 
Synechoccocus, and Prochlorococcus, 7. UbiX from Enterococcus+Lacrobacillus 8. UbiX from 
Halomonas, Pseudomonas, Vibrio, Helicobacter, Campylobacter, and Chlamydia. 
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Figure 3.3 Sequence identity correlation heatmap for various gram-negative, gram-positive, 
and yeast UbiX enzymes, where green represents highest similarity and red represents lowest 
similarity. 
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Figure 3.4 Sequence similarity network for HpUbiD constructed with 20% sequence identity 
threshold.  Major clusters are: 1. UbiD from archaea, 2. UbiD from E. coli and Enterococcus, 3. 
UbiD from Burkholderia and Vibrio, 4. UbiD from Halomonas and Pseudomonas, 5. UbiD from 
Klebsiella and Legionella, 6. UbiD from Neisseria and Salmonella, 7. UbiD from Campylobacter 
jejuni and other Campylobacter species, 8. UbiD from Helicobacter pylori, 9. UbiD from 
Helicobacter species, 10. UbiD from Streptomyces, 11. UbiD from Chlamydia, 12. UbiD from 
Sulfopirillum, Sulfuromonas, and Sulfurovum, 13. UbiD from Acrobacter, Geobacter, and 
Caulobacter. 
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Figure 3.5 Sequence identity correlation heatmap for various gram-negative, gram-positive, 
and yeast UbiD enzymes, where green represents highest similarity and red represents lowest 
similarity. 
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Figure 3.6 Purity characterization of HpUbiX. A. SDS-PAGE showing purity of HpUbiX. B. 
MALDI mass spectrum of HpUbiX with m/e- and m/2e- peaks.  
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Figure 3.7 Purity characterization of HpUbiD co-expressed with HpUbiX. A. SDS-PAGE 
showing percent-purity of HpUbiD and HpUbiX. B. Protein mass fingerprinting spectrometry 
report showing 42% coverage, indicating high probability of purified enzyme being HpUbiD. 
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Figure 3.8 1H-NMR spectra of cinnamic acid with HpUbiD co-expressed with HpUbiX 
collected over a period of 4 hours.  A. negative spectrum without the presence of enzymes. B. 
spectrum obtained at 30 minutes. C. 1 hour. D. 2 hours. E. 4 hours.  
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Figure 3.9 1H-NMR spectra of 4-hydroxy benzoic acid with HpUbiD co-expressed with 
HpUbiX collected over a period of 3.5 hours.  A. negative spectrum without the presence of 
enzymes. B. spectrum obtained at 30 minutes. C. 1.5 hours. D. 3.5 hours. 
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Figure 3.10 1H-NMR spectra of 2-carboxy-1,4-naphthoquinone with HpUbiD co-expressed 
with HpUbiX collected over a period of 4 hours.  A. negative spectrum without the presence of 
enzymes. B. spectrum obtained at 30 minutes. C. 1 hour. D. 4 hours. 
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Figure 3.11 1H-NMR spectra of 6-carboxy-1,4-naphthoquinone with HpUbiX collected over a 
period of ~3.5 hours.  A. negative spectrum without the presence of enzymes. B. spectrum obtained 
at 30 minutes. C. 2 hours. D. ~3.3 hours. E. at ~3.7 hours with HpUbiD added for 15 minutes.  
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Figure 3.12 1H-NMR spectra of 6-carboxy-1,4-naphthoquinone with HpUbiD collected over a 
period of ~3.5 hours.  A. negative spectrum without the presence of enzymes. B. spectrum obtained 
at 30 minutes. C. 2 hours. D. ~3.3 hours. E. at ~3.7 hours with HpUbiX added for 15 minutes.  
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Figure 3.13 Biosynthetic pathway of ubiquinone in Escherichia coli and many other bacteria 
using ubiquinone as electron transporter.  Reaction catalyzed by UbiA (prenylation) and 
UbiD/UbiX (decarboxylation) are highlighted.  
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Figure 3.14 1H-NMR spectrum of 6-carboxy-1,4-naphthoquinone in DMSO.  
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Figure 3.15 HPLC chromatograph of 6-carboxy-1,4-naphthoquinone (A) with mass spectrum 
showing a single peak at m/z = 203.0 (B).  
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Chapter 4 
Characterization of Potential Drug Targets Farnesyl Diphosphate 
Synthase and Geranylgeranyl Diphosphate Synthase in Schistosoma 
mansoni 
 
4.1 Notes and Acknowledgements 
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GM008276 (JD), and by the Beta Lambda Chapter of Phi Sigma at Illinois State University (to 
PDZ). Schistosome materials for this work were supplied in part from the Biomedical Research 
Institute through NIH contract HHSN272201000005I.  I thank Dr. Yonghui Zhang and Dr. Kai Li 
for synthesizing a variety of inhibitor compounds such as bisphosphonates, bisamidines, di-keto 
acids, benzoic acids, etc.  Many thanks to Dr. Yi-Liang Liu and Dr. Jikun Li for training me for 
radiometric assay measuring phosphate ion release that were essential to characterizing this 
enzyme and discovering its inhibitors.  
 
4.2 Introduction  
Human schistosomiasis, also known as bilharzia, is a disease caused by trematodes of three 
main species, Schistosoma mansoni, S. haematobium and S. japonicum. Some 200 million 
individuals are infected, 600 million are at risk, and there are almost 300,000 deaths annually (1). 
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The only current treatment for schistosomiasis is praziquantel. Laboratory strains and clinical 
isolates of the parasite with resistance to praziquantel have been identified (2–8). No other drugs 
are currently available for the treatment of the disease, and no new drug has entered clinical trials 
for schistosomiasis treatment in more than 30 years (9).  Moreover, as recently reported, (1) 
vaccine development is very slow.  There is therefore, a need to develop alternative drugs for 
schistosomiasis treatment to be used in combination with praziquantel or to replace it should 
resistance become more widespread. 
One potential target for schistosomiasis drug development is the mevalonate pathway, 
which is involved in the synthesis of cholesterol, dolichols, quinones, and the isoprenoid 
compounds used for protein prenylation (10, 11). Starting with acetyl-CoA and acetoacetyl-CoA, 
3-hydroxy-3-methylglutaryl-CoA is synthesized by 3-hydroxy-3-methylglutaryl-CoA synthase. 3-
hydroxy-3-methylglutaryl-CoA is then reduced to mevalonate by 3-hydroxy-3-methylglutaryl-
CoA reductase (HMGR, Figure 4.1). A series of phosphorylation and decarboxylation reactions 
convert mevalonate to the 5-carbon intermediate, isopentenyl diphosphate (IPP, Figure 4.2A). IPP 
is then isomerized to dimethyl allyl diphosphate (DMAPP). The two molecules go through a 
condensation reaction catalyzed by farnesyl diphosphate synthase (FPPS) to form the 10-carbon 
geranyl diphosphate (GPP, Figure 4.2A). A second condensation reaction of GPP and IPP 
catalyzed by FPPS results in the formation of the 15-carbon farnesyl diphosphate (FPP). A branch 
point in this pathway occurs after the synthesis of FPP: either a reductive condensation reaction 
between two molecules of FPP produces squalene, the first committed intermediate in cholesterol 
biosynthesis, or a condensation of IPP and FPP produces the 20-carbon geranylgeranyl 
diphosphate (GGPP). The latter reaction is catalyzed by geranylgeranyl diphosphate synthase 
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(GGPPS). Therefore, FPP serves as the main precursor for synthesis of sterols as well as of 
nonsterol isoprenoids (11–15). 
It has been determined that S. mansoni does not make cholesterol (16): squalene synthase, 
the enzyme that catalyzes the synthesis of squalene from FPP is not present in the S. mansoni 
genome (17). Consequently, it has been proposed that the parasite obtains cholesterol from its 
human host (18). However, the mevalonate pathway is present in schistosomes (19), and 
isoprenoids derived from mevalonate have been identified in S. mansoni and are thought to be 
involved in post-translational prenylation of proteins with FPP and GGPP, as well as for non-sterol 
isoprenoid synthesis (20, 21). In S. mansoni, work from different groups has shown that 
schistosome Ras is farnesylated (22) and Rab and Rho orthologs are geranylgeranylated (23, 24). 
The mevalonate pathway thus serves as a potential target for schistosomiasis treatment for 
a number of reasons. Statins, which are widely used in hypercholesterolemia in humans through 
the inhibition of HMGR (25–27), have been used in experimental S. mansoni infections resulting 
in significant worm death (10). Statins, such as mevinolin are also reported to inhibit egg 
production in S. mansoni, possibly due to the lack of nonsterol lipids involved in egg production 
(18, 28). In these experiments, in the absence of mevinolin, parasites produced five to six times 
more eggs than worms cultured in mevinolin-containing media, and the activity of HMGR was 
tripled after exposure to low doses of the drug. Mevinolin caused worm death in infected mice 
when administered over several weeks (10). In the same study, in vitro experiments showed that 
mevinolin prevented the further development of schistosome eggs when added to the culture 
medium. However, due to slow activity of statins against worms, HMGR may not to be an ideal 
target for schistosomal therapy.  
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Although the importance of the mevalonate pathway for schistosomes and its potential as 
a drug target has been demonstrated, there is no information available on the other enzymes in this 
pathway. Therefore, we have undertaken a study to characterize FPPS and GGPPS in S. mansoni 
to determine if they are drug targets. Bisphosphonates (Figure 4.2B), which have been used to treat 
osteoporosis and similar diseases in millions of people (29), have been shown to be efficient FPPS 
(30) and GGPPS (31) inhibitors, and one approach for the development of drugs for neglected 
diseases is the repositioning of drugs currently in use (32). Bisphosphonates have been found to 
be active against a variety of protozoan parasites, for example, Trypanosoma brucei, T. cruzi, and 
Leishmania donovani (30, 33–35), Cryptosporidium parvum (36), Entamoeba histolytica (37), 
Toxoplasma gondii (38) and Plasmodium species (37, 39–42). However, no previous 
investigations on FPPS or GGPPS from a parasitic helminth have been published. Here, we show 
that FPPS and GGPPS from S. mansoni share similarities with orthologs from other species: both 
schistosome enzymes are inhibited by bisphosphonates, although to differing degrees. 
Investigations on the substrate specificities of FPPS and GGPPS indicate that their activities are 
redundant, suggesting that inhibition of both enzymes will be necessary for effective worm killing.  
Pyridinium group-containing lipophilic bisphosphonates tested against cultured ex vivo adult 
worms were able to kill worms, providing evidence that SmFPPS and SmGGPPS are essential for 
worm survival and that they are druggable targets.  
4.3 Results and Discussions 
Schistosoma Infection  
Schistosomiasis is a disease that affects approximately 200 million people worldwide with 
about 300,000 deaths annually (1). There is only one drug, praziquantel, available for its treatment. 
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In order to identify new schistosome targets for drug development, we have characterized two 
enzymes of the mevalonate pathway. These studies are justified by previous studies with statins, 
inhibitors of HMGR, which result in reductions in parasite egg production and worm death (10). 
FPPS and GGPPS are downstream of HMGR in the mevalonate pathway. Their activities yield 
important molecules such as dolichols, quinones and long chain isoprenoids involved in protein 
prenylation (27). Inhibition of these enzymes reduces the amount of these essential molecules and 
has deleterious effects on worm metabolism.  Bisphosphonates, including risedronate and 
zoledronate, are widely used to prevent and treat osteoporosis and have been shown to inhibit 
FPPS in many organisms including humans (31, 43) and some parasites (17). Digeranyl 
bisphosphonates are known to inhibit human GGPPS (44). No studies have been done on 
schistosome FPPS or GGPPS or on the activity of bisphosphonates against schistosomes. In this 
study we expressed and characterized recombinant SmFPPS and SmGGPPS to determine if it 
might be possible to use “new generation” lipophilic bisphosphonates for schistosomiasis 
treatment. We found that recombinant SmFPPS and SmGGPPS are inhibited by several 
bisphosphonates, and that some bisphosphonates have activity against cultured, ex vivo adult 
worms, suggesting that schistosome FPPS and GGPPS may be appropriate targets for drug 
development for schistosomiasis. 
Cloning and Analysis of S. mansoni FPPS and GGPPS.   
Multiple sequence alignments of FPPS and GGPPS were generated using CLUSTAL W 
2.0.12 in order to compare the schistosome proteins to orthologs present in other species. The 
results indicate that the schistosome proteins share the active site motifs found in orthologous 
proteins. The first aspartate rich motif (FARM) and second aspartate rich motif (SARM), which 
have been demonstrated to be the active sites in avian FPPS (45), are present in SmFPPS and 
102 
	
SmGGPPS. In addition to these conserved motifs, SmFPPS and SmGGPPS shared significant 
overall similarities and identities with other FPPS and GGPPS proteins (Table 2). For example, 
SmFPPS has 35% identity to human FPPS and 34% identity to Drosophila melanogaster FPPS, 
while SmGGPPS has 53% identity to human GGPPS and 46% identity to D. melanogaster 
GGPPS.  Of note, the amino acids proximal to the FARM are involved in determining and limiting 
the length of the allylic diphosphates able to bind in the active site (Figure 4.3). In human and 
other type-I FPPS proteins, two bulky residues (Phe, Tyr) form a ‘lid’, effectively limiting binding 
to shorter allylic diphosphates. In type-II and -III FPPS proteins, exemplified by bacterial and 
apicomplexan proteins, one of the bulky residues is replaced by a smaller residue (Ser, Cys, Ala). 
This motif in SmFPPS is similar to that found in type-III apicomplexan FPPS proteins, with Gly-
Phe present in the ‘lid’ region of the chain-length determining segment. Like other GGPPS 
enzymes, SmGGPPS has neither the aromatic amino acids at the fourth and/or fifth positions 
before the FARM found in FPPS enzymes, nor the two amino acid insertions that occur in FPPS 
and GGPPS from plants and bacteria. Instead, product chain-length is determined by a bulky 
residue two amino acids before a conserved GQ (46); this residue is conserved in SmGGPPS. 
Recombinant Protein Expression and Purification.   
SmFPPS and SmGGPPS were expressed in E. coli BL21 star (DE3) cells generating His-6 
tagged fusion proteins. The supernatants obtained from cell lysates were purified through a nickel 
column and elution fractions were analyzed on a 16% SDS gel. SmFPPS elutes in the 300 mM 
imidazole fractions and has a molecular weight of ~44.2 kDa, while recombinant SmGGPPS elutes 
in the 300 mM and 500 mM imidazole fractions, and has a molecular weight of ~38.3 kDa. 
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Kinetic Analysis of Recombinant S. mansoni FPPS and GGPPS.   
Recombinant SmFPPS and SmGGPPS proteins were analyzed for activity without removal 
of the His-6 tag. Both proteins were tested in reactions with 3H-IPP and allylic diphosphates 
(DMAPP, GPP, or FPP). Both proteins were active with all three allylic diphosphates. The Vmax 
for SmFPPS ranged from 1077 units/mg protein with DMAPP + IPP, to 22 units/mg protein with 
FPP + IPP (Table 4.2).  The Km for all substrates was ~17 µM (Table 3). The Vmax for SmGGPPS 
ranged from 67-371 units/mg for the different substrates, while the Km ranged from 2.5-7 µM 
(Table 4.2). 
FPPS and GGPPS Enzymes  
Comparisons of SmFPPS and SmGGPPS to orthologous FPPS and GGPPS proteins 
indicate that they have similar conserved, active-site motifs.  For instance, the active sites of both 
proteins typically contain two “aspartate-rich” motifs (47, 48). These are both present in the amino 
acid sequences of SmFPPS and SmGGPPS.  Interestingly, from a three dimensional structural 
perspective, the SmFPPS is predicted to have the closest structural homology to human FPPS 
(based on Phyre2 (49) structure prediction) with which it has the highest (38%) sequence identity 
among the prenyl transferases whose structures have been reported.  Likewise, SmGGPPS is also 
predicted to have the closest structural homology to human GGPPS (54% sequence identity).  
However, SmFPPS and SmGGPPS do have significant sequence differences to the human 
orthologs, which could be exploited for selective enzyme inhibition and drug development.  
We went on to investigate if the schistosome proteins have similarity in function by 
investigating the substrate specificity of the enzymes. We found that SmFPPS was active with 
DMAPP, GPP and FPP as substrates, but with substrate preferences of DMAPP > GPP > FPP 
under similar reaction conditions. In previous studies involving FPPS, the allylic substrates studied 
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were DMAPP and GPP, with FPPS enzymes showing a preference for DMAPP over GPP (50, 51). 
FPPS from Trypanosoma brucei (TbFPPS) and T. cruzi FPPS (TcFPPS) have specific activities of 
840 units/mg (52) and 325 units/mg (21) with IPP and GPP as substrates, values that are similar 
to what we have determined for SmFPPS. However, there has not been any reported activity of 
TbFPPS or TcFPPS with FPP. FPPS from the rubber-producing mushroom, Lactarius 
chrysorrheus, has been shown to be unable to form products with FPP as substrate (48), and data 
from the Comprehensive Enzyme Information System (http://www.brenda-enzymes.org/) indicate 
that only DMAPP and GPP are substrates for FPPS from over twenty different species. 
However, FPPS enzymes from a number of parasitic protozoa including Toxoplasma 
gondii, (51) Plasmodium vivax (53), and Cryptosporidium parvum (54), have recently been shown 
to have “bi-functional” prenyl synthases that are capable of accepting DMAPP, GPP, and FPP as 
substrates to produce FPP and GGPP as well as longer chain products.  It has been proposed that 
substitution of a small, hydrophilic amino acid residue for a bulky hydrophobic residue in the 
chain-length determining region of type-III FPPS proteins allows them to accept GPP and longer 
prenyl compounds as substrates. The chain-length determining region of SmFPPS is similar to 
type-III FPPS and indeed, the substrate specificity of SmFPPS is similar as well. In addition to 
changes in the chain-length determining region, several amino acid insertions are found in type-
III FPPS proteins, which may also enlarge the substrate binding pocket to accommodate larger 
prenyl precursors. Similar insertions are also found in SmFPPS, which again may be responsible 
for broadening the substrate range of the protein, and could be targeted in the development of 
SmFPPS-specific inhibitors. 
 
 
 
105 
	
Effect of Inhibitors on S. mansoni FPPS and GGPPS and ex vivo S. mansoni Worms.   
Ten bisphosphonates (Figure 4.2B) were tested against recombinant SmFPPS and 
SmGGPPS. The IC50 values of each inhibitor were determined by plotting a curve of inhibitor 
concentration vs. percent enzyme inhibition. IC50 values with SmFPPS ranged from 0.04 µM (703) 
to 10 µM (749), while for SmGGPPS IC50 values ranged from 2.1 µM (749) to 36 µM (811) (Table 
4.3, Figure 4.4).  
To determine the effect of bisphosphonates on S. mansoni worms, ex vivo adult worms 
were cultured in the presence of a bisphosphonate at 50 µM and visually monitored for 7 days. 
The worm culture was replenished daily with fresh media and 50 µM inhibitor. Out of the ten 
bisphosphonates tested (Table 4.3), only compound 715 was active, with worm death occurring 
after 4-7 days of exposure (Figure 4.5A). Ten other lipophilic bisphosphonates with pyridinium 
ring structure, which resemble 715, were then tested on adult worms, with compounds 746, 766, 
777, and 820 (Figure 4.5B) resulting in worm death occurring after 4 days.    
The inhibitory effects of bisphosphonates on recombinant SmFPPS and SmGGPPS 
proteins were determined for both enzymes using clinically relevant risedronate (2) and 
zoledronate (91), as well as experimental, lipophilic bisphosphonates (460, 703, 715, 749, 754, 
782, 811, and 1186). 2 and 91 are known to inhibit FPPS.  In studies with trypanosomes, 2 and 91 
were found to inhibit TcFPPS (34) and TbFPPS with IC50s of 37 nM and 42 nM, (35), respectively, 
and human FPPS at 3.9 nM and 40 nM for (39, 55). The IC50 of 2 against SmFPPS was 0.19 µM, 
while 91 had an IC50 value of 0.14 µM against SmFPPS, in the same range as against human FPPS 
(0.137 µM) (55). The lipophilic bisphosphonates were also efficient SmFPPS inhibitors with IC50s 
from 0.04 µM (703) to 10 µM (749), with 754 being slightly more inhibitory against SmFPPS (1.9 
µM) than against human FPPS (5 µM) (56). In general, all compounds were less active against 
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SmGGPPS than against either SmFPPS or human GGPPS (Table 4.3, Figure 4.4), except 749 (2.1 
µM), which contains two geranyl moieties. Compounds 715, 754, and 782, which are known 
inhibitors of GGPPS (35), had IC50 values in the micromolar range (4.1-9.1 µM) against 
SmGGPPS. 460, 811, and 1186 were the least inhibitory against SmGGPPS (23-36 µM).  715 and 
782 have been shown to inhibit both FPPS and GGPPS in human tumor cells, with IC50 values 
between 100 - 200 nM (57).  Unusually, these three lipophilic bisphosphonates were more active 
against SmFPPS than against SmGGPPS. This weak inhibition against SmGGPPS could be the 
basis for selective toxicity against schistosome parasites. 
Since these compounds had some inhibitory activity against SmFPPS and SmGGPPS 
proteins, we next investigated if they had activity against cultured ex vivo adult S. mansoni worms. 
Only long chain compounds with pyridinium group 715, 746, 766, 777 and 820 had killing activity 
against worms under the tested conditions. 2 and 91 have been shown to have good activity in 
experimental infections of T. cruzi, T. brucei, T. gondii, and P. falciparum, all of which contain 
only an FPPS-like enzymes (40).  91, which was an effective inhibitor of both SmFPPS and 
SmGGPPS (IC50 of 0.1 µM and 5.0 µM respectively), is highly charged and hydrophilic and may 
have low bioavailability and not be taken up by the worms.  From these results, we hypothesize 
that since both SmFPPS and SmGGPPS are able to catalyze the formation of GPP, FPP, and GGPP 
and since none of the compounds were extremely potent inhibitors of SmGGPPS, even if FPPS 
activity was reduced, all essential molecules needed from the mevalonate pathway could still be 
synthesized by SmGGPPS and, therefore, FPPS or GGPPS inhibition alone would not adversely 
affect worm survival. Therefore, due to the redundancy in substrate utilization by SmFPPS and 
SmGGPPS, worm killing would only occur when both enzymes are inhibited. 
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4.4 Conclusions 
This is the first characterization of the FPPS and GGPPS enzymes from a helminth parasite 
and the first time that bisphosphonates have been tested against schistosomes. Although there are 
orthologs in humans, we find that the substrate specificities and inhibition by bisphosphonates of 
the schistosome enzymes are significantly dissimilar to the results found with the host enzymes.  
These differences, along with differences in primary amino acid sequences of the proteins, may 
allow for the development of parasite enzyme specific inhibitors.  This must be tempered by the 
finding that SmFPPS and SmGGPPS appear to have overlapping and redundant functions and 
therefore, that inhibition of both enzymes may be necessary to cause worm death.  Nevertheless, 
our results provide proof-of-principle that SmFPPS and SmGGPPS are essential, druggable 
parasite enzymes and that lipophilic bisphosphonates may serve as starting points for the 
development of new drugs for the treatment of schistosomiasis.  
 
4.5 Methods and Materials  
 
Materials   
Radioactive 3H-IPP was obtained from American Radiolabeled Chemicals (St. Louis, 
MO).  Escherichia coli BL21 star (DE3) cells were obtained from Invitrogen (Carlsbad, CA). 
Isopropyl-ß-D-thiogalactodinoside (IPTG) was obtained from Gold Biotechnology (St Louis, 
MO). RPMI 1640 media was obtained from Sigma-Aldrich. (St. Louis, MO). 
Clones and Plasmids 
Total RNA was extracted from S. mansoni eggs isolated from mouse livers (44) using 
TriReagent (Sigma-Aldrich, St. Louis, MO) following the manufacturer’s instructions. First strand 
cDNA synthesis was performed on 1 µg total RNA using SuperScript II (Stratagene, La Jolla, CA). 
108 
	
PCR amplification of FPPS and GGPPS was accomplished using gene-specific primers (IDT, 
Coralville, IA) designed using sequences identified in the S. mansoni genome and EST databases 
after queries with known FPPS and GGPPS sequences: SmFPPS forward 5’-
caccATGCCAACCTCTGATATACATA; SmFPPS reverse 5’-
TTAACAAGCACGTTGAAAAAGTAATTC; SmGGPPS forward 5’-
caccATGGATGCAGAAAGAAGTGG; SmGGPPS reverse 5’-
TTATCTCTCATTTAGAAACAGG and Pfu or Vent DNA polymerase. The PCR products were 
cloned into pET100 (Invitrogen, Carlsbad, CA), transformed into E. coli BL21 star (DE3) cells, 
plated on LB containing 50 µg/mL ampicillin, and cultured overnight at 37ºC to select for 
ampicillin resistant clones. The clones were confirmed by DNA sequencing. 
Recombinant Protein Expression and Purification 
A single colony was used to inoculate a 1 mL liquid broth containing 50 µg/mL ampicillin 
at 37ºC overnight. The overnight culture was transferred to a 500 mL culture of LB-broth 
containing 50 µg/mL ampicillin at 37ºC and shaken at 200 rpm to an OD600 of 0.5. Recombinant 
protein expression was induced in the culture with 1 mM isopropyl-ß-D-thiogalactodinoside 
(IPTG) and incubated for a further 3 h. The cells were harvested by centrifugation (Sorvall 
Evolution RC) at 9000 rpm for 15 min. Protein was obtained by lysing cells by freeze and thaw 
cycles followed by sonication (Branson Digital Sonifier) for 6 min.  Sonicated cells were 
centrifuged again at 23000 rpm for 30 minutes. The recombinant proteins were purified from the 
supernatant by nickel-affinity chromatography (GE Healthcare) using 10 mM phosphate buffer, 
pH 7.4, containing 10 mM imidazole, and eluted with increasing concentrations of imidazole (100 
mM, 300 mM and 500 mM) in 10 mM phosphate buffer, pH 7.4. The purified protein was run on 
a 16% SDS polyacrylamide gel to ascertain its size and purity, after which glycerol stocks of BL21 
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star (DE3) containing the correct gene inserts of each enzyme were made and stored at -80º C for 
future use. 
Radiometric Assays for SmFPPS and SmGGPPS 
The FPPS enzyme assays were performed essentially as described (34). In this radiometric 
assay, 14C-labeled IPP reacts with the allylic diphosphates, DMAPP, GPP, or FPP, catalyzed by 
FPPS. The products of these reactions are GPP, FPP and GGPP, respectively. 100 µL of assay 
buffer containing 10 mM HEPES, pH 7.4, 5 mM MgCl2, 2 mM dithiothreitol, 47 µM [4-14C] IPP 
(55 mCi/mmol) and 55 µM of the allylic diphosphate, was pre-warmed to 37º C. The assay was 
initiated by addition of 20 ng of recombinant SmFPPS and allowed to proceed for 30 min. The 
reaction was terminated by addition of 10 µL of 6 M HCl and made alkaline by addition of 15 µL 
of 6 M NaOH diluted with 0.7 mL of water and extracted with 1 mL of hexane. The hexane solution 
was washed with water and transferred to a scintillation vial for counting. One unit of enzyme 
activity is defined as the activity required for incorporating 1 nmol of [4-14C] IPP into 14C-labeled 
product in 1 min.  
The GGPPS assays were performed as described (20, 24). In this assay, 14C-labeled IPP 
reacts with the allylic diphosphates (DMAPP, GPP or FPP) to form, GPP, FPP or GGPP, 
respectively. The 20 µL assay set up consisted of 25 mM HEPES, 2 mM MgCl2, 0.5% n-octyl-β-
glycopyranoside, 10 µM [4-14C] IPP (55 mCi/mmol) and 10 µM of the allylic diphosphate. The 
reactions were initiated by addition of 200 ng of recombinant SmGGPPS and were allowed to 
proceed for 15 min at 37º C. The reactions were stopped by the addition of 2 mL of n-butanol 
saturated with water, followed by 1 mL of 6 M KCl, and were then vortexed for 1 min. The butanol 
phase was transferred to a scintillation vial for counting. Enzyme activity was determined as the 
amount of protein needed to incorporate 1 nmol of [4-14C] IPP into 14C-labeled product in 1 min. 
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Kinetic Analysis: Km and Vmax 
The Michaelis-Menten constant (Km) and the maximum velocity (Vmax) of SmFPPS were 
determined at an IPP concentration of 47 µM with concentrations of DMAPP, GPP and FPP 
varying from 0 µM to 100 µM, or with IPP from 0 µM to 100 µM, while keeping the concentrations 
of DMAPP, GPP, and FPP constant at 55 µM. For SmGGPPS, IPP or DMAPP/GPP/FPP was 
maintained at 10 µM while the second substrate was varied from 0 µM to 50 µM. Km and Vmax for 
all substrate and enzyme combinations were determined by plotting velocity vs. substrate 
concentration using SigmaPlot (Systat Software Inc., Chicago, IL). 
Inhibition of SmFPPS and SmGGPPS by Bisphosphonates 
Depending on solubility, bisphosphonates were typically prepared as 500 µM stock 
solutions in DMSO or basic deionized water.  Gradients of bisphosphonate concentrations (100 
µM to 5 nM) were prepared by serial dilution.  Inhibitors and 200 ng of enzyme were incubated at 
room temperature for 10 minutes in the assay buffer (10 mM HEPES, 150 mM NaCl, 1 mM MgCl2, 
pH 7.5) before adding GPP and 3H-IPP to 50 µM final concentration.  The reactions were allowed 
to proceed for 20 minutes in water bath at 37◦ C, then terminated by addition of 3 mM HCl in 
MeOH.  The reaction mixtures were neutralized by NaOH/hexane and the organic phases were 
collected for radioactive counting.  If significant inhibition (>80%) was seen at 50 µM inhibitor, 
the inhibitor concentration was titrated to determine the 50% inhibitory concentration (IC50) value, 
using Prism 5 (GraphPad Software, Inc., La Jolla, CA).  
Activity of Bisphosphonates Against Adult S. mansoni Worms.   
Experiments were performed as described (43).  Infection of mice (NIH Swiss, National 
Cancer Institute, Rockville, MD) with S. mansoni cercariae (NMRI strain) obtained from infected 
Biomphalaria glabrata snails and perfusion of adult worms (6–7 weeks) from mice were carried 
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out as described previously (44). Adult worms were obtained by perfusing the portal veins of mice 
45-50 days post infection using DMEM. Live worms were washed thoroughly with DMEM and 
incubated in 5 mL RPMI media (Sigma-Aldrich) supplemented with 100 units/mL penicillin, 50 
µg/mL streptomycin sulfate, 2 mM L-glutamine, and 10% fetal calf serum (Invitrogen). 
Bisphosphonates at 50 µM were added to each well and the culture was replenished every day with 
fresh media and inhibitors. Worms were checked and counted every day for worm pairing, 
motility, and the presence of live and dead worms. Dead worms were identified as those worms 
that showed zero motility for several minutes. This study was approved by the Institutional Animal 
Care and Use Committee at Rush University Medical center (IACUC number 08-058; DHHS 
animal welfare assurance number A3120-01). 
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4.6 Tables and Figures  
 
Table 4.1 Comparison of SmFPPS and SmGGPPS with orthologs from other species.  
Schistosoma mansoni FPPS: XP_002578266 and S. mansoni GGPPS: XP_002573680. 
 
 
  
Organism Enzyme % Identity % Similarity Accession number 
Xenopus laevis FPPS 36 53 NP_001084626 
Danio rerio FPPS 37 55 AAH83515 
Homo sapiens FPPS 35 54 NP_001995 
Drosophila melanogaster FPPS 34 54 NP_477380 
Trypanosoma brucei gambiense FPPS 36 54 CBH12431 
Plasmodium vivax FPPS 37 60 XP_001615401 
Xenopus laevis GGPPS 53 71 NP_001091413 
Danio rerio GGPPS 56 72 XP_002664282 
Homo sapiens GGPPS 53 71 NP_004828 
Drosophila melanogaster GGPPS 46 66 NP_523958 
Mus musculus GGPPS 55 72 NP_034412 
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Table 4.2 Catalytic activity of Schistosoma mansoni FPPS and GGPPS. In each reaction the 
substrate being varied appears first. All Vmax and Km values are each calculated from the mean 
of three independent reactions ± standard errors.  One active unit is defined as one nmol of product 
formed per minute.  
Enzyme Reaction Vmax(units/mg) Km (µM) 
SmFPPS 
IPP + DMAPP 1100 ± 90 18 ± 5 
DMAPP + IPP 1100 ± 50 17 ± 2 
GPP + IPP 400 ± 20 19 ± 3 
IPP + GPP 750 ± 40 17 ± 2 
FPP + IPP 15 ± 1 12 ± 2 
IPP + FPP 22 ± 1 19 ± 1 
  
SmGGPPS 
IPP + DMAPP 70 ± 4 2.5 ± 1 
DMAPP + IPP 67 ± 5 3.0 ± 1 
GPP + IPP 370 ± 30 7.0 ± 1 
IPP + GPP 180 ± 10 6.0 ± 2 
FPP + IPP 120 ± 9 3.6 ± 1 
IPP + FPP 180 ± 1 7.0 ± 2 
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Table 4.3  Activity of bisphosphonates against Schistosoma mansoni FPPS and GGPPS.  
Activities of the bisphosphonates against human FPPS and GGPPS are shown for ease of 
comparison (53).  ND, not determined.  
 
  Inhibitor IC50 (µM) 
Compound SmFPPS SmGGPPS HsFPPS HsGGPPS 
2 (risedronate) 0.19 6.4 0.24 350 
91(zoledronate) 0.14 5.0 0.11 100 
460 0.53 32 1.72 ND 
703 0.038 3.4 1.0 2.0 
715 0.65 4.4 2.0 0.28 
749 9.9 2.1 35 0.98 
754 1.9 9.1 550 0.59 
782 1.9 4.1 ND ND 
811 0.037 35 ND 4.5 
1186 1.9 23 7 ND 
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Figure 4.1 Schematic representation of the mevalonate pathway in Schistosoma mansoni. 3-
hydroxy-3-methylglutaryl-CoenzymeA (HMG-CoA), the product of HMG-CoA synthase is 
converted to mevalonate by HMG-CoA reductase, the target of the cholesterol-reducing statins.   
A series of reactions converts mevalonate to dimethylallyl diphosphate (DMAPP), which is 
converted to its isomer isopentenyl diphosphate (IPP). Condensations of one DMAPP and one IPP 
to produce geranyl diphosphate (GPP), and IPP with GPP to form farnesyl diphosphate (FPP) are 
carried out by FPP synthase (FPPS), and are the target of bisphosphonate therapies. Condensation 
of FPP and IPP leads to the production of geranylgeranyl diphosphate (GGPP) by GGPP synthase 
(GGPPS). FPP is used to synthesize various quinones, GGPP is used to synthesize dolichols, and 
both are essential in the post-translational prenylation of a variety of proteins (e.g., the small 
GTPases Ras, Rab and Rho) that are important for cell signaling and survival. Rhodoquinones play 
a crucial role in electron transport chain during cellular respiration in S. mansoni mitochondria.  
Conversion of FPP to squalene does not occur in S. mansoni, and therefore, there is no cholesterol 
synthesis. 
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Figure 4.2  Mechanism of FPP, GGPP, and downstream isoprenoids biosynthesis. 
A. Structures of substrates and products of SmFPPS and SmGGPPS catalysis. B. Structures of 
bisphosphonate compounds used in this study.   
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Figure 4.3 The most conserved motifs, i.e., the first aspartate-rich motif (FARM) and the 
second aspartate-rich motif (SARM), in three different types of FPPS and GGPPS enzymes from 
various species.  Residues that form a “lid,” effectively limiting binding to shorter allylic 
diphosphates, are shown with arrows. Sc, Saccharomyces cerevisiae; Hs, human; Ec, 
Escherichia coli; Bs, Bacillus stearothermophilus; Tg, Toxoplasma gondii; Pv, Plasmodium 
vivax; Sm, Schistosoma mansoni; Sa, Sulfolobus acidocaldarius; Mt, Methanobacterium 
thermoautotrophicum; Pa, Pantoea ananatis; At, Arabidopsis thaliana. 
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Figure 4.4  Dose-response curves for bisphosphonates inhibiting S. mansoni FPPS and 
GGPPS enzymes.  A.  IC50 curves of inhibitor concentration vs. percent FPPS inhibition.  B. IC50 
curves of inhibitor concentration vs. percent GGPPS inhibition.   
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Figure 4.5 Dose-response curves for bisphosphonates inhibiting ex vivo adult S. mansoni 
worm growth.  A. Survival of ex vivo adult S. mansoni worms cultured in the presence of 50 µM 
bisphosphonates risedronate, zoledronate, and 715 as a function of time.  B.  Survival of ex vivo 
adult S. mansoni worms cultured with 50 µM risedronate, zoledronate, and 715 and with various 
concentrations of compounds 746, 766, 777, and 820. Worms were cultured in RPMI medium with 
inhibitors, with the medium and inhibitors replaced daily. Worms were observed for survival (as 
assessed by motility) over 6 days. The LD50s of the compounds for adult worms are ~25 µM. 
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Chapter 5 
Lipophilic Aromatic Bisphosphonates Inhibiting Farnesyl 
Diphosphate Synthase and Gram-negative Bacterial Cell Growth 
 
5.1 Notes and Acknowledgements 
 Y. Wang synthesized the bisphosphonate inhibitors.  This work was supported by the 
United States Public Health Service (NIH grants CA158191 and GM065307), a Harriet A. Harlin 
Professorship, and the University of Illinois Foundation/Oldfield Research Fund.  The authors 
thank Dr. Robert Schnell and Professor Gunter Schneider for providing the P. aeruginosa FPPS 
expression system and Professor Douglas Mitchell for providing the bacterial strains.  I thank Dr. 
Furong Sun and Dr. Li Zhong for providing mass spectroscopy facilities.  NMR spectra were 
collected using NMR Laboratory of School of Chemical Sciences. 
 
5.2 Introduction 
 The emergence of resistance to antibiotics is a public health threat (1) so new drugs and 
new drug leads acting on new targets are of interest (2, 3). Many of the antibiotics that, over time, 
have been of particular importance inhibit enzymes involved in bacterial cell wall biosynthesis 
which is, therefore, a potentially important area for drug discovery. Isoprenoids are essential for 
synthesis of a variety of cell components such as steroids, quinones, cell wall, etc.  Bacterial cell 
wall biosynthesis involves many enzymes with initially, dimethylallyl diphosphate (DMAPP, 1), 
and isopentenyl diphosphate (IPP, 2) being produced by either the 2-C-methyl-D-erythritol-4-
phosphate or the mevalonate pathways (Figure 5.1). In most bacteria, DMAPP then reacts, 
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sequentially, with two IPP molecules to form trans-farnesyldiphosphate (FPP, 3) in a reaction 
catalyzed by FPP synthase (FPPS).  FPP then acts as the substrate for undecaprenyl diphosphate 
synthase (UPPS) and octaprenyl diphosphate synthase (OPPS) to form the (C55) isoprenoid, 
undecaprenyl diphosphate (UPP, 4) and (C40) isoprenoid, octaprenyl diphosphate (OPP, 5), 
respectively (4).  UPP is then used (in most bacteria) for peptidoglycan, lipopolysaccharide and 
wall teichoic acid biosynthesis; whereas, OPP is used in the ubiquinone biosynthesis, which is an 
essential electron transporter (5).  FPPS being the upstream enzyme controlling multiple 
biosynthetic pathways, is thus of interest for the development of novel anti-infectives. In 
mycobacteria, cell wall biosynthesis is different and begins with formation of cis-FPP, not trans-
FPP, followed by formation of cis-decaprenyl (not undecaprenyl) diphosphate, and will not be 
further discussed here. 
 
Scheme 5.1 Structures of substrates and inhibitors discussed in the Text.   
 
In our group, we previously reported that the lipophilic bisphosphonate 6 had modest 
activity against E. coli (IC50 ~30 µM) (6) and exhibited potent synergy (fractional inhibitory 
concentration index, FICI = 0.18) with fosmidomycin (7), which inhibits the MEP pathway (7).  
Here, we synthesized and tested a several bisphosphonates containing electron-withdrawing and 
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electron-donating groups, and tested them for prenyl synthase activity and for activity against both 
gram-positive as well as gram-negative bacteria. 
 
5.3 Results and Discussions  
Farnesyl Diphosphate Synthase as an Antibacterial Target 
FPPS is the target for bisphosphonate bone resorption drugs such as zoledronate (8), though 
8 has essentially no antibacterial activity. However, as noted above, in earlier work (6) we found 
that the lipophilic bisphosphonate 6 (an FPPS inhibitor first made (8) by Widler et al. as a potential 
bone resorption drug) had weak but measurable (~30 µM) activity against the gram-negative 
bacterium E. coli. We also found activity against FPPS from the trypanosomatid parasite 
Trypanosoma brucei (TbFPPS) and we solved the X-ray crystallographic structure of a TbFPPS•6 
complex (9). What was of interest in the crystal structure was that the phenyl group in 6 was close 
(~4 Å) to a tyrosine group (Y99) which in human FPPS (HsFPPS) is a Phe (F99). This Phe in 
HsFPPS is thought to be involved in limiting chain elongation to C15 and is present in FPPSs from 
other eukaryotes such as that from Schistosoma mansoni (10).  A partial alignment of TbFPPS, 
HsFPPS, SmFPPS as well as gram-positive and gram-negative bacterial FPPSs (S. aureus, B. 
subtilis, E. coli, Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa) 
is shown in Figure 5.2. 
 The bacterial FPPSs are different to those from eukaryotes in that there are two extra amino 
acids in the first aspartate-rich domain (which is involved in catalysis), plus, there is a conserved 
YS sequence: both motifs are illustrated in yellow in Figure 5.2.  In our earlier work we found that 
longer- or shorter-chain analogs of 6 had less activity than did 6 against FPPS, and E. coli cell 
growth (6). Also, based on structure alignments (discussed more below), it appeared that the 
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aromatic group in 6 (or its analogs) might interact with the electron-rich Tyr in the bacterial YS 
motif.  We thus hypothesized that it might be possible to obtain improved activity by incorporating 
electron-withdrawing substituents on the phenyl group in 6 or its analogs, leading to a tyrosine-
inhibitor charge transfer interaction. In contrast, addition of an electron-donating substituent might 
decrease activity, basically as we suggested in earlier work on bisphosphonate inhibitors of ATP-
mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3′-azido, 3′-
deoxythymidine (11). We thus made 3 analogs of 6, 9-11 and tested them against various FPPSs 
as well as in bacterial cell growth inhibition assays. 
As can be seen in Scheme 5.1, in addition to adding substituents (F2, Br or OMe) to the 
phenyl group, we replaced the amine with an imidazolium group since in other work (12) we found 
such species to be potent FPPS inhibitors with good in vivo activity, plus, we replaced the 1-OH 
group with a 1-H since the hydroxyl group is involved (in other bisphosphonates) in potent bone 
binding (13). Plus, these analogs appeared to be more readily synthesized than the corresponding 
amines. We then tested all 3 compounds against FPPSs from E. coli, P. aeruginosa, T. brucei, 
human, and S. mansoni, as well as against human geranylgeranyl diphosphate synthase 
(HsGGPPS). Results are shown in Table 5.1.  As can be seen in Table 5.1, two of the three 
bisphosphonates had activity in the ~70-600 nM range against EcFPPS, PaFPPS, TbFPPS, 
HsFPPS, SmFPPS, and HsGGPPS, generally similar to that we see (under the same assay 
conditions) with zoledronate, although zoledronate is only a weak HsGGPPS inhibitor (12) while 
9-11 are all active against HsGGPPS, consistent with previous work on other lipophilic 
bisphosphonates. 
However, with the two bacterial enzymes, EcFPPS and PaFPPS, there is essentially no 
FPPS inhibition by the methoxy analog 11. This was the behavior that was originally predicted so 
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the differences between the EcFPPS/PaFPPS and other FPPS inhibition results with 9-11 may be 
due to interactions with a Tyr (Y79), combined with small differences between the Type II 
(EcFPPS; eubacterial) and type I (eukaryotic) FPPS structures. At present, we do not have the 
structures of 9, 10, or 11 bound to a bacterial FPPS. However, we show in Figure 5.3 a structural 
alignment of TbFPPS•6 (PDB ID code 2P1C) with EcFPPS (PDB ID code 1RQJ) from which it 
can be seen that the conserved YS residues in EcFPPS could align with their Tyr residue in close 
proximity (~3 Å) to the phenyl group in the TbFPPS•6 structure, consistent with a role for a charge-
transfer interaction (11). This is of course a speculative proposal, but clearly there are major 
differences in FPPS inhibition between 9, 10, and 11 in the bacterial and eukaryotic systems and 
charge transfer seems a likely reason for the differences observed.  
We next tested 9-11 in growth inhibition assays. First, against the gram positives S. aureus 
and Bacillus subtilis, as well as Mycobacterium smegmatis.  Second, against the gram negatives 
E. coli, P. aeruginosa, K. pneumoniae and A. baumannii.  Third, against a human embryonic 
kidney (HEK293) cell line.  Results are shown in Table 5.1 and Figures 5.4, 5.5. There was little 
or no activity of 9-11 against S. aureus or B. subtilis, but there was some activity against M. 
smegmatis (corresponding to an IC50 of ~7 µg/mL for 9 and 10).  However, the difluoro-species 9 
as well as the bromo-species 10 had promising activity against all four gram negatives, in the ~1-
4 µg/mL range, but the methoxy analog 11 was inactive, Table 5.1. These results are of interest 
since they indicate that in the gram negatives, 9-11 exhibit the same overall pattern of activity in 
cells that we find for EcFPPS and PaFPPS enzyme inhibition, Table 5.1, where 11 was inactive. 
Why there is less activity against S. aureus and B. subtilis cell growth is not known and naturally 
could involve both differences in uptake/efflux as well as FPPS inhibition, although the latter 
possibility seems unlikely given the strong sequence similarities in the active site regions, Figure 
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5.2.  But how can we further test whether FPPS is actually a target for 9 and 10 in the gram-
negative organisms? 
To help answer this question, we first investigated whether there were synergistic effects 
between bisphosphonate 9 and fosmidomycin (7) in E. coli, A. baumannii, K. pneumoniae and P. 
aeruginosa, basically as we described previously for 6 in E. coli.  More specifically, we determined 
the fractional inhibitory concentration index (FICI) values for each combination using the FICI 
formula (14, 15): 
𝐹𝐼𝐶𝐼 = 𝐹𝐼𝐶. + 𝐹𝐼𝐶/ = 𝑀𝐼𝐶(𝐴𝐵)𝑀𝐼𝐶(𝐴) + 𝑀𝐼𝐶(𝐵𝐴)𝑀𝐼𝐶(𝐵)  
where FICA and FICB are the fractional inhibitory concentrations of drugs A and B, 
MIC(A) and MIC(B) are the MIC values of drugs A and B acting alone, and MIC(AB) and 
MIC(BA) are the MIC values of the most effective combination of drug A or B in the presence of 
drug B or A. Using this method, FICI values of <0.5 represent synergy, >0.5 and <1.0 represent 
additivity, >1 and <2 represent an indifferent effect, and ≥2 represents antagonism (16). In 
addition, we evaluated isobolograms using the method of Berenbaum (17). FICI values are shown 
in Table 5.2 and isobolograms in Figure 5.6. We find FICI values of 0.39 ± 0.15 (E. coli); 0.64 ± 
0.23 (A. baumannii); 0.22 ± 0.026 (K. pneumoniae) and 0.44 ± 0.12 (P. aeruginosa), Table 5.2. 
FICI values of <0.5 are generally taken to indicate a synergistic interaction so these results are 
consistent with 9 inhibiting the same pathway as does fosmidomycin, that is, isoprenoid 
biosynthesis. 
Another possible test of whether FPPS is a target is whether cell growth inhibition is 
“rescued” by addition of farnesol. The use of farnesol, farnesyl diphosphate, geraniol and 
geranylgeranyl diphosphate has been used previously—in mammalian cell lines as well as in 
trypanosomes (parasitic protozoa)—to assess the effects of bisphosphonates on cell growth, and 
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in mammalian cell lines it is known that there are kinases that convert GGOH à GGPP (18, 19), 
with GGOH rescuing cells from bisphosphonate growth inhibition.  There are also kinases that can 
convert e.g. FOH to FP but whether such prenol kinases are present in the organisms studied here 
is not known so caution needs to be exercised in interpreting the results. We grew all four gram-
negative bacteria in the absence or presence of 200 µM FOH resulting in, on average, an ~8x 
increase in the IC50 for growth inhibition by the bisphosphonates 9 and 10, consistent with an FPPS 
target, Table 5.3 and Figure 5.7. 
Next, we carried out growth inhibition assays of 9 and 10 against an E. coli strain that 
overexpressed PaFPPS (20), again resulting in a considerable (~9x) increase in the IC50 values for 
both 9 and 10, Table 5.3.  So, based on the patterns of FPPS and cell growth inhibition by 9-11; 
synergistic activity with fosmidomycin; partial rescue of cell growth inhibition by FOH, and the  
FPPS overexpression results, we conclude that the activity of 9 and 10 in the gram-negative 
bacteria is due—at least in part—to FPPS inhibition. The two active compounds 9 and 10 contain 
electron-withdrawing substituents and are likely to undergo charge-transfer interactions with the 
conserved Tyr79 (Figures 5.2, 5.3), an interaction that would be absent with the methoxy side-
chain containing species 11. It is also possible that there are additional targets, but the key point is 
that 9, 10 are the first bisphosphonates to have promising (1-4 µg/mL) IC50 values against these 
four gram-negative bacteria—values that are about an order of magnitude higher than found with 
6; FPPS is at least one of the targets involved; and there was little effect on HEK293 cell growth. 
 
5.4 Conclusions 
The results we have reported above are of interest for several reasons. We synthesized a 
bisphosphonates containing electron-withdrawing and electron-donating substituents in order to 
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find novel inhibitors of isoprenoid biosynthesis that also inhibited bacterial cell growth. Based on 
earlier work on E. coli cell growth inhibition and the structure of a T. brucei FPPS-bisphosphonate 
complex, we made novel bisphosphonates containing electron-withdrawing aryl substituents that 
inhibited E. coli, K. pneumoniae, A. baumannii and P. aeruginosa cell growth in the 1-4 µg/mL 
range. Growth inhibition was partially rescued (an increase in IC50 by a factor of ~8) by addition 
as farnesol, and in cells overexpressing FPPS, and FICI values with one bisphosphonate with 
fosmidomycin were 0.42 ± 0.17, consistent with an isoprenoid biosynthesis target. Overall, the 
results are of interest since we have found new prenyl synthase inhibitors that target FPPS that 
have single-digit micromolar activity against numerous pathogenic bacteria. 
 
5.5 Methods and Materials  
Materials  
Purine nucleoside phosphorylase (PNP) and pyrophosphatase (inorganic, baker’s yeast) 
were purchased from Sigma-Aldrich (St. Louis, MO).  7-Methyl-6-thioguanosine (MESG) was 
purchased from Berry Associates (Dexter, MI).  PaFPPS cloned plasmid was provided by Prof. 
Gunter Schneider.  Escherichia coli BL21-CodonPlus (DE3)-RIPL cells were obtained from 
Agilent Technologies (Santa Clara, CA).  Isopropyl-β-D-thiogalactopyranoside (IPTG) was from 
Gold Biotechnology (St. Louis, MO).   
E. coli Growth Inhibition Assay 
IC50 values for E. coli cell growth inhibition were determined using a microdilution 
method. Stationary overnight starter cultures of E. coli (K-12 or BL21 (DE3) strains), were diluted 
1000-fold and grown to an OD600 of ~0.3. These log-phase cultures were then diluted 500-fold into 
fresh LB broth to generate a “working solution”.  200 µL of working solution was transferred into 
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each well of a 96-well culture plate (Corning 3370). Inhibitors were then added at 1 mM and 
sequentially diluted 3x to 46 nM, keeping volume and culture broth composition constant.  Plates 
were incubated for 12 hours at 37°C, shaking at 200 RPM, then absorbance at 600 nm measured 
to assess bacterial cell growth. IC50 values were determined using nonlinear regression whereas 
minimum inhibitory concentration (MIC) values in the synergy assays were calculated by using a 
Gompertz function in Prism 5 (GraphPad Software, Inc., La Jolla, CA). 
Gram-negative Bacterial Cell Growth Inhibition Assay 
As with the E. coli inhibition assays, overnight cultures (in cation-adjusted Mueller-Hinton 
broth, CAMHB) of A. baumannii (Bouvet and Grimont, ATCC 19606); K. pneumoniae (subsp. 
Pneumoniae Schroeter Trevisan ATCC 27736); and P. aeruginosa (PA01) were diluted 1000-fold 
(in fresh CAMHB) to create a “working solution”.  Working solutions were then transferred into 
flat-bottom 96-well plates and inhibitors added at 1 mM and sequentially diluted 3x to 46 nM. 
Plates were incubated at 37°C, shaking at 200 RPM, overnight.  The OD600 was then measured to 
determine bacterial growth inhibition. 
B. subtilis Growth Inhibition Assay 
An overnight starter culture (in LB broth) of B. subtilis (subsp. subtilis (Ehrenberg) Cohn 
ATCC 6051) was diluted 1000-fold (in fresh LB media) to create a “working solution”. Working 
solutions were then transferred into flat-bottom 96-well plates and inhibitors were added at 1 mM 
and sequentially diluted 3x to 46 nM. Plates were incubated at 37°C, shaking at 200 RPM 
overnight. The OD600 was then measured to determine bacterial growth inhibition. 
S. aureus Growth Inhibition Assay 
An overnight starter culture of S. aureus (Newman strain) in tryptic soy broth was diluted 
1000-fold in fresh tryptic soy media to create a “working solution”. Working solutions were 
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transferred into flat-bottom 96-well plates and inhibitors added at 1 mM and sequentially diluted 
3x to 46 nM.   Plates were incubated at 37°C, shaking at 200 RPM overnight. The OD600 was then 
measured to determine bacterial growth inhibition. 
HEK293 Toxicity Assay 
A frozen stock of human embryonic kidney cells (HEK293 ATCC CRL-1573) was used to 
grow a first generation of cells in DMEM (4.5 g/mL glucose with L-glutamine) containing 10% 
fetal bovine serum (FBS) and 1% penicillin-streptomycin (10,000 U/mL).  This generation was 
harvested in 0.25 % trypsin/2.1 µM EDTA and cells were counted under a light microscope.  A 
"working solution" was generated containing 105 cells/mL, which was then transferred into a flat-
bottom 96-well plate for 36 hours.  At this time, 20 µL of inhibitor solutions ranging from 1 mM 
to 46 nM were added and cells were allowed to grow in the presence of the inhibitors for an 
additional 24 hours.  Then 10 µL of MTT solution (5mg/mL in PBS) was added to each well and 
incubated for 4 hours.  100 µL of 100 mM HCl in isopropanol was added to each well and 
absorbance at 570 nm was measured.  MIC values were calculated by using a Gompertz function 
in Prism 5 (GraphPad Software, Inc. La Jolla, USA). 
Synergy/Antagonism Assays 
In order to investigate possible synergistic interactions between compound 9 and 
fosmidomycin, we carried out two-drug combination assays.  Bacteria were incubated with a 3x 
gradient of fosmidomycin ranging from 40 µg/mL to 18 ng/mL in the presence half-MIC 
concentrations of 9, in addition to a 3x gradient of 9 ranging from 40 µg/mL to 18 ng/mL in the 
presence of half-MIC concentrations of fosmidomycin.  New MIC values were calculated by using 
a Gompertz function in Prism 5 (GraphPad Software, Inc., La Jolla, CA). 
 
138 
	
Enzyme Inhibition Assays 
FPPS enzymes were expressed and purified as described previously (6, 8–10, 12, 20).  
FPPS assays were carried out using a phosphate release assay (6).   Depending on the solubility, 
bisphosphonates inhibitors were prepared as 10 mM stock solutions in basic water (pH~10), and 
then serially diluted from 1 mM to 1 nM.  Inhibitors were incubated with 25 ng of various FPPS 
enzymes at room temperature for 10 minutes in a pH 7.0 buffer (10 mM HEPES, 150 mM NaCl, 
5 mM MgCl2) before adding “reaction mixture” containing 50 µM GPP, 50 µM IPP, 3 U/mL purine 
nucleoside phosphorylase, 1 U/mL inorganic phosphatase, and ~600 µM 7-methyl-6-
thioguanosine (MESG), again in the same buffer.  FPPS reactions were monitored for 15 minutes 
with the rate of increase in absorbance at 360 nm taken as the rate of FPP synthesis.  IC50 values 
were calculated by using Prism 5 (GraphPad Software, Inc., La Jolla, CA).  
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5.6 Tables and Figures 
 
Table 5.1 IC50 values of 9-11 against FPPS (in µM), GGPPS (in µM), bacteria (µg/mL) and 
human cells in (µg/mL) 
 
  
Enzymes / 
Organisms  
P
O
HO
HO
N N
F
F
P
HO O
O
9  
P
O
HO
HO
N N
P
HO O
O
Br
10  
P
O
HO
HO
N N
P
HO O
O
O
11  
EcFPPS 0.12 ± 0.025 1.6 ± 0.28 >100 
PaFPPS 0.32 ± 0.068 0.58 ± 0.15 >100 
TbFPPS 0.12 ± 0.026 0.16 ± 0.029 0.51 ± 0.20 
HsFPPS 0.065 ± 0.012 0.12 ± 0.026 0.084 ± 0.0083 
SmFPPS 0.57 ± 0.11 0.33 ± 0.054 0.50 ± 0.065 
HsGGPPS 0.39 ± 0.073 0.33 ± 0.089 0.53 ± 0.11 
S. aureus >100 >100 >100 
B. subtilis 39 ± 13 26 ± 5.9 >100 
M. smegmatis 6.8 ± 3.0 7.5 ± 2.4 20 ± 5.3 
E. coli 2.1 ± 0.57 1.7 ± 0.38 >100 
A. baumannii 2.8 ± 0.70 2.0 ± 0.50 >100 
K. pneumonia 2.3 ± 0.49 2.4 ± 0.43 >100 
P. aeruginosa 3.5 ± 0.78 3.3 ± 0.68 >100 
HEK293 27 ± 4.0 36 ± 8.6 82 ± 22 
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Table 5.2 Combination of 9 with fosmidomycin against gram-negative bacteria. 
  
  
Organism 
MIC 
fosmidomycin 
(µg/mL) 
FIC  
fosmidomycin 
MIC 11  
(µg/mL) FIC 11 FIC Index 
E. coli 5 0.14 ± 0.13 6 0.24 ± 0.023 0.39 ± 0.15 
A. baumannii 5 0.27 ± 0.057 6 0.37 ± 0.17 0.64 ± 0.23 
K. pneumoniae 5 0.12 ± 0.014 6 0.097 ± 0.012 0.22 ± 0.026 
P. aeruginosa 3 0.18 ± 0.066 10 0.27 ± 0.057 0.44 ± 0.12 
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Table 5.3 IC50 values (in µg/mL) of 9, and 10 in E. coli, A. baumannii, K. pneumoniae, P. 
aeruginosa, in the presence of 200 µM farnesol and E. coli overexpressing P. aeruginosa FPPS 
(PaFPPS++). 
 
  
Organism Inhibitor Rescuing Agent (RA) 
IC50 
w/o RA 
IC50 
w/ RA 
E. coli 9 Farnesol 2.1 ± 0.57 19 ± 4.1 
E. coli 10 Farnesol 1.7 ± 0.38 28 ± 9.0 
A. baumannii 9 Farnesol 2.8 ± 0.70 18 ± 4.9 
A. baumannii 10 Farnesol 2.0 ± 0.50 22 ± 2.4 
K. pneumoniae 9 Farnesol 2.3 ± 0.49 13 ± 1.8 
K. pneumoniae 10 Farnesol 2.4 ± 0.43 21 ± 4.2 
P. aeruginosa 9 Farnesol 3.5 ± 0.78 23 ± 7.8 
P. aeruginosa 10 Farnesol 3.3 ± 0.68 22 ± 3.5 
E. coli  9 PaFPPS++ 2.1 ± 0.57 19 ± 2.4 
E. coli  10 PaFPPS++ 1.7 ± 0.38 15 ± 3.6 
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Figure 5.1 Illustration of selected molecules involved in ubiquinone and cell wall biosynthesis 
in most bacteria. Also shown are sites of action of fosmidomycin and potential targets, discussed 
in the Text.  
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Figure 5.2 ClustalW alignments of T. brucei, human, S. mansoni and six bacterial FPPSs. The 
YS pair is present in all of the bacterial FPPSs and the Tyr is proposed here to interact with 
electron-deficient aryl groups in bisphosphonate inhibitors.  FARM = first aspartate-rich motif; 
SARM = second aspartate-rich motif.  The squiggly lines represent residues omitted from the 
alignment, for clarity.  
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Figure 5.3 Stereo representation of superimposition of TbFPPS•6 (PDB code 2P1C) with 
EcFPPS (PDB ID code 1RQJ). Side chains of HY (red) and YS (yellow) amino acids are shown 
in stick format.  6 is shown in purple.  Aspartate-rich motif (FARM) is shown in magenta. Mg2+ 
are orange spheres.  
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Figure 5.4 Dose-response curves for 9 and 10 inhibiting gram-negative bacterial cell growth.  
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Figure 5.5 Dose-response curves and MIC values for 9-11 inhibiting human embryonic kidney 
(HEK 293) cell growth.  
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Figure 5.6 Isobolograms for bacterial cell growth inhibition by 9 and fosmidomycin (7) against 
A, E. coli, B, A. baumannii, C, K. pneumoniae and D, P. aeruginosa.  The FICI (fractional 
inhibitory concentration indices) are shown in Table 2. The mean FICI value is 0.42 ± 0.17 
indicating synergistic activity (in most cases). 
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Figure 5.7 Partial rescue of cell growth inhibition by farnesol or PaFPPS overexpression.  
Addition of 200 µM farnesol (FOH) to the growth medium increases the IC50 of 9 and 10 for cell 
growth inhibition by a factor of ~8. A, E. coli K-12 w/ FOH; B, A. baumannii w/ FOH; C, K. 
pneumoniae w/ FOH; and D, P. aeruginosa w/ FOH; E, E. coli BL21(DE3) w/ PaFPPS 
overexpression.  
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Chapter 6 
Bacterial Cell Growth Inhibitors Targeting Undecaprenyl 
Diphosphate Synthase and Undecaprenyl Diphosphate Phosphatase 
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6.2 Introduction 
There is without doubt a pressing need for the development of novel antibiotics having new 
structures and new targets, to help combat the development of drug resistance (1). Over the past 
~70 years, many antibiotics that target bacterial cell wall biosynthesis, compounds such as 
penicillin, methicillin and bacitracin, have been discovered and developed and so the enzymes that 
are used in cell wall biosynthesis are attractive drug targets. A simplified version of bacterial cell 
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wall biosynthesis is shown in Figure 6.1.  Initial steps involve formation of the (C5) isoprenoids 
dimethylallyl diphosphate (DMAPP, 1) and isopentenyl diphosphate (IPP, 2), formed in either the 
mevalonate pathway (in e.g. Staphylococcus aureus) or the 2-C-methyl-D-erythritol 4-phosphate 
(MEP) pathway (in e.g. E. coli), with fosmidomycin inhibiting the MEP pathway (2).  DMAPP 
then condenses, sequentially, with two molecules of IPP to form the (C15) species, farnesyl 
diphosphate (FPP, 3) in a reaction catalyzed by farnesyl diphosphate synthase (FPPS). The FPP so 
produced then condenses with 8 additional IPP molecules to form (C55) undecaprenyl diphosphate 
(UPP, 4) in a reaction catalyzed by undecaprenyl diphosphate synthase (UPPS). UPPS is an 
attractive drug target since it is not used by humans and several inhibitors (tetramic/tetronic acids; 
diamidines and benzoic acids) have been reported (3-5).  UPP is then converted by undecaprenyl 
diphosphate phosphatase (UPPP) to undecaprenyl phosphate (UP, 5) which acts as a membrane 
"anchor" for formation of glycosylated products (Lipid I, Lipid II) which are then converted to 
peptidoglycan cell wall products, as outlined in Figure 6.1. Antibiotics such as bacitracin, 
vancomycin and methicillin target these later stages in cell wall biosynthesis, again as shown in 
Figure 6.1. In this work, we sought to find novel benzoic acid inhibitors of UPPS and potentially 
UPPP since in earlier work, (4) we had found that (2-(3-(decyloxy)benzamido)-5-nitrobenzoic 
acid, 6, Figure 6.1) inhibited UPPS and we reasoned that such lipophilic, anionic species might 
also mimic the UPPP substrate, UPP.  We thus synthesized 30 analogs of 6, 7-36, primarily benzoic 
acids but also, four phosphonic acid analogs, and tested them for activity against Staphylococcus 
aureus and Bacillus subtilis, as well as UPPS and UPPP, and in several cases FPPS. In addition, 
we investigated their possible synergistic activity with a range of known antibiotics that either 
target, or do not target, bacterial cell wall biosynthesis. 
 
154 
6.3 Results and Discussions 
In previous work we found that the benzoic acid 6 (Figure 6.1) was a promising inhibitor 
of both E. coli UPPS (EcUPPS; IC50 = 3.0 µM) and S. aureus UPPS (SaUPPS; IC50 = 0.49 µM).  
but there was no activity against the gram-negative bacterium, E. coli, presumably because of poor 
cell penetration. However, in later work we found that several related lipophilic benzoic acids had 
activity against gram-positive (but not gram-negative) bacteria with 6 having a 1.3 µM IC50 value 
against B. subtilis, but no activity against E. coli, leading us to synthesize the 30 compounds whose 
structures and activities are shown in Table 6.1.  The rationale for the synthesis of these compounds 
was first, to investigate a series of compounds (7-16, 19, 21) in which we varied the substituent 
meta to the carboxyl group, covering a wide range of Hammett σm values (0 for H, 0.71 for NO2) 
which we reasoned would affect the acidity of the carboxyl group, the more electron-withdrawing 
groups yielding, perhaps, a better isostere (carboxylate) of the diphosphate group (in FPP and 
UPP). We also investigated whether phosphonic acids (18, 31, 36) might be better inhibitors than 
benzoic acids, plus, we investigated a broad range of other benzoic acid ring-substitution patterns, 
as well as different "side-chains" (corresponding to the octyloxy group in e.g. 7), in order to probe 
both enzyme as well as cell activity. We then investigated the cell growth inhibition activity of 
these compounds against S. aureus and B. subtilis and IC50 values (in µg/mL) are shown in Table 
6.1 (rank ordered by SaUPPS inhibition, as discussed below). We also screened for activity against 
the yeast Saccharomyces cerevisiae and the gram-negative, E. coli, but there was no activity with 
any compound (IC50 values > 200 µM).  
Typical dose-response curves for 3 compounds: benzoic acids with electron withdrawing 
(7) or electron donating (13) ring substituents, plus a phosphonic acid analog (18), are shown in 
Figure 6.2.  There were several active compounds amongst the 30 investigated, with the most 
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active being the m-trifluoromethoxy analog 11, with an IC50 value of 0.082 µg/mL against S. 
aureus. The most active bacterial cell growth inhibitors were all lipophilic benzoic acids with 
highly electron-withdrawing (-NO2, OCF3) ring substituents, Table 6.1.  The presence of electron-
donating groups (13, 14) decreased activity, as did the presence of substituents that might 
hydrogen-bond to water (19, 22, 27, 29). The phosphonic acids (19, 31, 36) had little or no cell 
activity although the diethyl phosphonate 21 was active, consistent with the observation that all 
compounds with additional ionizable groups on the benzoic acid have poor cell activity—an effect 
that might simply be due to poor cell penetration, rather than enzyme inhibition.  
 The question then arises: what might the targets of these inhibitors be? Such lipophilic, 
anionic species could be isosteres of e.g. intermediates in fatty acid biosynthesis, or of isoprenoid 
phosphates or diphosphates, and as noted above we previously found that 6 inhibited and bound 
to UPPS (4) (PDB ID code 4H2O), so UPPS inhibition appeared likely. The compounds were 
designed based on the UPPS inhibition precedent with 6, but FPPS and UPPP inhibition also 
seemed possible (with some carboxylic acids being known, potent FPPS inhibitors, (6) binding to 
an allosteric site). Moreover, if these molecules have a similar pharmacophore to e.g. FPP, then 
there could be other targets, such as MenA, involved in quinone biosynthesis, as well as enzymes 
involved in heme A biosynthesis (7).  To try and narrow down the possibilities as well as open up 
potential routes to synergistic combinations, we next investigated whether or not one of the most 
active compounds, the fluoro-benzoic acid 7, exhibited synergistic, additive, indifferent or 
antagonistic activity with a broad range of antibiotics that act either by inhibiting bacterial cell 
wall biosynthesis, or by other mechanisms. This is basically the approach used previously to 
discover the novel SaUPPS inhibitor, clomiphene (8).  The antibiotics that act by targeting cell 
wall biosynthesis were fosmidomycin, carbenicillin, vancomycin, ampicillin, bacitracin, 
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fosfomycin, and cefotaxime. The compounds that do not target bacterial cell wall biosynthesis 
were kanamycin, tetracycline, sulfamethoxazole, trimethoprim, spectinomycin, and 
chloramphenicol. 
We determined the fractional inhibitory concentration index (FICI) values for each 
combination using the FICI formula: (9, 10) 
FICI = FIC8 + FIC9 = MIC(AB)MIC(A) + MIC(BA)MIC(B)  
where FICA, FICB are the fractional inhibitory concentrations of drugs A and B, MIC(A) and 
MIC(B) are the MIC values of drugs A and B acting alone, and MIC(AB) and MIC(BA) are the 
MIC values of the most effective combination of drug A or B in the presence of drug B or A. Using 
this method, FICI values of <0.5 indicate synergy, >0.5 and <1.0 indicate additivity, >1 and <2 
indicate an indifferent effect, and ≥2 indicates antagonism (11).  In addition, we evaluated 
isobolograms using the method of Berenbaum (12).  FICI values are shown in Table 6.2 and 
selected representative isobolograms are in Figure 6.3. 
As can be seen in Table 6.2, there are very distinct differences between the FICI values 
obtained with 7 and the cell wall biosynthesis inhibitors, and those obtained with 7 and the non-
cell wall biosynthesis inhibitors. For S. aureus, the mean FICI with a cell wall biosynthesis 
inhibitor is 0.32 ± 0.12, and for B. subtilis, 0.37 ± 0.14. These values represent synergism (i.e. the 
FICI is <0.5) and suggest that 7 acts in the cell wall biosynthesis pathway. With the non-cell wall 
biosynthesis inhibitors, the mean FICI for S. aureus in 1.42 ± 0.37, and for B. subtilis, 1.47 ± 0.28, 
meaning indifferent effects, as expected. Clearly then, in both S. aureus as well as in B. subtilis, 7 
is targeting primarily one or more enzymes involved in cell wall biosynthesis (and not e.g. MenA 
or heme A synthase) and likely candidates that utilize long, lipophilic anionic substrates are UPPS, 
UPPP, and perhaps FPPS. We thus next tested all compounds against UPPS (from S. aureus), since 
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in earlier work we had found 6 was a UPPS inhibitor, plus, we tested all compounds against a 
UPP-phosphatase. UPPP is a membrane protein and we used the fusion hybrid of E. coli UPPP 
with Haloarcula marismortui bacteriorhodopsin, (13) which is active in detergent-based assays 
and is inhibited by bacitracin. We also tested the most active compounds against an EcFPPS, but 
there was no inhibition (up to 200 µM). Typical dose-response curves for SaUPPS and EcUPPP 
are shown in Figure 6.4 and include for UPPP, results for the known inhibitor, bacitracin, which 
has an IC50 = 32 µM, as also reported by Chang et al (14).  Inhibition results for all compounds 
are shown in Table 6.1.  
As can be seen in Table 6.1, the most active cell growth inhibitors are also some of the 
most potent UPPS and UPPP inhibitors with IC50 values as low as 320 nM (for UPPS) and 1.3 µM 
(for UPPP). For the top 8 most potent SaUPPS inhibitors (7, 8, 9, 10, 11, 13, 14, 15) there is a 
good correlation with reported Hammett σm values (R2=0.79, data not shown) but this breaks down 
with bulkier substituents. For example, the electron-withdrawing group (EtO)2PO has weak 
activity. We have not been able to obtain X-ray structures of SaUPPS with bound inhibitors, but 
we have reported the structure of 6 bound to EcUPPS (PDB ID code 4H2O), which suggests a 
possible explanation for the results reported here. Specifically, 6 has a decyloxy sidechain and the 
two molecules that bind to UPPS have relatively exposed nitrobenzoate sidechains (4). This 
solvent exposure will have an associated energy penalty. The shorter C8 sidechain in 8 could 
improve enzyme inhibition by reducing this solvent exposure, but the effect is small (0.33 µM vs 
0.49 µM). However, with another pair of ligands: the fluorobenzoate 7 with a C8 sidechain and the 
fluorobenzoate 23 with a C6 sidechain, the shorter chain species has a 4.9 µM IC50 while the longer-
chain species has a much smaller IC50 (IC50=0.32 µM). Taken together, these results indicate that 
inhibitors with a C8 side-chain and small, electron-withdrawing ring substituents have close to 
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optimum activity. Consistent with this, the bulkier methyl sulfone and the diethyl phosphonate—
while being very electron withdrawing—likely contribute to a decrease in binding affinity because 
the added ligand volume will be located nearer to the surface of the protein. This binding mode (as 
seen in PDB ID code 4H2O) in which the alkyloxy groups are buried in the interior of UPPS while 
the benzoates are more solvent exposed, would also explain why adding ionizable electron-
withdrawing groups such as carboxylates or phosphonates also reduces activity, since the added 
ligands are likely to hydrogen bond with the solvent.  Interestingly, as can be seen in Figure 6.5A, 
there is a very good correlation between the pIC50 (= –log10 IC50 [µM]) values for S. aureus and B. 
subtilis cell growth inhibition (a Pearson r-value correlation-coefficient r = 0.90), strongly 
suggesting that the same targets are involved in both systems. And as shown in Figure 6.5B, the 
correlation for S. aureus cell growth versus SaUPPS inhibition is also high with an r = 0.85. Figure 
6.5C shows a Pearson r-value correlation-coefficient matrix (15) for all cell and enzyme activities 
as well as for logD (estimated using the chemicalize.org web portal, http://www.chemaxon.com), 
from which it can be seen that both UPPS inhibition as well as UPPP inhibition correlate with cell 
growth inhibition. There are weaker correlations between cell growth inhibition and logD, and the 
enzyme inhibition results are essentially uncorrelated with logD so, as expected, 
permeability/transport plays a role in overall activity in cell growth inhibition. The enzyme/cell 
correlations are better than those we discussed in a previous study (16) where we found for 10 
different cell/putative enzyme target inhibition assays (three from our group, seven randomly 
chosen from the literature) that on average the correlation between the enzyme and cell assay 
results was r~0.55. 
What is also apparent from the results shown in Table 6.1 is that, in general, the IC50 values 
for UPPP inhibition are larger than the IC50 values for UPPS inhibition, suggesting that in cells, 
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UPPS and not UPPP is the primary target. This is, however, likely to be an over-simplification 
since the enzyme assays were all detergent based; substrate concentrations in cells are not known; 
UPPP is a membrane protein and inhibitors may accumulate in membranes; and we used an 
EcUPPP-bacteriorhodopsin fusion in our assay together with FPP, and not UPP.  Nevertheless, as 
can be seen in Table 6.1, several of the most potent cell growth inhibitors do target both enzymes, 
and inhibition of two consecutive enzymes in the bacterial cell wall biosynthesis pathway is 
expected to result in enhanced activity over single target inhibition. Moreover, we find good 
enzyme inhibition/cell growth correlations (Figure 6.5B), plus, as shown in Figure 6.3, addition of 
any of the known cell wall biosynthesis inhibitors to 7 results in synergistic cell growth inhibition 
with, on average, FICI values of ~0.35. 
 
6.4 Conclusions 
The results reported here are of interest since we find that several lipophilic benzoic acids 
with electron-withdrawing ring substituents have activity against S. aureus and B. subtilis cell 
growth. One of the most potent compounds exhibited synergistic activity with numerous known 
cell wall biosynthesis inhibitors (FICIavg~0.35, n=13 different cell/inhibitor combinations), but an 
indifferent effect (FICIavg~1.45, n=11 cell/inhibitor combinations) with non-cell wall biosynthesis 
antibiotics. We tested all compounds against UPPS and UPPP and in some cases FPPS finding 
several promising UPPS as well as UPPP inhibitors. The most potent UPPP inhibitor 11 was ~40x 
more active than the known UPPP inhibitor, the antibiotic bacitracin, and also inhibited UPPS and 
was active against S. aureus (IC50 ~82 ng/mL). Electron-withdrawing substituents were essential 
for enzyme/cell inhibition by the benzoic acids, presumably because they make the benzoates 
much stronger acids (that are fully dissociated) and more akin to the phosphate/diphosphate 
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enzyme substrates, although the presence of multiple acid groups reduced both enzyme and cell 
activity. The phosphonic acids were worse UPPS/UPPP inhibitors and were mostly inactive in 
cells. There were good correlations between cell growth inhibition and UPPS as well as UPPP 
inhibition, but UPPS inhibition was more potent. Overall, the results are of interest since we show 
for the first time that lipophilic benzoic acids inhibit both UPPS and UPPP and are active in cells 
where they act synergistically with known cell wall biosynthesis inhibitors and as such, they may 
represent new leads for developing bacterial cell wall biosynthesis inhibitors. 
 
6.5 Methods and Materials  
Materials  
Purine nucleoside phosphorylase (PNP) and pyrophosphatase (inorganic, baker’s yeast) 
were purchased from Sigma-Aldrich (St. Louis, MO).  7-Methyl-6-thioguanosine (MESG) was 
purchased from Berry Associates (Dexter, MI).  Malachite green phosphate assay kit was 
purchased from Cayman Chemical (Ann Arbor, MI).   
B. subtilis Growth Inhibition Assay 
IC50 values for B. subtilis cell growth inhibition were determined using a microdilution 
method. A stationary overnight starter culture of B. subtilis (Bacillus subtilis subsp. subtilis 
(Ehrenberg) Cohn ATCC 6051) was diluted 1000-fold and grown to an OD600 of ~0.3. This log-
phase culture was again diluted 500-fold into fresh LB broth to generate the “working solution”.  
200 µL of working solution was transferred into each well of a 96-well culture plate (Corning 
3370). Inhibitors were then added at 1 mM and sequentially diluted 3x to 46 nM, keeping volume 
and culture broth composition constant.  Plates were incubated for 12 hours at 37°C, shaking at 
200 RPM, then absorbance at 600 nm was measured to assess bacterial cell growth. IC50 values 
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were determined using nonlinear regression whereas minimum inhibitory concentration (MIC) 
values for each antibiotic and 7 in the synergy assays were calculated by using a Gompertz function 
in Prism 5 (GraphPad Software, Inc., La Jolla, CA). 
S. aureus Growth Inhibition Assay 
As with the B. subtilis growth inhibition assay, an overnight starter culture of S. aureus 
(Newman strain) was diluted 1000-fold to create a “working solution”. Working solutions were 
transferred into flat-bottom 96-well plates and inhibitors added at 1 mM and sequentially diluted 
3x to 46 nM.   Plates were incubated at 37°C, shaking at 200 RPM for 24 hours. The OD600 was 
then measured to determine bacterial growth inhibition. 
Synergy/Antagonism Assays 
In order to investigate possible synergistic interactions between compound 7 and a range 
of antibiotics, we carried out two-drug combination assays.  Bacterial cells were incubated with a 
3x gradient of antibiotic typically ranging from 40 µg/mL to 18 ng/mL (200 µg/mL to 90 ng/mL 
for bacitracin, fosfomycin, and sulfamethoxazole) in the presence half-MIC concentrations of 7, 
in addition to a 3x gradient of 7 ranging from 40 µg/mL to 18 ng/mL in the presence of half-MIC 
concentrations of each antibiotic.  New MIC values were calculated by using a Gompertz function 
in Prism 5 (GraphPad Software, Inc., La Jolla, CA). 
Enzyme Inhibition Assays 
SaUPPS and EcUPPP were expressed and purified as described previously (4, 16).  UPPS 
assays were carried out using a phosphate release assay (4).   Benzoic acids and phosphonic acids 
were prepared as 10 mM stock solutions in DMSO, and were then serially diluted from 1 mM to 
1 nM.  Inhibitors were incubated with 25 ng of SaUPPS at room temperature for 10 minutes in a 
pH 7.5 buffer (50 mM HEPES, 150 mM NaCl, 10 mM MgCl2, and 0.02% n-dodecyl-β-D-
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maltopyranoside) before adding “reaction mixture” containing 5 μM FPP, 50 μM IPP, 3 U/mL 
purine nucleoside phosphorylase, 1 U/mL inorganic phosphatase, and ~600 μM 7-methyl-6-
thioguanosine (MESG). Reactions were monitored for 15 minutes with the rate of increase in 
OD360 taken as the rate of UPP synthesis.  IC50 values were calculated by using Prism 5 (GraphPad 
Software, Inc., La Jolla, CA).  The UPPP inhibition assay was carried out using a malachite-green 
reagent as described previously (17).   Inhibitors were incubated with 20 nM EcUPPP at room 
temperature for 15 minutes before adding FPP to 35 μM. Reaction mixtures were incubated at 
37°C for 20 minutes, then quenched by adding 30 μL of malachite-green reagent. In this assay, the 
phosphate released from FPP reacts with ammonium molybdate to form phosphomolybdate 
(yellow) which then forms a complex (λmax ~ 620 nm) with malachite-green, used to assess 
phosphatase activity. Phosphate release was measured at 620 nm and quantified based on a 
phosphate standard curve, and the OD620 values used to construct dose-response curves. 
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6.6 Tables and Figures   
 
Table 6.1 Cell growth inhibition and enzyme inhibition results with standard errors.  
Compound BPH#a B. subtilisb S. aureusb SaUPPSc EcUPPPc 
O
O
NH
OHO
F
7  
1463 0.14 ± 0.023 0.16 ± 0.033 0.32 ± 0.059 2.7 ± 1.8 
O
O
NH
OHO
O 2N
8  
1247 0.21 ± 0.030 0.24 ± 0.041 0.33 ± 0.062 1.3 ± 0.78 
O
O
NH
OHO
Br
9  
1264 0.42 ± 0.013 0.79 ± 0.22 0.54 ± 0.10 4.2 ± 1.8 
O
O
NH
OHO
Cl
10  
1466 0.56 ± 0.085 0.23 ± 0.044 0.60 ± 0.15 3.0 ± 1.1 
O
O
NH
OHO
F3CO
11  
1477 0.21 ± 0.10 0.082 ± 0.045 0.78 ± 0.39 0.83 ± 0.11 
O
O
NH
OHO
F
F
12  
1455 0.53 ± 0.10 0.18 ± 0.036 0.96 ± 0.28 3.4 ± 1.8 
O
O
NH
OHO
HO
13  
1457 1.4 ± 0.18 0.42 ± 0.062 1.3 ± 0.20 11 ± 2.8 
O
O
NH
OHO
MeO
14  
1456 1.2 ± 0.18 0.64 ± 0.21 1.3 ± 0.25 >200 
O
O
NH
OHO 15  
1167 0.85 ± 0.11 1.2 ± 0.22 1.6 ± 0.26 10 ± 2.9 
O
O
NH
OHO
S
O
O
16  
1467 2.5 ± 0.47 1.4 ± 0.21 2.0 ± 0.48 9.8 ± 1.5 
O
O
NH
OHO 17  
1262 4.1 ± 1.0 0.82 ± 0.30 2.4 ± 1.3 45 ± 19 
OO
P
B r
O
OH
OH
18  
1297 23 ± 2.3 11 ± 1.3 2.5 ± 0.59 6.7 ± 0.94 
O
O
NH
OHO
PHO
O
HO
19  
1493 >100 >100 3.0 ± 1.0 4.2 ± 1.2 
O
O
NH
OHO
F
20  
1462 2.7 ± 0.42 3.1 ± 0.70 3.2 ± 1.2 8.5 ± 1.9 
O
O
NH
OHO
PEtO
O
EtO
21  
1496 2.3 ± 0.56 3.9 ± 1.5 3.4 ± 1.3 >200 
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Table 6.1 (contd.) Cell growth inhibition and enzyme inhibition results with standard errors.  
Compound BPH#a B. subtilisb S. aureusb SaUPPSc EcUPPPc 
O
O
NH
OHOO
HO
22  
1461 >100 >100 4.5 ± 1.5 >200 
O
O
NH
OHO
F
23  
1468 3.6 ± 0.60 1.3 ±0.20 4.9 ± 1.6 20 ± 6.2 
O
O
NH
OH
HO
O
24  
1458 >100 >100 4.9 ± 1.3 31 ± 15 
O
O
NH
OHO
MeO
25  
1480 3.0 ± 0.39 1.6 ± 0.56 6.0 ± 1.9 >200 
O
NH
OHO
Br
26  
1289 3.4 ± 0.64 0.6 ± 0.16 6.9 ± 2.1 >200 
O
O
HNH O
O
H O O 27  
1464 >100 >100 7.0 ± 1.7 >200 
O
O
N
OHO 28  
1439 20 ± 2.5 18 ± 3.0 8.0 ± 1.6 >200 
O
O
NH
OHO
HO
O
29  
1460 >100 3.0 ± 0.67 8.5 ± 2.8 >200 
O
O
NH
OHO
MeO
OO
30  
1481 2.7 ± 0.60 2.2 ± 0.62 10 ± 3.5 >200 
O
O
NHP OHO OH 31  
1440 >100 41 ± 4.0 39 ± 8.7 6.5 ± 0.90 
O
O
NH
NH2O 32  
1470 >100 >100 60 ± 14 >200 
O
O
NH
Br
O OH O
O
O
33  
1267 >100 33 ± 3.9 130 ± 27 >200 
O
O
NH
O
OH 34  
1465 20 ± 2.7 42 ± 4.4 >200 73 ± 26 
O
O
NH
OHO 35
MeO
OMe
OMe
 
1483 >100 >100 >200 >200 
O
O
NHP
O
HO OH
36  
1432 >100 >100 >200 7.1 ± 7.5 
a compound code #; b IC50 in g/mL; c IC50 in M 
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Table 6.2 Combinations of 7 and antibiotics against B. subtilis and S. aureus. 
B. subtilis 
 Antibiotic MIC antibiotic (µg/mL) 
FIC  
antibiotic 
MIC 7 
(µg/mL) FIC 7 FIC Index 
Cell Wall  
Biosynthesis  
Inhibitors 
Fosmidomycin 5 0.039 ± 0.0053 1 0.13 ± 0.056 0.17 ± 0.056 
Carbenicillin 5 0.22 ± 0.073 1 0.15 ± 0.071 0.37 ± 0.10 
Cefotaxime 2.5 0.17 ± 0.026 1 0.14 ± 0.081 0.31 ± 0.085 
Vancomycin 0.5 0.27 ± 0.24 1 0.17 ± 0.063 0.44 ± 0.25 
Fosfomycin 200 0.16 ± 0.15 1 0.063 ± 0.022 0.22 ± 0.15 
Ampicillin 0.5 0.30 ± 0.072 1 0.23 ± 0.084 0.53 ± 0.11 
Bacitracin 200 0.18 ± 0.089 1 0.36 ± 0.14 0.53 ± 0.17 
Protein  
Biosynthesis  
Inhibitors 
Chloramphenicol 0.5 0.75 ± 0.18 1 0.97 ± 0.42 1.72 ± 0.46 
Kanamycin 1.5 0.64 ± 0.14 1 0.71 ± 0.30 1.36 ± 0.33 
Tetracycline 5 0.48 ± 0.047 1 0.57 ± 0.50 1.04 ± 0.50 
Nucleic Acid 
Inhibitors 
Sulfamethoxazole 200 0.78 ± 0.21 1 0.94 ± 0.64 1.72 ± 0.67 
Trimethoprim 0.5 0.66 ± 0.13 1 0.85 ± 0.29 1.51 ± 0.32 
    
S. aureus 
 Antibiotic MIC antibiotic (µg/mL) 
FIC  
antibiotic 
MIC 7 
(µg/mL) FIC 7 FIC Index 
Cell Wall  
Biosynthesis  
Inhibitors 
Carbenicillin 15 0.23 ± 0.048 1 0.077 ± 0.026 0.30 ± 0.055 
Cefotaxime 2 0.18 ± 0.055 1 0.084 ± 0.031 0.27 ± 0.063 
Vancomycin 1.5 0.14 ± 0.034 1 0.15 ± 0.062 0.29 ± 0.071 
Fosfomycin 200 0.20 ± 0.11 1 0.091 ± 0.034 0.29 ± 0.36 
Ampicillin 0.5 0.41 ± 0.17 1 0.15 ± 0.071 0.56 ± 0.18 
Bacitracin 200 0.16 ± 0.11 1 0.044 ± 0.019 0.20 ± 0.11 
Protein  
Biosynthesis  
Inhibitors 
Spectinomycin 40 0.75 ± 0.43 1 0.81 ± 0.32 1.56 ± 0.54 
Chloramphenicol 5 0.88 ± 0.47 1 0.81 ± 0.31 1.69 ± 0.56 
Kanamycin 1.5 0.89 ± 0.68 1 0.83 ± 0.29 1.72 ± 0.74 
Tetracycline 0.5 0.24 ± 0.11 1 0.51 ± 0.24 0.75 ± 0.26 
Nucleic Acid 
Inhibitors 
Sulfamethoxazole 200 0.54 ± 0.13 1 0.98 ± 0.37 1.53 ± 0.39 
Trimethoprim 15 0.69 ± 0.32 1 0.57 ± 0.25 1.26 ± 0.41 
       
Mean 
FICIs: 
B. subtilis 
inhibitors targeting cell wall biosynthesis 0.37 ± 0.14 
inhibitors targeting nucleic acids and protein biosynthesis 1.47 ± 0.28 
S. aureus 
inhibitors targeting cell wall biosynthesis 0.32 ± 0.12 
inhibitors targeting nucleic acids and protein biosynthesis 1.42 ± 0.37 
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Figure 6.1 Schematic outline of cell wall biosynthesis (in most bacteria) delineating the role 
of isoprenoid biosynthesis in the early stages of peptidoglycan formation, together with the 
reactions targeted by several compounds discussed in the Text.  
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Figure 6.2 Representative dose-response curves for three inhibitors (7, 13 and 18) against B. 
subtilis and S. aureus. 
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Figure 6.3 Representative isobolograms for 7 with antibiotics having known mechanisms of 
action. A, 7+fosmidomycin in B. subtilis showing synergy (FICI=0.17) of 7 with a cell wall 
biosynthesis inhibitor (that targets DXR, 1-deoxy-D-xylulose 5-phosphate reductoisomerase, in 
the non-mevalonate pathway). B, 7+sulfamethoxazole in B. subtilis showing an indifferent effect 
(FICI=1.72) of 7 with a nucleic acid biosynthesis inhibitor (that targets dihydropteroate synthase). 
C, 7+bacitracin in S. aureus showing synergy (FICI=0.20) of 7 with a cell wall biosynthesis 
inhibitor (that targets UPPP). D, 7+ kanamycin in S. aureus showing an indifferent effect 
(FICI=1.72) of 7 with a protein biosynthesis inhibitor (that targets ribosome function). 
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Figure 6.4 Dose-response curves of various benzoic acid and phenyl phosphonic acid 
derivatives against SaUPPS and EcUPPP.  The benzoic acids were ~40x more potent UPPP 
inhibitors than bacitracin, a known UPPP inhibitor used as a topical antibiotic. 
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Figure 6.5 Correlations between cell growth and enzyme inhibition results. A, Correlation 
between S. aureus and B. subtilis cell growth inhibition based on pIC50 (=-log10IC50 [µM]) results. 
B, Correlation between S. aureus cell growth inhibition and SaUPPS inhibition. C, Pearson r-value 
correlation matrix/heat map for S. aureus cell growth inhibition, B. subtilis cell growth inhibition, 
SaUPPS and EcUPPP enzyme inhibition (all based on pIC50 values), and logD. The Pearson r-
values are indicated and red/orange=high correlation, green=low correlation. 
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Chapter 7 
Lipophilic Dihydroxy Acids and Hydroxyphosphonic Acids 
Inhibiting Cell Wall Biosynthesis in Staphylococcus aureus  
 
7.1 Notes and Acknowledgements 
K. Wang synthesized the dihydroxy acid and hydroxy-monophosphonate inhibitors.  This 
work was supported by the United States Public Health Service (NIH grants CA158191 and 
GM065307), a Harriet A. Harlin Professorship, and the University of Illinois Foundation/Oldfield 
Research Fund.  I sincerely thank Prof. Douglas Mitchell for providing gram-positive, gram-
negative and mycobacterium strains.  I thank Dr. Furong Sun and Dr. Li Zhong for providing mass 
spectroscopy facilities.  NMR spectra were collected using NMR Laboratory of School of 
Chemical Sciences.  Many thanks to Guodong Rao for initiating this project and characterizing 
dihydroxy acid dehydratase (DHAD) from E. coli and M. tuberculosis. 
 
7.2 Introduction   
 The emergence of resistance to antibiotics is a public health threat (1) so new drugs and 
new drug leads acting on new targets are of interest (2, 3). Many of the antibiotics that, over time, 
have been of particular importance inhibit enzymes involved in bacterial cell wall biosynthesis 
which is, therefore, a potentially important area for drug discovery. Bacterial cell wall biosynthesis 
involves many enzymes with initially, dimethylallyl diphosphate (DMAPP, 1), and isopentenyl 
diphosphate (IPP, 2) being produced by either the 2-C-methyl-D-erythritol-4-phosphate or the 
mevalonate pathways, Figure 7.1. In most bacteria, DMAPP then reacts, sequentially, with two 
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IPP molecules to form trans-farnesyldiphosphate (FPP, 3) in a reaction catalyzed by FPP synthase 
(FPPS), then FPP acts as the substrate for undecaprenyl diphosphate synthase (UPPS) to form the 
(C55) isoprenoid, undecaprenyl diphosphate (UPP, 4). UPP is hydrolyzed by an enzyme called UPP 
phosphatase (UPPP) to form undecaprenyl phosphate (UP, 5) which is then used (in most bacteria) 
for peptidoglycan, lipopolysaccharide and wall teichoic acid biosynthesis. Enzymes imperative to 
cell wall biosynthesis such as UPPS and UPPP are of interest as targets for novel anti-infectives. 
In mycobacteria, cell wall biosynthesis is different and begins with formation of cis-FPP, not trans-
FPP, followed by formation of cis-decaprenyl (not undecaprenyl) diphosphate, and will not be 
further discussed here. 
	
Scheme 7.1 Structures of substrates and inhibitors discussed in the Text.  
  
In our group, we previously reported that several benzoic acids as well as diamidines such 
as 7, inhibited UPPS and 7 acted synergistically with methicillin against a MRSA (methicillin 
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resistant Staphylococcus aureus) strain of S. aureus (4).  7 was also active in vivo in a mouse model 
of infection. We also found that the fertility drug clomiphene (8) was a UPPS inhibitor (5), as well 
as an uncoupler of oxidative phosphorylation (6), the two effects presumably contributing to cell 
growth inhibition. Here, we synthesized and tested a series of bisphosphonates, phosphonates as 
well as carboxylic acids and tested them for prenyl synthase activity and for activity against both 
gram-positive as well as gram-negative bacteria. 
7.3 Results and Discussions  
Alkyl Phosphonate and Carboxylate Inhibitors 
We next synthesized a series of OH-containing alkyl phosphonates and carboxylates. Our 
initial interest in these types of compounds (structures shown in Figure 7.2) was that they might 
inhibit the enzyme dihydroxyacid dehydratase (DHAD) which in many bacteria is essential for 
branched-chain amino-acid biosynthesis with Flint and Nudelman having reported that e.g. the 
2,3-dihydroxyoctanoic acid 9 and the 1-hydroxy-2-methylpropylphosphonic acid 10 (Scheme 7.1), 
were inhibitors of DHAD from plants and E. coli (7). The compounds were shown to bind to 
enzymes that contain Fe-S clusters, but it appeared to us that they might also have prenyl 
transferase inhibition activity. So we synthesized and tested a series of dihydroxy acids and 
hydroxyphosphonates (11-36, Figure 7.2) and tested them against S. aureus, B. subtilis, M. 
smegmatis, E. coli, A. baumannii, K. pneumoniae and P. aeruginosa.  
Compounds 11, 12, 18, 19, 21, 23, 24, 29-33 were inactive.  Results for all active 
compounds are shown in Table 7.1 and structures of all 26 compounds are given in Figure 7.2. 
Several compounds containing long-alkyl sidechains, such as 27 and 36 had activity in the 2-6 
µg/mL range against gram-positive, but not gram-negative bacteria, Table 7.1 and Figure 7.3. 
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These results then raise the question: how do these compounds inhibit bacterial cell growth?  Such 
lipophilic, anionic species could be isosteres of e.g. intermediates in fatty acid biosynthesis, or of 
isoprenoid phosphates or diphosphates, so UPPS and/or UPPP inhibition appeared likely. There is 
some similarity between the more potent bacterial cell growth inhibitors—the lipophilic 
hydroxyphosphonates 27 and 36—and GPP or FPP, substrates involved in many prenyl transferase 
reactions. 
To try and narrow down the possibilities as well as open up potential routes to synergistic 
combinations, we next investigated whether or not one of the most active compounds, the 
lipophilic hydroxyphosphonate 27, exhibited synergistic, additive, indifferent or antagonistic 
activity with a broad range of antibiotics that act either by inhibiting bacterial cell wall 
biosynthesis, or by other mechanisms. This is basically the approach used previously to discover 
the novel SaUPPS inhibitor, clomiphene (5).  The antibiotics that act by targeting cell wall 
biosynthesis were fosmidomycin, carbenicillin, vancomycin, ampicillin, bacitracin, fosfomycin, 
and cefotaxime. The compounds that do not target bacterial cell wall biosynthesis were kanamycin, 
tetracycline, sulfamethoxazole, trimethoprim, spectinomycin, and chloramphenicol.  We obtained 
data on two organisms: B. subtilis, chosen because it utilizes the non-mevalonate (MEP) pathway 
and is inhibited by fosmidomycin (which targets 1-deoxy-D-xylulose-5-phosphate 
reductoisomerase, DXR), and S. aureus, which uses the mevalonate pathway. 
We determined the fractional inhibitory concentration index (FICI) values for each 
combination using the FICI formula: (8, 9) 
 
FICI = FIC8 + FIC9 = MIC(AB)MIC(A) + MIC(BA)MIC(B)  
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where FICA, FICB are the fractional inhibitory concentrations of drugs A and B, MIC(A) and 
MIC(B) are the MIC values of drugs A and B acting alone, and MIC(AB) and MIC(BA) are the 
MIC values of the most effective combination of drug A or B in the presence of drug B or A. Using 
this method, FICI values of <0.5 indicate synergy, >0.5 and <1.0 indicate additivity, >1 and <2 
indicate an indifferent effect, and ≥2 indicates antagonism (10).  In addition, we evaluated 
isobolograms using the method of Berenbaum (11).   
FICI values are shown in Table 7.2 and selected representative isobolograms are in Figure 
7.4.  The results shown in Table 7.2 show that in each case where the second inhibitor targets 
isoprenoid/cell wall biosynthesis, there is a synergistic interaction (FICIavg = 0.31 ± 0.11, n = 13) 
while in each case where the second inhibitor is not involved in isoprenoid/cell wall biosynthesis, 
there is an indifferent (though not antagonistic) effect (FICIavg = 1.53 ± 0.19, n = 11). We again 
use the definition that FICI values <0.5 mean synergy; 0.5-1 additivity; 1-2 indifference and >2, 
antagonism. These results strongly support the idea that this hydroxyphosphonate, 27 targets 
isoprenoid/cell wall biosynthesis. Some possible targets, based on structure, would be FPPS, UPPS 
and UPPP, since these are all in the isoprenoid/cell wall biosynthesis pathway while e.g. prenyl 
synthases, such as those involved in quinone biosynthesis, are not. 
We tested all compounds against EcFPPS, SaUPPS and EcUPPP (12) using phosphate-
release assays (13, 14). There was no activity (IC50 > 300 µM) against EcFPPS or PaFPPS (data 
not shown) but several compounds were active against UPPS and UPPP and dose-response curves 
for the most active species are shown in Figure 7.5A, B.  Both the 1-OH and 2-OH phosphonates 
(27 and 36) were active against SaUPPS with IC50 values of ~1-3 µM. For the UPPP activity 
inhibition assay, we found that 27 and 36 inhibited UPPP with IC50 values of ~1-4 µM 
(corresponding to a Ki ~300-980 nM, assuming competitive inhibition) (15). Under the same assay 
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conditions, the IC50 for UPPP inhibition by bacitracin was 32 µM, Figure 7.5B. So, 27 and 36 
inhibit both UPPS as well as UPPP, consistent with the observation that 27 shows synergistic 
activity with all isoprenoid/cell wall biosynthesis inhibitors tested. The dihydroxy acid, 15 showed 
weak inhibition against SaUPPS and no inhibition (>200 µM) against EcUPPP, resulting in less 
activity in cells.  We also found that overexpressing EcUPPS caused a ~13x increase in the IC50 
for E. coli cell growth inhibition by both 27 and 36, Table 7.3 and Figure 7.5C.  We thus conclude 
that both UPPS as well as UPPP are likely targets for the most potent hydroxyphosphonates.  And 
finally, we tested 15, 27 and 36 for their effects on growth of the human embryonic kidney cell 
line HEK-293. The MIC values for cell growth inhibition were in the range of 90 µg/mL to 410 
µg/mL, Figure 7.6, so these compounds are not highly toxic to at least this human cell line. 
 
7.4 Conclusions 
The results we have reported above are of interest for several reasons. We synthesized a 
broad range of hydroxyphosphonates and dihydroxyacids in order to find novel inhibitors of 
isoprenoid biosynthesis that also inhibited bacterial cell growth.  These inhibitors were active 
against gram-positive (but not gram-negative) and mycobacterium cell growth in 2-6 µg/mL range, 
with showing synergistic activity with antibiotics targeting cell wall biosynthesis (FICIavg = 0.31 
± 0.11, n = 13).  Hydroxyphosphonates were found to be active against S. aureus UPPS and E. coli 
UPPP enzymes, with cell growth inhibition partially being rescued (an increase in IC50 by a factor 
of ~13x) by overexpression of E. coli UPPS, consistent with an isoprenoid biosynthesis target.  
Overall, the results are of interest since we have found new prenyl synthase inhibitors that target 
UPPS as well as UPPP that have single-digit micromolar activity against a gram-positive pathogen.   
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7.5 Methods and Materials 
Materials  
Purine nucleoside phosphorylase (PNP) and pyrophosphatase (inorganic, baker’s yeast) 
were purchased from Sigma-Aldrich (St. Louis, MO).  7-Methyl-6-thioguanosine (MESG) was 
purchased from Berry Associates (Dexter, MI).  Malachite green phosphate assay kit was 
purchased from Cayman Chemical (Ann Arbor, MI).   
E. coli Growth Inhibition Assay 
IC50 values for E. coli cell growth inhibition were determined using a microdilution 
method. Stationary overnight starter cultures of E. coli (K-12 or BL21 (DE3) strains), were diluted 
1000-fold and grown to an OD600 of ~0.3. These log-phase cultures were then diluted 500-fold into 
fresh LB broth to generate a “working solution”.  200 µL of working solution was transferred into 
each well of a 96-well culture plate (Corning 3370). Inhibitors were then added at 1 mM and 
sequentially diluted 3x to 46 nM, keeping volume and culture broth composition constant.  Plates 
were incubated for 12 hours at 37°C, shaking at 200 RPM, then absorbance at 600 nm measured 
to assess bacterial cell growth. IC50 values were determined using nonlinear regression whereas 
minimum inhibitory concentration (MIC) values in the synergy assays were calculated by using a 
Gompertz function in Prism 5 (GraphPad Software, Inc., La Jolla, CA). 
Gram-negative Bacterial Cell Growth Inhibition Assay 
As with the E. coli inhibition assays, overnight cultures (in cation-adjusted Mueller-Hinton 
broth, CAMHB) of A. baumannii (Bouvet and Grimont, ATCC 19606); K. pneumoniae (subsp. 
Pneumoniae Schroeter Trevisan ATCC 27736); and P. aeruginosa (PA01) were diluted 1000-fold 
(in fresh CAMHB) to create a “working solution”.  Working solutions were then transferred into 
flat-bottom 96-well plates and inhibitors added at 1 mM and sequentially diluted 3x to 46 nM. 
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Plates were incubated at 37°C, shaking at 200 RPM, overnight.  The OD600 was then measured to 
determine bacterial growth inhibition. 
B. subtilis Growth Inhibition Assay 
An overnight starter culture (in LB broth) of B. subtilis (subsp. subtilis (Ehrenberg) Cohn 
ATCC 6051) was diluted 1000-fold (in fresh LB media) to create a “working solution”. Working 
solutions were then transferred into flat-bottom 96-well plates and inhibitors were added at 1 mM 
and sequentially diluted 3x to 46 nM. Plates were incubated at 37°C, shaking at 200 RPM 
overnight. The OD600 was then measured to determine bacterial growth inhibition. 
S. aureus Growth Inhibition Assay 
An overnight starter culture of S. aureus (Newman strain) in tryptic soy broth was diluted 
1000-fold in fresh tryptic soy media to create a “working solution”. Working solutions were 
transferred into flat-bottom 96-well plates and inhibitors added at 1 mM and sequentially diluted 
3x to 46 nM.   Plates were incubated at 37°C, shaking at 200 RPM overnight. The OD600 was then 
measured to determine bacterial growth inhibition. 
HEK293 Toxicity Assay 
A frozen stock of human embryonic kidney cells (HEK293 ATCC CRL-1573) was used to 
grow a first generation of cells in DMEM (4.5 g/mL glucose with L-glutamine) containing 10% 
fetal bovine serum (FBS) and 1% penicillin-streptomycin (10,000 U/mL).  This generation was 
harvested in 0.25 % trypsin/2.1 µM EDTA and cells were counted under a light microscope.  A 
"working solution" was generated containing 105 cells/mL, which was then transferred into a flat-
bottom 96-well plate for 36 hours.  At this time, 20 µL of inhibitor solutions ranging from 1 mM 
to 46 nM were added and cells were allowed to grow in the presence of the inhibitors for an 
additional 24 hours.  Then 10 µL of MTT solution (5mg/mL in PBS) was added to each well and 
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incubated for 4 hours.  100 µL of 100 mM HCl in isopropanol was added to each well and 
absorbance at 570 nm was measured.  MIC values were calculated by using a Gompertz function 
in Prism 5 (GraphPad Software, Inc. La Jolla, USA). 
Synergy/Antagonism Assays 
In order to investigate possible synergistic interactions between compound 27 and a range 
of antibiotics, we carried out two-drug combination assays.  Bacteria were incubated with a 3x 
gradient of antibiotic typically ranging from 40 µg/mL to 18 ng/mL (200 µg/mL to 90 ng/mL for 
bacitracin, fosfomycin, and sulfamethoxazole) in the presence half-MIC concentrations of 27, in 
addition to a 3x gradient of 27 ranging from 40 µg/mL to 18 ng/mL in the presence of half-MIC 
concentrations of each antibiotic.  New MIC values were calculated by using a Gompertz function 
in Prism 5 (GraphPad Software, Inc., La Jolla, CA). 
Enzyme Inhibition Assays 
SaUPPS and EcUPPP were expressed and purified as described previously (4, 15).  UPPS 
assays were carried out using a phosphate release assay (13, 14).  Hydroxyphosphonates and 
dihydroxy-acids were prepared as 10 mM stock solutions in DMSO, and then serially diluted from 
1 mM to 1 nM.  Inhibitors were incubated with 25 ng of SaUPPS at room temperature for 10 
minutes in a pH 7.5 buffer (50 mM HEPES, 150 mM NaCl, 10 mM MgCl2, and 0.02% n-dodecyl-
β-D-maltopyranoside) before adding “reaction mixture” containing 5 µM FPP, 50 µM IPP, 3 U/mL 
purine nucleoside phosphorylase, 1 U/mL inorganic phosphatase, and ~600 µM 7-methyl-6-
thioguanosine (MESG), again in the same buffer.  Enzymatic reactions were monitored for 15 
minutes with the rate of increase in absorbance at 360 nm taken as the rate of UPP synthesis.  IC50 
values were calculated by using Prism 5 (GraphPad Software, Inc., La Jolla, CA). The UPPP 
inhibition assay was carried out using a malachite-green reagent as described previously (18).   The 
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same 10 mM inhibitor stock solutions and assay buffer as for the SaUPPS assays were used to test 
for UPPP inhibition. Inhibitors were incubated with 20 nM EcUPPP at room temperature for 15 
minutes before adding FPP to 35 µM. Reaction mixtures were incubated at 37°C for 20 minutes, 
then quenched by adding 30 µL of malachite-green reagent. In this assay, the phosphate released 
from FPP reacts with ammonium molybdate to form phosphomolybdate (yellow) which then forms 
a complex (λmax ~ 620 nm) with malachite-green, used to assess phosphatase activity. Phosphate 
release was measured at 620 nm and quantified based on a phosphate standard curve, and the OD 
values used to construct dose-response curves. 
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7.6 Tables and Figures 
Table 7.1          IC50 values of dihydroxy acids and hydroxyphosphonic acids against bacterial cells 
and enzymes (in µM). 
Compounds 
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>200 >200 >200 >200 >200 >200 >200 >200 >200 
 
>200 >200 >200 >200 >200 >200 >200 120 ± 15 >200 
 
>200 150 ± 37 >200 >200 >200 >200 >200 180 ± 33 >200 
 
20 ± 3.4 150 ± 27 55 ± 11 31 ± 4.9 >200 >200 >200 39 ± 9.5 >200 
 
40 ± 6.9 >200 73 ± 8.5 45 ± 10 >200 >200 >200 56 ± 6.7 >200 
 
120 ± 17 190 ± 28 >200 >200 >200 >200 >200 >200 >200 
 
>200 >200 >200 >200 >200 >200 >200 >200 >200 
 
33 ± 6.0 26 ± 5.4 >200 >200 >200 >200 >200 46 ± 8.3 >200 
 
>200 130 ± 18 >200 >200 >200 >200 >200 >200 >200 
 
>200 >200 110 ± 19 >200 >200 >200 >200 33 ± 7.3 32 ± 6.6 
 
>200 >200 96 ± 5.9 >200 >200 >200 >200 12 ± 2.1 15 ± 1.7 
 
6.3 ± 0.82 7.5 ± 0.69 14 ± 1.7 24 ± 3.3 22 ± 4.1 24 ± 5.3 140 ± 25 0.73 ± 0.06 0.92 ± 0.12 
 
11 ± 2.0 18 ± 3.8 31 ± 4.0 29 ± 4.9 22 ± 3.2 84 ± 11 >200 2.4 ± 0.72 3.7 ± 1.1 
 
>200 190 ± 56 >200 >200 >200 >200 >200 >200 >200 
 
>200 >200 83 ± 13 >200 >200 >200 >200 25 ± 5.7 11 ± 3.1 
 
23 ± 5.6 37 ± 6.8 25 ± 4.3 32 ± 5.7 49 ± 8.2 90 ± 13 >200 2.8 ± 0.63 3.4 ± 0.89 
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Table 7.2         Effects of addition of different known bacterial cell growth inhibitors on B. 
subtilis and S. aureus cell growth inhibition by 27.  
B. subtilis 
 Antibiotic MIC antibiotic  (µg/mL) 
FIC  
antibiotic 
MIC 27 
(µg/mL) FIC 27 FIC Index 
Cell Wall 
Biosynthesis 
Inhibitors 
Fosmidomycin 5 0.25 ± 0.043 10 0.013 ± 0.0037 0.27 ± 0.046 
Carbenicillin 5 0.25 ± 0.043 10 0.097 ± 0.049 0.34 ± 0.048 
Cefotaxime 2.5 0.30 ± 0.044 10 0.075 ± 0.012 0.38 ± 0.056 
Vancomycin 0.5 0.33 ± 0.058 10 0.080 ± 0.059 0.41 ± 0.12 
Fosfomycin 200 0.21 ± 0.025 10 0.22 ± 0.052 0.43 ± 0.077 
Ampicillin 0.5 0.18 ± 0.041 10 0.048 ± 0.023 0.23 ± 0.063 
Bacitracin 200 0.12 ± 0.028 10 0.23 ± 0.010 0.35 ± 0.13 
Protein 
Biosynthesis 
Inhibitors 
Kanamycin 1.5 0.61 ± 0.097 10 0.95 ± 0.097 1.55 ± 0.19 
Tetracycline 5 0.82 ± 0.21 10 0.80 ± 0.15 1.61 ± 0.35 
Chloramphenicol 0.5 0.55 ± 0.13 10 0.93 ± 0.32  1.47 ± 0.45 
Nucleic 
Acid 
Inhibitors 
Sulfamethoxazole 200 0.87 ± 0.23 10 0.91 ± 0.25 1.78 ± 0.48 
Trimethoprim 0.5 0.77 ± 0.18 10 0.60 ± 0.084 1.37 ± 0.26 
       
S. aureus 
 Antibiotic MIC antibiotic  (µg/mL) 
FIC  
antibiotic 
MIC 27 
(µg/mL) FIC 27 FIC Index 
Cell Wall 
Biosynthesis 
Inhibitors 
Carbenicillin 15 0.27 ± 0.015 10 0.052 ± 0.0077 0.32 ± 0.022 
Cefotaxime 2 0.21 ± 0.048 10 0.18 ± 0.057 0.40 ± 0.11 
Vancomycin 1.5 0.19 ± 0.019 10 0.16 ± 0.033 0.34 ± 0.052 
Fosfomycin 200 0.13 ± 0.022 10 0.052 ± 0.014 0.18 ± 0.036 
Ampicillin 0.5 0.30 ± 0.095 10 0.056 ± 0.012 0.35 ± 0.11 
Bacitracin 200 0.21 ± 0.039 10 0.027 ± 0.0090 0.24 ± 0.048 
Protein 
Biosynthesis 
Inhibitors 
Kanamycin 1.5 0.81 ± 0.17 10 0.83 ± 0.17 1.64 ± 0.34 
Tetracycline 0.5 0.83 ± 0.38 10 0.93 ± 0.13 1.76 ± 0.51 
Chloramphenicol 5 0.71 ± 0.11 10 0.73 ± 0.21 1.44 ± 0.33 
Spectinomycin 40 0.45 ± 0.091 10 0.84 ± 0.22 1.29 ± 0.31 
Nucleic 
Acid 
Inhibitors 
Sulfamethoxazole 200 0.75 ± 0.20 10 0.99 ± 0.17 1.74 ± 0.37 
Trimethoprim 15 0.69 ± 0.32 10 0.53 ± 0.13 1.22 ± 0.45 
             
Mean 
FICIs: 
B. subtilis 
inhibitors targeting cell wall biosynthesis 0.31 ± 0.14 
inhibitors targeting nucleic acids and protein biosynthesis 1.56 ± 0.15 
S. aureus 
inhibitors targeting cell wall biosynthesis 0.31 ± 0.080 
inhibitors targeting nucleic acids and protein biosynthesis 1.52 ± 0.23 
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Table 7.3          IC50 values (in µg/mL) of 27 and 36 in E. coli overexpressing E. coli UPPS 
(EcUPPS++) 
Organism Inhibitor Rescuing Agent (RA) 
IC50 
w/o RA 
IC50 
w/ RA 
E. coli  27 EcUPPS++ 6.4 ± 1.3 86 ± 17 
E. coli  36 EcUPPS++ 9.0 ± 1.5 107 ± 15 
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Figure 7.1 Illustration of selected molecules involved in cell wall biosynthesis in most 
bacteria. Also shown are sites of action of some antibiotics and potential targets, discussed in the 
Text. 
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Figure 7.2	 Structures of dihydroxy-acids and hydroxyphosphonates. 
 
*Compounds showing inhibition activity against enzyme or cell growth are listed in Table 7.1. 
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Figure 7.3 Dose-response curves for 15, 27 and 36 inhibiting B. subtilis (A) and S. aureus 
cell growth (B).  
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Figure 7.4 Representative isobolograms for 27 with antibiotics having known mechanisms of 
action. A, 27+fosmidomycin in B. subtilis showing synergy (FICI=0.27) of 27 with a cell wall 
biosynthesis inhibitor (that targets DXR, 1-deoxy-D-xylulose-5-phosphate reductoisomerase, in 
the non-mevalonate pathway). B, 27+sulfamethoxazole in B. subtilis showing an indifferent effect 
(FICI=1.78) of 27 with a nucleic acid biosynthesis inhibitor (that targets dihydropteroate synthase). 
C, 27+bacitracin in S. aureus showing synergy (FICI=0.24) of 27 and a cell wall biosynthesis 
inhibitor (that targets UPPP). D, 27+tetracycline in S. aureus showing an indifferent effect 
(FICI=1.61) of 27 with a protein synthesis inhibitor (that targets ribosome function).  
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Figure 7.5 Enzyme and cell growth inhibition by the dihydroxyacid 15 and 
hydroxyphosphonates 27 and 36. A, SaUPPS inhibition; B, EcUPPP inhibition together with result 
for bacitracin; C, partial rescue of E. coli cell growth inhibition by EcUPPS overexpression. 
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Figure 7.6 Dose-response curves and MIC values for 15, 27, and 36 inhibiting human 
embryonic kidney (HEK 293) cell growth. 
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